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Abstract 
Faecal Peritonitis is a common cause of sepsis and admission to the Intensive 
Care Unit (ICU). The Genetics of Sepsis & Septic Shock in Europe (GenOSept) 
project and the GAinS (Genomic Advances in Sepsis) are genetic epidemiology 
studies set up to investigate the influence of genetic variation on the host response 
and outcomes. The studies included two large cohorts of post-operative critically ill 
patients with sepsis from faecal peritonitis admitted to European and UK ICUs, 
respectively. 
In my thesis, I define the clinical characteristics, outcomes and risk factors for 
mortality in these patients, relying on the clinical data available from these large 
databases. 
The GenOSept study provided data for 977 faecal peritonitis patients, 
recruited to 102 centres across 16 countries between 29/09/2005 and 5/01/2011. 
The median age was 69.2 years (IQR, Interquartile range 58.3-77.1). The most 
common causes of faecal peritonitis were perforated diverticular disease (32.1%) 
and surgical anastomotic breakdown (31.1%). The mortality rate at 28 days was 
19.1% and 31.6% at six months.  
The cause of faecal peritonitis, pre-existing co-morbidities and time from 
estimated onset of symptoms to surgery did not impact on survival. The strongest 
independent risk factors associated with an increased rate of death at 6 months 
included age, higher APACHE (Acute Physiology and Chronic Health Evaluation) II 
score, acute renal and cardiovascular dysfunction within one week of admission to 
ICU, hypothermia, lower haematocrit and bradycardia on day 1 of ICU stay. 
When analysing trends in all variables available for the first week of ICU stay, 
the trends over the first 7 days ICU stay (primary analysis) retained in multivariate 
14 
 
analysis as independently associated with 6 months outcome were worsening 
thrombocytopaenia (mortality Hazard Ratio, HR=1.02, 95% CI 1.01-1.03, p<0.001) 
and renal function (total daily urine output HR=1.02, 95%CI 1.01-1.03, p<0.001; 
worsening renal SOFA - Sequential Organ Failure Assessment - sub-score HR=0.87, 
95%CI 0.75-0.99, p=0.047), and worsening trends in the highest recorded level of 
bilirubin (HR=0.99, 95%CI 0.99-0.99, p=0.02) and GCS SOFA sub-score (HR=0.81, 
95%CI 0.68-0.98, p=0.028). Changes in renal function (total daily urine output and 
renal component of the SOFA score), GCS component of the SOFA score, total 
SOFA and worsening thrombocytopaenia were also independently associated with 
secondary outcomes (ICU, hospital and 28 day mortality). Dynamic trends over the 
first 7 days ICU stay in all other measured laboratory and physiological variables and 
in radiological findings failed to be retained as independently associated with 
outcome on multivariate analyses. Furthermore, changes in respiratory support, 
renal replacement therapy and inotrope and/or vasopressor requirements were not 
independently associated with any of the primary or secondary outcomes. 
A further set of analyses aimed to develop two prognostic models for the 
prediction of 28 day  and long term (6 months) mortality, using non-parametric boot-
strapping techniques of sampling from the UK portion of the GenOSept cohort, to 
derive a prognostic model. The non-UK portion of the GenOSept cohort, and the 
GAinS cohort were used for geographic and temporal external validation purposes of 
the prognostic model. 
Five variables (age, SOFA score, lowest temperature, highest heart rate, 
haematocrit) were entered into the prognostic models. The discriminatory 
performance of the 6 month prognostic model yielded an AuROC (Area under the 
Receiver Operating Characteristic curve) 0.81 (95% Confidence Interval, CI, 0.76 - 
15 
 
0.86), 0.73 (95% CI 0.69 - 0.78), and 0.76 (95% CI 0.69-0.83) for the derivation, 
geographic and temporal external validation cohorts, respectively. The 28 day 
prognostic tool yielded an AuROC 0.82 (95% CI 0.77 - 0.88), 0.75 (95% CI 0.69 - 
0.80) and 0.79 (95% CI 0.71-0.87) for the same cohorts. These AuROCs were 
consistently superior to those obtained with the SOFA and APACHE II scores. 
Hence, the two prognostic models developed for 6 month and 28 day mortality 
prediction in critically ill septic patients with FP, in the post-operative phase, 
enhanced the SOFA score's predictive utility by adding few key variables. External 
validation in larger cohorts of their predictive capability is needed, before introduction 
of the scores into clinical practice to inform decision making and the design of clinical 
studies. 
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Chapter 1 - Introduction 
Sepsis is a clinical condition with high mortality. Faecal peritonitis is a 
common cause of admission to the Intensive Care Unit (ICU) with sepsis. 
Epidemiological data on the outcome and prognostic factors specifically related to 
patients admitted with faecal peritonitis to critical care are scarce in literature. The 
present chapter describes sepsis and septic shock, outlines the literature previously 
reported on secondary peritonitis in general, the limited literature specific to faecal 
peritonitis and outcomes of patients in the critical care setting, and provides the 
background on the currently used prognostic indices and tools available to help the 
clinician assess potential outcomes. 
 
1.1 Sepsis and septic shock 
1.1.1 Definitions of sepsis and septic shock 
For the purpose of the studies presented in this thesis, I have relied on the 
definition of sepsis, severe sepsis and septic shock presented here. 
 
1.1.1.1 Sepsis 
Sepsis is defined as the presence of a confirmed (or suspected) infection plus 
a Systemic Inflammatory Response Syndrome (SIRS). SIRS is a physiological 
response to a triggering factor, not necessarily infective, which is characterized by at 
least two of the following features (Bone et al. 1992): 
 Temperature >38oC or <36oC 
 Heart Rate >90 beats/min 
 Respiratory rate >20 breaths/min 
 White blood Cells count (WCC): 
26 
 
o >12,000/mm3 or 
o <4,000/mm3 or  
o >10% immature neutrophils 
 
1.1.1.2 Severe Sepsis 
Severe Sepsis is defined as sepsis accompanied by organ dysfunction or 
tissue hypoperfusion (Bone et al. 1992; Bernard et al. 2001), as evidenced by 
cardiovascular instability (refractory hypotension), serum lactate level above the 
upper limit of normality, renal involvement (urine output of <0.5 ml/kg/hour for 2 
hours despite adequate fluid resuscitation), respiratory failure, hepatic function 
derangement, coagulopathy, central nervous system hypoperfusion, or a 
combination of these factors (Levy et al. 2003; R Phillip Dellinger et al. 2013). 
 
1.1.1.3 Septic Shock 
Septic Shock is defined as sepsis induced hypotension despite adequate fluid 
resuscitation, with the presence of hypoperfusion abnormalities or organ dysfunction 
(Bone et al. 1992; R Phillip Dellinger et al. 2013). Sepsis induced tissue 
hypoperfusion is defined as the presence of hypotension caused by infection with 
elevated serum lactate and/or oliguria (R Phillip Dellinger et al. 2013).   
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1.1.1.4 Sepsis 3 
Subsequent to the studies presented in this thesis, a task force with expertise 
in sepsis, clinical trials, and epidemiology was convened by the Society of Critical 
Care Medicine and the European Society of Intensive Care Medicine to develop The 
Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). 
The task force developed a new set of definitions of the sepsis and septic shock 
syndromes. These definitions were published in 2016, suggesting that “sepsis should 
be defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection. For clinical operationalization, organ dysfunction can be 
represented by an increase in the Sequential [Sepsis-related] Organ Failure 
Assessment (SOFA) score of 2 points or more, which is associated with an in-
hospital mortality greater than 10%”. Furthermore, the new definitions suggest that 
“septic shock should be defined as a subset of sepsis in which particularly profound 
circulatory, cellular, and metabolic abnormalities are associated with a greater risk of 
mortality than with sepsis alone” (Singer et al. 2016). The document highlights how 
septic shock patients can be identified by detecting a serum lactate level above 2 
mmol/L, and the need to use vasopressors to maintain a mean arterial pressure 
equal or above 65 mmHg, in the absence of hypovolemia. Patients at risk of 
increased mortality are those who have two or more of the criteria included in the 
new quickSOFA (qSOFA) score:  
 respiratory rate equal or above 22/min 
 altered mentation 
 systolic blood pressure equal or below 100 mmHg 
The new set of definitions regards the term “severe sepsis” as redundant and does 
not rely on the use of the SIRS criteria (Singer et al. 2016). 
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1.1.1.5 The new sepsis criteria: controversies 
The introduction of the new set of definitions (Sepsis 3) of the sepsis and septic 
shock syndromes has generated a vigorous debate in the scientific community about 
the appropriateness of the criteria used. The major criticisms surround the 
decreased sensitivity of the Sepsis 3 criteria, which abandon the use of SIRS, 
leading to the potential under detection of the condition. Such effect is an obviously 
undesirable feature for a screening tool and crucially, critics argue, likely detrimental 
to patient care (Simpson 2016). Others have argued that neither of definitions is 
perfect. The lethality of sepsis requires a highly sensitive screening tool, without 
necessarily loosing specificity. Furthermore, both definitions fail to adequately cater 
for those patients with an infection and high risk of mortality who do not meet SIRS 
criteria nor display features of organ failure at presentation (Bermejo-Martin et al. 
2017). 
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1.1.2 Incidence 
The incidence of severe sepsis has been estimated as being around 0.5 - 3 
cases / 1000 population / year admitted to Intensive Care Units (ICUs) in both the 
US and the UK (Angus et al. 2001; Padkin et al. 2003; R Phillip Dellinger et al. 
2013). The incidence of severe sepsis has been increasing, as a result of increased 
awareness and diagnosis, and an ageing population with increasingly complex 
comorbidities (Iwashyna et al. 2012; R Phillip Dellinger et al. 2013). A study 
conducted with the aim of establishing the incidence and mortality from severe 
sepsis in the United States over a period of 6 years (2004-2009) produced estimates 
relying on four different methodologies. The study highlighted significant differences 
in the estimates obtained, depending of the method adopted for the calculations, with 
the average annual incidence varying between 0.3 and 1.03 cases / 1000 population 
/ year. Nevertheless, over the same period, an average annual increase in the 
incidence of severe sepsis was detected, whichever the method used. Furthermore 
hospital mortality varied between 14.7% and 29.9%, but decreased across the same 
period (Gaieski et al. 2013). 
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1.1.3 Causes 
 
1.1.3.1 Site of infection 
A large pan-European study documented the high frequency of sepsis in 
critically ill patients. The majority of cases are related to infections of the respiratory 
tract (40-70%), the genitourinary system (10%), the intra-abdominal viscera (10%) or 
bacteraemia of unspecified origin (10-20%) (Angus et al. 2001; Padkin et al. 2003; R 
Phillip Dellinger et al. 2013; Vincent et al. 2006). In a study by Mayr and colleagues, 
a gender related difference regarding the site of infections was highlighted, with the 
genitourinary site being almost twice as frequent in women compared to men. In 
both genders the respiratory site is the most common, followed by bacteraemias of 
unspecified origin, genitourinary, abdominal, indwelling device, wound and other soft 
tissues, central nervous system, endocarditis and other sites (Mayr et al. 2014). 
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1.1.3.2 Microbiological isolates 
The frequency of isolates being Gram-positive organisms as a cause of 
sepsis has increased over time, becoming almost as common as Gram-negative 
infections, possibly as a result of increased proportion of healthcare associated 
infections and larger use of invasive procedures (Bone 1994). The use of broad-
spectrum antimicrobials in the intensive care settings has been related to the 
development of antimicrobial resistance. The type of organism responsible for 
severe sepsis is a key prognostic variable. The European Prevalence of Infection in 
Intensive Care (EPIC II) study showed that isolates from septic patients were more 
likely to be Gram-negative organisms compared to Gram positive ones (62.2% vs. 
46.8%), predominantly Staphylococcus aureus (20.5%), Pseudomonas aeruginosa 
(19.9%), Enterobacteriacae (primarily Escherichia coli, 16.0%), and fungal species 
(19%). The organisms associated with hospital mortality were Enterococcus spp., 
Pseudomonas aeruginosa, and Acinetobacter spp. (Vincent et al. 2009). 
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1.1.4 Management 
The management of patients suffering from severe sepsis and septic shock is 
based on the principles described in the various versions of the Surviving Sepsis 
Campaign guidelines (Dellinger et al. 2008; R P Dellinger et al. 2013; Rhodes et al. 
2017), summarised below. 
 
 
Resuscitation and Early Goal Directed Therapy 
A protocolised and target driven approach to resuscitation, integral to initial 
sepsis management, was described by Rivers and colleagues, who introduced the 
concept of Early Goal Directed Therapy (EGDT) and demonstrated improved 
outcomes with its utilisation. EGDT aims to adjust the cardiac preload, afterload, and 
contractility, by employing a combination of resuscitative measures, including 
intravenous fluids, vasopressors, inotropic support and red blood cells transfusions, 
to achieve central hemodynamic targets with the aim of improving the balance 
between delivery and demand of oxygen. According to the principles of EGDT, 
resuscitation should be initiated early and based on protocols targeting sepsis-
related organ hypoperfusion (defined as documented persistent hypotension despite 
fluid challenge or a lactate concentration ≥ 4 mmol/L) with a set of specific goals 
within the first 6 hours, such as ensuring a central venous pressure of 8–12 mmHg, a 
mean arterial pressure ≥ 65 mmHg, a urine output ≥ 0.5 mL/kg/hr, a central venous 
haemoglobin oxygen saturation of 70% or a mixed venous oxygen saturation 65%. In 
their single centre randomised controlled trial Rivers and colleagues randomised 263 
patients presenting to the emergency department with severe sepsis and septic 
shock, to receive EGDT or usual care. The intervention arm of the trial received 
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Early Goal Directed Therapy for six hours, prior to admission to the intensive care 
unit, versus standard therapy in the control arm. The study demonstrated a 
significant improvement in the achieved central venous oxygen saturation, lower 
lactate concentration, lower base deficit and higher pH in the intervention arm. 
Furthermore, the intervention arm showed an improvement in serial APACHE (Acute 
Physiology and Chronic Health Evaluation) II scores and significant improvement in 
hospital mortality, which was 30.5% in the Early Goal Directed Therapy arm, versus 
46.5% in the control arm (Rivers et al. 2001). These findings have since been 
challenged by subsequent large scale randomised controlled trials (Yealy et al. 2014; 
Peake et al. 2014; Mouncey et al. 2015). 
The ProCESS (Protocolised Care for Early Septic Shock) investigators 
performed a trial, which aimed at re-appraising EGDT and determining whether the 
components of the protocol described by Rivers and co-workers were all necessary. 
They randomised 1341 patients with septic shock from 31 emergency departments 
in the United States to one of three arms: protocol based EGDT, protocol based 
standard care and standard care. The protocol-based standard therapy differed from 
the EGDT in the fact that it did not require the placement of a central venous 
catheter, administration of inotropes, or blood transfusions. The authors found no 
significant differences in 60 day, 90 day and 1 year mortality rates and need for 
organ support across all three study arms (Yealy et al. 2014). 
The ARISE (Australasian Resuscitation in Sepsis Evaluation) trial was 
conducted at 51 emergency department (mainly in Australia and New Zealand). It 
randomly allocated 1600 patients with early septic shock to receive either Early Goal 
Directed Therapy or standard care. The ARISE trial failed to demonstrate any 
significant difference in all-cause mortality at 90 days, survival time, hospital 
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mortality, duration of organ support, or length of hospital stay. The patients enrolled 
in the intervention arm (EGDT) were, compared to the usual care arm, more likely to 
received higher volumes of resuscitative intravenous fluids in the first 6 hours, vaso-
active and inotropic medications, and red blood cell transfusions, with differences 
which were highly statistically significant (Peake et al. 2014). 
The PROMISE (Protocolised Management in Sepsis) trial investigators 
conducted a pragmatic randomized controlled trial in 56 hospitals in England, 
enrolling 1260 patients, who were allocated to receive either EGDT or standard care. 
Despite the higher intensity of treatments in the EGDT arm (increased use of 
intravenous fluids, vasoactive medications, and red blood cells utilisation), the 
patients in such arm had significantly worse organ failure scores, received 
cardiovascular support for longer periods of time and had longer stays in the 
intensive care unit, but did not obtain any survival advantages. Implementing the 
Early Goal Directed Therapy also meant increased costs (Mouncey et al. 2015). 
A systematic review and meta-analysis of EGDT for septic shock performed 
by the ARISE, ProCESS and ProMISe investigators concluded that EGDT is as 
effective as usual care in the treatment of patients with septic shock, but means 
higher utilisation of critical care resources (Angus et al. 2015). 
As a result of the above studies, EGDT is not currently recommended in its 
original form. The most recent iteration of the Surviving Sepsis Campaign (2016) 
guidelines recommends initial intravenous crystalloids resuscitation (at a dose of 30 
ml/kg body weight over the first 3 hours), with additional fluids administration guided 
by regular reassessment of haemodynamic status, targeting a mean arterial 
pressure of 65 mmHg and aimed at normalising the serum lactate levels (Rhodes et 
al. 2017). The use of a target Central Venous Pressure (CVP) range is, therefore, no 
35 
 
longer recommended. More emphasis is now placed on the use of dynamic variables 
(passive leg raises, fluid challenges against stroke volume measurements, systolic 
or pulse pressure variations to changes in intra-thoracic pressure), over the static 
ones, and the increasing use of echocardiography (Rhodes et al. 2017). 
 
Micorbiological diagnosis 
In order to establish a microbiological diagnosis, cultures (as clinically 
indicated) are recommended prior to commencement of antimicrobial therapy, unless 
this causes excessive delays, in which case treatment should be started even before 
culturing. Imaging studies can be used to aid source identification. Routine 
microbiological cultures should always include at least two sets of blood cultures 
(aerobic and anaerobic) (Rhodes et al. 2017). 
 
Antimicrobial therapy 
The appropriate antimicrobial therapy should be administered intravenously 
within one hour of recognition of severe sepsis or septic shock, relying on a 
combination of one or more such medications in order to obtain a broad spectrum of 
activity towards all potential etiological agents (bacterial, fungal, viral), with adequate 
penetration and concentration in the affected tissues (Kumar et al. 2006; Puskarich 
et al. 2011). The empirical broad spectrum anti-infective treatment should not 
continue beyond 3-5 days and should be reassessed daily and de-escalated as soon 
as possible, based on microbiological results, biomarkers of infection, laboratory 
findings and, most importantly, the overall clinical picture. The duration of 
antimicrobial treatments is usually 7 to 10 days (R P Dellinger et al. 2013; Rhodes et 
al. 2017). Where the patient fails to adequately improve or in cases where source 
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control is not achievable, consideration should be given to prolongation of therapy; 
this is also appropriate for specific infections, such as those caused by fungal 
organisms, in cases of Staphylococcus aureus bacteraemia, or for 
immunocompromised / neutropaenic patients (R Phillip Dellinger et al. 2013; Rhodes 
et al. 2017). 
 
Source control 
Source Control should be achieved as soon as feasible, with early 
consideration of which possible areas are amenable to intervention. This should be 
performed in the least invasive way and without delay (R Phillip Dellinger et al. 2013; 
Rhodes et al. 2017), with the exception of the specific case of peri-pancreatic 
necrotic tissue infection, where it is preferable for treatment to be deferred until non-
viable tissue can be clearly distinguished from the viable (Mier et al. 1997; van 
Santvoort et al. 2010). 
 
Supportive therapy 
Crystalloids are the first choice of fluids to initiate resuscitation (at a dose of 
30 mL/kg), while hydroxyethyl starches should be avoided. Albumin can be used in 
cases requiring excessive crystalloids replacement. Fluid challenge is normally 
continued for as long as it produces hemodynamic improvement (Perner et al. 2012; 
Myburgh et al. 2012; Schortgen et al. 2001; Rhodes et al. 2017). 
When using vasopressor therapy a target mean arterial pressure (MAP) of 65 
mmHg should be aimed for, using noradrenaline (0.01 - 1 μg/kg/min) as first choice 
agent, with the possible addition of vasopressin (0.03 units/min; higher vasopressin 
doses are for salvage therapy only), or substitution with/addition of adrenaline (0.01 - 
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1 μg/kg/min). A higher target MAP (80-85 mmHg) may be of benefit for patients with 
chronic hypertension (Asfar et al. 2014). Dobutamine can be added as inotropic 
agent where indicated (myocardial dysfunction, low cardiac output states), in 
presence of optimised cardiac pre-load conditions and adequate vasopressor 
therapy administration. Hydrocortisone (200 mg/24 hrs) should be reserved for those 
cases where fluid resuscitation and vasopressor / inotropic agents fail to achieve 
haemodynamic stabilization, as recommended by the Surviving Sepsis guidelines (R 
Phillip Dellinger et al. 2013; Rhodes et al. 2017), although the evidence about its 
benefit is still limited (Patel & Balk 2012). A large randomised controlled trial (The 
ADRENAL study) is currently recruiting, with the aim of establishing whether low 
dose corticosteroids are of benefit as adjunctive treatment in critically ill patients with 
septic shock (Venkatesh et al. 2013).  
A target haemoblobin of at least 7 g/dL should be aimed for unless there are 
conditions such as concurrent myocardial ischemia, severe hypoxemia, acute 
hemorrhage, ischemic heart disease, requiring higher haemoglobin levels (R Phillip 
Dellinger et al. 2013; Rhodes et al. 2017). Although anaemia may be associated with 
a poor outcome, data on the effects of blood transfusion is conflicting, with most 
reports not demonstrating benefit from transfusion aimed at achieving a higher 
haemoglobin threshold (Hébert et al. 1999; Holst et al. 2015). 
Fresh frozen plasma (FFP) is not recommended to correct laboratory clotting 
abnormalities in case of non-bleeding patients. In patients with severe sepsis, 
platelets should be infused when counts are <10,000/mm3 (10 x 109/L), even in 
absence of obvious bleeding. The threshold for platelets administration should be 
increased to 20,000/mm3 (20 x 109/L) where significant risk of haemorrhage is 
present. Even higher platelet counts (≥50,000/mm3 or 50 x 109/L) are recommended 
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in case of active bleeding, or when surgical or invasive interventions are planned (R 
Phillip Dellinger et al. 2013; Rhodes et al. 2017). 
Invasive mechanical ventilation of sepsis-related acute respiratory distress 
syndrome (ARDS) should be based on a lung-protective strategy (Brower et al. 
2000), using tidal volumes of 6 mL/kg of ideal body weight, plateau pressures ≤30 
cm H2O and application of positive end-expiratory pressure (PEEP). Higher levels of 
PEEP are applied to patients with sepsis-induced moderate or severe acute 
respiratory distress syndrome (ARDS), with prone positioning reserved for severe 
cases (Pao2/Fio2 ratio ≤100 mm Hg) (Ranieri et al. 2012; Brower et al. 2000; Brower 
et al. 2004; Rhodes et al. 2017). 
Mechanical ventilation should be performed with head elevation (30-45 
degrees), adequate sedation and analgesia, and titrated to pre-specified and 
personalised targets, avoiding excessive sedation. Protocol based daily interruptions 
of sedation can be performed in order to facilitate extubation, accompanied by the 
use of a weaning protocol (Kress et al. 2000; Girard et al. 2008; Mehta et al. 2012). 
Neuro-muscular blocking agents (NMBAs) can be used in ventilating patients with 
severe ARDS, as they have been demonstrated to improve survival and increase 
ventilator-free time without increasing muscle weakness (Papazian et al. 2010; 
Rhodes et al. 2017). 
A fluid strategy aimed at maintaining an even fluid balance should be, ideally, 
relied upon in patients with sepsis-induced ARDS, in the absence of tissue 
hypoperfusion (Acheampong & Vincent 2015; Sirvent et al. 2015; Alsous et al. 2000; 
Rhodes et al. 2017). 
When two consecutive blood glucose readings are above the threshold of 180 
mg/dL (10 mmol/L), glycaemic control should be initiated based on protocols, aiming 
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to keep blood glucose levels below such limit. Blood glucose monitoring should be 
carried out one to two hourly until euglycaemia is reached and every four hours once 
this is achieved. Tight glycaemic control is no longer recommended (Van den Berghe 
et al. 2001; Van den Berghe et al. 2006; The NICE-SUGAR Study Investigators 
2009; Rhodes et al. 2017). 
Renal replacement therapies in the form of continuous and intermittent 
treatment are deemed equivalent in efficacy for managing septic patients with acute 
renal failure, with continuous strategies preferred in the hemodynamically unstable 
septic patients and for the purpose of fluid management (Ronco et al. 2015; Rhodes 
et al. 2017). 
Stress ulcer prophylaxis should be provided in the form of proton pump 
inhibitors (PPIs) or anti-hystamines (H2 receptor blockers) according to the Survivng 
Sepsis guidance (Plummer et al. 2014; Rhodes et al. 2017). 
Nutrition should be maintained preferably by oral means, or via the enteral 
route, at least in the first instance. If the oral/enteral routes fail to achieve adequate 
nutritional intake, parenteral nutrition should be instituted with specialist guidance, 
but usually not within the first 7 days of critical illness (Casaer et al. 2011; Mueller et 
al. 2011; Cove & Pinsky 2011; Rhodes et al. 2017). 
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1.1.5 Prognosis 
Mortality from sepsis increases with worsening severity and an increasing 
number of organs affected: it rises from 25-30% for severe sepsis up to 40-70% for 
septic shock, reaching 90% with five organ system failure (Padkin et al. 2003; Lever 
& Mackenzie 2007). 
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1.1.6 Generic severity of disease classification and scoring systems for prognostic 
evaluation 
 
Numerous severity of disease classification and scoring systems have been 
employed for the purposes of either predicting outcomes in patients suffering with 
sepsis or simply describing a sequence of organ/system deteriorations or 
improvements. Both disease-independent (generic) and disease-specific systems 
exist. The most commonly used generic scoring systems are: 
 APACHE II (Acute Physiology and Chronic Health Evaluation II) score 
(Knaus et al. 1985)  
 SOFA (Sepsis-related Organ Failure Assessment) score (Vincent et al. 
1996)  
 
Table 1 summarises the characteristics of these two generic scoring systems. 
Disease specific scoring systems have also been developed. Those relevant to 
peritonitis are described in a subsequent section. 
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1.1.6.1 APACHE II score 
The APACHE II score was developed and validated by Knaus and co-workers 
in the 1980s (Knaus et al. 1985). The APACHE II score includes three components: 
the acute physiology score (APS), the age and the chronic health components. The 
acute physiological part of the score assigns points based on the values of 12 
routine physiological measurements on admission to intensive care (temperature, 
mean arterial pressure [MAP], heart rate, respiratory rate [RR], oxygenation, arterial 
pH, serum sodium [Na], serum potassium [K], serum creatinine, haematocrit [Ht], 
white blood cell count [WCC] and Glasgow coma score [GCS]). The age component 
assigns points based on the patient’s age, according to 5 pre-specified ranges, while 
the chronic health part of the score evaluates the previous health status and, in 
particular, the presence of severe pre-existing organ system failure, immuno-
compromise and operative status (non-operative, elective or emergency). The sum 
of these three components (ranging from 0 to 71) can be interpreted as providing an 
overall measure of disease severity. The score was found to correlate closely with 
hospital mortality in 5815 intensive care patients from 13 hospitals. The APACHE II 
score, used together with an accurate description of disease, can stratify acutely ill 
patients based on prognosis (Knaus et al. 1985).  
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1.1.6.2 SOFA score 
The SOFA score was devised by Vincent and co-workers, on behalf of the 
European Society of Intensive Care Medicine (ESICM) in 1994, with the aim of 
setting criteria for the definition of a scale indicating the level of organ dysfunction, 
over time, for the various organs/systems identified (Vincent et al. 1996). The score 
was developed with the major aims of, first, aiding the comprehension of the natural 
evolution of organ dysfunction, by quantifying the various organs’ improving or 
deteriorating function with a numerical descriptor, second, describing the relationship 
between the various failing organs, and, third, evaluating the effects of therapeutic 
interventions, by assessing the impact on the relevant organs’ function. The score 
assigns a value ranging from 0 to 4 for each of the six organ systems assessed 
(respiratory, coagulation, liver, cardiovascular, central nervous system [CNS] and 
renal) (Vincent et al. 1996). Although the score was originally devised for the 
purpose of tracking and describing changes in various organs’ function/dysfunction 
over time, it is often also employed as a prognostic tool. Multiple studies have 
reported using the SOFA score, both in isolation (Hynninen et al. 2008; van Ruler et 
al. 2011; van Ruler, Lamme, et al. 2007; Sumi et al. 2014; Jones et al. 2009) and in 
combination with other parameters (Zügel et al. 2011; Matsumura et al. 2014), for 
outcome prediction. 
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Table 1 Characteristics of the APACHE II and SOFA generic scoring systems 
Name  
 
range Factors evaluated 
APACHE II 
(Knaus et al., 1985) 
0-71 - Acute physiological derangement (12 
variables) 
- Age 
- Chronic Health 
SOFA  
(Vincent et al., 1996) 
0-24 - respiratory system 
- coagulation 
- liver 
- cardiovascular system 
- CNS 
- renal system 
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1.2 Peritonitis  
 
1.2.1 Definition of peritonitis 
Peritonitis is a potentially lethal condition, characterised by inflammation of the 
serosal membrane lining the abdominal cavity and the intra-abdominal organs. It 
frequently occurs in association with infection within the intra-peritoneal cavity, 
usually accompanied by bacteraemia and sepsis or septic shock (Longo et al. 2011; 
Berger & Buttenschoen 1998; Calandra & Cohen 2005).  
 
1.2.2 Classification of peritonitis 
Depending on the underlying physio-pathological mechanism, peritonitis may 
be infective (where the inflammatory reaction is induced by microbiological 
organisms) or sterile (where a microbiological cause has been excluded).  
 
Peritonitis has been classified as primary, secondary and tertiary (Longo et al. 
2011; Berger & Buttenschoen 1998; Calandra & Cohen 2005). 
Primary peritonitis is a peritoneal infection arising without any anatomical 
damage to the intra-abdominal organs, with invasion of the peritoneal cavity via a 
haematic, lymphatic or luminal route (as in the context of ascites with liver cirrhosis 
or peritoneal dialysis) (Longo et al. 2011; Berger & Buttenschoen 1998; Calandra & 
Cohen 2005). 
Secondary peritonitis develops as a consequence of bacterial or non bacterial 
contamination of the peritoneum as a result of leakage from an intra-abdominal 
viscus. Secondary bacterial peritonitis can result from anastomotic breakdown, 
abscess formation, perforation, ischaemia or necrosis, penetrating injury to the intra-
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abdominal contents, or any other event causing loss of barrier function of the gastro-
intestinal tract or any other intra-abdominal organ, with consequent bacterial spread 
from organs normally or pathologically colonised with bacteria or containing some 
other inflammatory substance, such as gastric acid. 
Tertiary (or persisting) peritonitis has been defined as “peritonitis persisting or 
recurring after 48 hours following apparently successful management of primary or 
secondary bacterial peritonitis” (Longo et al. 2011; Berger & Buttenschoen 1998; 
Calandra & Cohen 2005). 
Depending on the site of leakage, the local inflammation can be mainly due to 
chemical irritation (for example in case of acidic gastric content with relatively low 
burden of organisms) or bacterial load (in case of faecal soiling) (Longo et al. 2011). 
Faecal peritonitis is a specific type of secondary bacterial peritonitis related to 
spillage of faecal material into peritoneum. Almost inevitably the microbiology of 
secondary peritonitis is characterized by a multi-microbial flora, with predominant 
facultative Gram-negative bacilli and anaerobes, especially when the origin is 
colonic. The most common isolates are Gram negative Bacilli, such as Escherichia 
coli, other Enterobacteriaceae, and anaerobes, in particular Bacterioides fragilis. 
(Longo et al. 2011; Berger & Buttenschoen 1998; Calandra & Cohen 2005). It also 
involves Gram-positive cocci such as enterococci and in the upper gastrointestinal 
tract can also involve viridans Streptococci (Streptococcus mutans, milleri group, 
mitis, oralis, sanguinis, sobrinus); it is important to mention the role of Candida spp., 
particularly in those patients recently treated with broad spectrum antimicrobials 
(Longo et al. 2011; Berger & Buttenschoen 1998; Calandra & Cohen 2005). 
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The normal colonic flora below the ligament of Treitz contains approximately 
1011 anaerobic organisms per gram of faeces and 108 aerobes per gram. Anaerobic 
species constitute the overwhelming majority of bacteria (Longo et al. 2011). 
 
48 
 
1.2.3 Pathophysiology of peritonitis 
As inflammation develops, organisms contaminate the sterile peritoneal 
cavity. Intraperitoneal infections cause a severe systemic inflammatory response. 
Peritoneal defence mechanisms will aim at localising and isolating the infection and, 
where the untreated patient survives, the natural history usually involves evolution to 
a peritonitic phase of infection and abscess formation (Berger & Buttenschoen 1998; 
Calandra & Cohen 2005; Wittmann et al. 1996).  
The initial phase of the inflammatory response is characterised by peritoneal 
macrophage activation, which respond and release pro-inflammatory cytokines.  The 
inflammatory response is responsible for direct and indirect damage to tissues. 
Bacteria, viruses, and fungi have specific molecules on their external surfaces which 
are recognised by toll like receptors (TLRs) of immune cells. The lipopeptides of 
gram-positive bacteria and the lipopolysaccharide of gram-negative bacteria are 
capable of binding to TLR2 and TLR4, respectively. Activation of the TLR2 and TLR4 
receptors is transduced at intracellular level with the activation of the cytosolic 
nuclear factor kB (NF-kB). The NF-kB factor binds to transcription initiation sites to 
increase intra-nuclear transcription of cytokines, such as Tumour Necrosis Factor α 
(TNF-α), Interleukin-1β (IL-1β), and interleukin-10 (IL-10). TNF-α and IL-1β (pro-
inflammatory cytokines) trigger the adaptive immune response and add to the 
inflammatory injury. IL-10 has various anti-inflammatory effects, including the 
inactivation of macrophages. Endothelial cells, activated by the cytokines, are 
responsible for enhanced adhesion and recruitment of neutrophils, monocytes, 
macrophages, and platelets, with subsequent additional release of pro-inflammatory 
mediators (proteases, oxidants, prostaglandins, and leukotrienes), responsible for 
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direct damage to endothelial cells, increased permeability, vasodilation, and 
alteration of the coagulation balance (Russell 2006). 
Macrophages and other leukocytes capable of phagocytosis are also 
responsible for removing dead host cells, via the process of efferocytosis. This is an 
important process of inflammation resolution (Martin et al. 2014).  
 
1.2.4 The management of peritonitis 
Management of secondary peritonitis requires a combination of surgical 
treatment (Wittmann et al. 1996), source control, medical and supportive therapy, 
with timely administration of empirical antimicrobial regimens (Wong et al. 2005; 
Solomkin et al. 2010).  
A Cochrane review conducted by the Colorectal Cancer Group aimed at 
ascertaining the efficacy of different antimicrobial regimens in treating intra-
abdominal infections in adults. The review included randomised and quasi-
randomised controlled trials comparing different treatment regimens. Forty studies 
were included, with a total of 5094 adult patients, comparing 16 different regimens. 
All antimicrobials showed approximate equivalence in terms of clinical success and 
the mortality did not differ between different regimens. The review therefore made no 
specific recommendations for first line antimicrobial treatment in secondary 
peritonitis (Wong et al. 2005). The advantage of routinely adding antifungals remains 
unclear. Khoury and co-workers evaluated the effects of empirical anti-candida 
treatment in a retrospectively gathered cohort of patients with peritonitis caused by 
lower gastrointestinal tract perforation. The cohort included generalized faecal / 
purulent peritonitis patients. All patients had undergone exploratory laparotomy and 
had been subsequently admitted to intensive care (Khoury et al. 2010). Two patients’ 
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groups were distinguished: those receiving an empirical course of fluconazole (n=24) 
and those who did not (n=77). All empirically treated patients and 40 of the 77 non 
fluconazole treated group required admission to intensive care unit and were 
included in the authors’ study. Postoperative candida infection and mortality rates 
were similar between the two groups (Candida spp. infection 4% for the treated 
group versus 7% for the untreated group, and mortality 21% for the treated versus 
22.5% for the untreated group, respectively, p value not significant). The authors 
concluded that empirical yeast treatment with fluconazole in patients with perforation 
peritonitis did not improve patients' outcome, although this was not a randomized 
controlled trial, and therefore the possibility of confounding and bias must be 
considered.  The choice of antimicrobial therapy also needs to reflect local trends in 
development of antimicrobial resistance (Sartelli et al. 2011). Timely and judicious 
antimicrobial therapy is important, but ancillary and complementary to the surgical 
treatment of peritonitis, which is paramount to achieve infection source control and 
reduce bacterial and toxins load from the abdominal cavity (Marshall et al. 2004; 
Schein & Marshall 2004; Sartelli 2010).  
The optimal surgical management strategy of severe secondary peritonitis 
has recently been the object of a randomised controlled trial. The RELAP trial 
randomised a total of 232 patients to “on-demand” (n=116) or “planned” (n=116) 
repeat laparotomy, showing no significant difference in the primary end point (death 
and/or peritonitis related morbidity within 12 months). In the case of planned repeat 
laparotomies, these were performed at regular intervals (1-2 days) after the initial 
laparotomy, until the abdomen was deemed macroscopically clean. In the on-
demand repeat laparotomy group, the repeat laparotomy was performed in cases 
where patients were clinically deteriorating, after ruling out other possible (non-
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abdominal) causes. Direct medical costs were reduced by 23% using the on-demand 
strategy (van Ruler, Mahler, et al. 2007). 
 
1.2.5 Natural history and assessment of prognosis in peritonitis 
The mortality rates of patients with secondary peritonitis reported in the 
literature vary widely between 5.8% and 63% (Berger & Buttenschoen 1998; 
Wittmann et al. 1996; Sartelli et al. 2011; Sartelli 2010; van Ruler, Mahler, et al. 
2007). This large variability possibly reflects differences in the studied populations, 
the type and severity of disease and the treatment practices.  
While there is a wealth of literature related to secondary peritonitis from 
multiple causes, studies specifically investigating faecal peritonitis tend to be less 
common. Nevertheless, despite the relative paucity of data, this specific sub-set of 
peritonitis patients is rather frequent. According to the Intensive Care National Audit 
and Research Centre (ICNARC) database (https://www.icnarc.org/) faecal peritonitis 
represents 2.8% of all ICU admissions in the UK. 
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1.3 Prognostic factors and scoring systems in peritonitis 
 
In order to understand the evidence published so far on the topic of prognostic 
evaluation in faecal peritonitis, a literature search was conducted. 
 
1.3.1 Strategy for reviewing the literature    
 
Before commencing my project I performed a review of the literature to 
determine the extent of knowledge related to faecal peritonitis. Prior to commencing 
the search, I drafted a review protocol, to determine the databases to be searched, 
the search modality and keywords, inclusion criteria for the review, data extraction 
and aggregation methodology. 
Eligibility criteria for inclusion in the review were: 
 Studies involving adult patients specifically suffering with faecal 
peritonitis and admitted to ICUs 
 Studies evaluating prognostic factors or indices in faecal peritonitis 
 
The NHS Health Information Resources web interface was adopted 
(http://www.library.nhs.uk/booksandjournals/default.aspx), which allows 
simultaneous searching of all major scientific literature databases, including 
MEDLINE (1950 – present), EMBASE (1980 – present), CINAHL (1981 – present), 
and other resources.  
The search was performed in January 2013 and aimed at identifying studies 
meeting all of the above eligibility criteria. The search strategy used the following 
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string: “((((faecal) OR fecal) AND peritonitis) AND (mortality OR death) AND 
(prognosis OR outcome)).ti,ab”. 
There were neither temporal nor language restrictions. I did not include grey 
literature (academic literature that is not formally published, or not divulgated within 
the traditional commercial or academic distribution or publishing channels).  
 
1.3.2 Review findings 
A total of 102 records were identified through database searching. These 
included 44 duplicate results, which were removed. The remaining records were 
screened and assessed for eligibility. Of the non-duplicated 58 records, 18 pertained 
to studies performed on laboratory animals or experimental models. Of the remaining 
40 conducted on humans, 22 were conducted on non-ICU patient outcomes or 
examined different patient populations altogether (such as those with any cause of 
secondary peritonitis, or selected patients with chronic ambulatory peritoneal 
dialysis, iatrogenic post-colonoscopy, cancer-associated, diverticulosis-related or 
post-radiation-damage perforations), 15 were related to the illustration and 
description of new surgical techniques or other aspects of surgical treatment (such 
as post-operative management and/or complication rates) rather than post-operative 
outcome of the critically ill with the condition, 4 were case reports or small case 
series, 4 specifically investigated the role of microbiological aetiology, patterns of 
antimicrobial resistance and antimicrobial regimens. Some of the studies had more 
than one characteristic that made them not useful for the purposes of evaluating 
prognostic factors in critically ill patients with faecal peritonitis in the post-operative 
phase. 
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Only two records were identified which reported outcomes of faecal peritonitis 
specifically in the ICU setting, and both were only reported in the form of conference 
abstracts (Pawa et al. 2009; Sayer et al. 2012). The characteristics of the two 
abstracts retrieved are summarized in Table 2. The difference in mortality rates 
reported in the two studies is marked. Sayer et al. reported in-hospital mortality rates 
of 21.6% and 38.1%, for the malignancy and non-malignancy sub-groups 
respectively, while Pawa et al. reported 30 days mortality rates of 46% for patients 
aged <75 years and 78% for patients aged > 75 years, suggesting that, despite the 
fact that both studies have been conducted in the ICU setting, other factors must 
have influenced outcomes, such as local practices of admission to ICU, periods 
considered, evolution in concurrent treatments and underlying characteristics of the 
populations (other than admission diagnosis). Neither of the two abstracts reported 
microbiological isolates. Pawa and co-workers report age as the strongest factor 
influencing outcome. The effect of potential confounding factors appears not to have 
been fully explored by the authors. The study from Sayer and colleagues suggests 
that hypo-albuminaemia and the presence of malignancy influence outcome. The 
authors of both studies were contacted for further information, but no additional data 
could be obtained. 
Figure 1 details the review flow of information diagram, as per the PRISMA 
statement guidance (Moher et al. 2009). Altogether this emphasises the limited data 
available on this topic in the existing literature and highlights the need for 
investigating this condition further. 
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Figure 1 Flow of information diagram 
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Table 2 Characteristics of previously reported prognostic studies specifically 
conducted on patients suffering with faecal peritonitis admitted to ICU 
Author, 
Country, 
year of 
publication 
Number of 
FP patients 
included 
Study design 
and period 
Reported 
overall 
mortality 
rates 
Factors 
identified as 
influencing 
outcome 
 
Microbiologi
cal data 
reported? 
Pawa et al. 
UK, 
2009 
(Pawa et 
al., 2009) 
360  single UK 
centre 
retrospective 
cohort 
(1990-2007) 
46% (30 day 
mortality, age 
<75 years) 
 
78% (30 day 
mortality, age 
>75 years) 
 
age No 
Sayer et 
al. 
UK, 
2012 
(Sayer et 
al., 2012) 
133  single UK 
centre 
retrospective 
cohort 
(2005-2012) 
21.6% 
hospital 
mortality 
(malignancy 
group)  
 
38.1% (non-
malignancy) 
 
malignancy 
(protective) 
hypo-
albuminaemia 
No 
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1.3.3 Prognostic evaluation in secondary peritonitis 
Given the scarcity of data with which to inform prognostic evaluation 
specifically in faecal peritonitis patients, some inferences may be appropriate, based 
on evidence surrounding secondary peritonitis in general. 
Prognostic evaluation of complex intra-abdominal infections, in general, is 
important to assess severity and predict outcome. A multiplicity of disease-specific 
and generic (disease-independent) scoring systems have been devised and tested, 
with the purpose of helping in the process of prognostication. I have described the 
APACHE II and the SOFA scores in one of the previous sections. These are disease 
independent scores, but surgical and peritonitis specific scores have been 
developed, such as the Mannheim Peritonitis Index (MPI) and the Peritonitis Index 
Altona II (PIA II) (Linder et al. 1987; Wittmann et al. 1987). I will now describe these 
disease-specific scoring systems. 
 
 
The Mannheim Peritonitis Index (MPI) 
The MPI was developed by Linder and colleagues in 1982-1984. It includes 
several factors to allow prognostic evaluation of abdominal sepsis: age (using a 
single cut-off of 50 years), female gender, organ failure (cardiovascular, respiratory, 
intestinal, renal), presence of malignancy, pre-operative duration of peritonitis 
(greater or less than 24 hours), non-colonic origin of sepsis, presence of diffuse 
generalized peritonitis and type of exudate (clear, cloudy/purulent or faecal) (Linder 
et al. 1987). 
The performance of the MPI was evaluated by Billing and others for a set of 
different populations in a study including 2003 patients from seven European 
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centres. When using a threshold score of 26, the sensitivity was measured as 86% 
(range 54-98%), the specificity as 74% (range 58-97%) and the accuracy in 
predicting mortality as 83% (range 70-94%). For patients with MPI<21 the mortality 
rate was 2.3% (range 0-11%), for MPI in the range 21-29 mortality rose to 22.5% 
(range 10.6-50%), while the mortality was 59.1% (range 41-87%) for MPI>29 (Billing 
et al. 1994).   
 
 
The Peritonitis Index Altona II 
The Peritonitis Index Altona II (PIA II) was developed by Wittmann and 
colleagues and published in 1987. A cohort of 567 patients who had undergone 
surgical intervention for infections of intra-abdominal origin was used to identify 
variables which could discriminate between survivors and non-survivors. The authors 
relied on discriminant analysis to rank the variables in order of usefulness in 
classifying patients as likely survivors versus non survivors. The variables selected 
for this purpose were: male sex, age (with a 60 years cut-off), duration of infection 
longer than 48 hours, congestive heart failure (CHF), insulin-dependent diabetes 
mellitus (IDDM), white cell count (WCC) <5 or WCC >26 ×109/litre, creatinine, extent 
and cause of peritonitis (mesenteric infarction, intestinal strangulation, perforated 
peptic ulcer, perforated appendix, perforated colon). The PIA II was found to 
correctly classify 89% of all patients in the derivation cohort, and 81.4% of the 
validation group (Wittmann et al. 1987).  
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Multiple factors, including age, markers of nutritional state, comorbidities, 
coexistence of sepsis, extent of organ failures, time from onset of faecal peritonitis to 
surgical intervention and source control, have been reported in other studies to 
influence outcome (Christou et al. 1993; Ohmann et al. 1993; Demmel et al. 1994; 
Billing et al. 1994; McLauchlan et al. 1995; Pacelli et al. 1996; Koperna & Schulz 
2000; Koperna et al. 2001; Mulier et al. 2003; Scapellato et al. 2004; Notash et al. 
2005; Horiuchi et al. 2007; Torer et al. 2010; Singh et al. 2011). 
The characteristics of some of the studies examining factors influencing 
outcome in peritonitis are summarised in Table 3. It must be emphasised that studies 
included in this Table report mortality rates regarding heterogeneous populations 
and measured at different time points; the Table specifies the proportion of patients 
with peritonitis of colo-rectal origin. It is noteworthy that many studies did not report 
microbiological isolates and that, for the ones where microbiological isolates were 
described, no relation was reported between type of microbial isolate and outcome. 
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Table 3 Characteristics of previous prognostic studies of patients with peritonitis 
 
Author, 
Country, year 
of publication 
Number and 
characteristics 
of patients 
included 
Number 
(%) in 
colo-rectal 
origin 
subset 
Study design and aims Reported mortality rates  Factors identified as 
influencing outcome 
Microbiological 
data reported 
Christou et al. 
Canada, 1993 
(Christou et 
al., 1993) 
239 
Surgical 
abdominal 
infection with 
APACHE 
II>10 
35 
(14.6%) 
multi-centre, non-
randomized, un-
blinded trial, aimed at 
comparing two 
surgical techniques 
31% (peri-operative – 
closed arm) 
44% (peri -operative- open 
arm) 
42% (re-operation group) 
27% (non-reoperation 
group) 
APACHE II 
low albumin 
NYHA  
Yes (no influence 
on outcome 
reported) 
Ohmann et al. 
Germany, 
1993 
(Ohmann et 
al., 1993) 
271 
Laparotomy 
confirmed 
peritonitis 
49 
(18.1%) 
prospective, 
multicentre cohort, to 
evaluate three scoring 
systems (APACHE II, 
MPI, PIA II) 
37.6% (at 30 days, of 
which 21% post-operative 
79% due to infection) 
22% (at 30 days – large 
bowels perforation subset) 
APACHE II 
MPI 
PIA II 
No 
Demmel et al. 
Germany, 
1994 (Demmel 
et al., 1994) 
438 Intra-
abdominal 
infection 
(multiple 
causes) 
55 
(12.6%) 
prospective, single 
centre cohort to 
validate MPI  
14.4% (peri-operative) pre-operative shock 
MPI 
concomitant disease 
sepsis 
No 
Billing et al. 
Germany 
1994 (Billing et 
al., 1994) 
2003 
Peritonitis 
(multiple 
causes) 
not 
reported 
prospective, 
multicentre cohort to 
evaluate MPI 
19.5% (peri-operative) MPI No 
McLauchlan et 
al. 
UK, 1995 
(McLauchlan 
et al., 1995) 
125 
Abdominal 
sepsis 
admitted to 
ICU 
37 
(29.6%) 
retrospective, single 
centre cohort to 
assess factors 
associated with 
outcome 
63% (Hospital) age 
APACHE II 
Acute Physiology of 
APACHE II 
female sex 
source control 
No 
Pacelli et al. 
Italy, 1996 
(Pacelli et al., 
1996) 
604 
Intra-
abdominal 
infections 
(multiple 
causes) 
 
42 (7%) retrospective, single 
centre, case series to 
identify outcome 
predictors and 
compare three 
scoring systems 
13.9% (peri-operative, 
overall) 
26.2% (peri-operative, 
large bowel origin 
subgroup) 
APACHE II 
MPI 
low albumin 
low cholesterol 
pre-operative organ 
impairment 
Yes (no influence 
on outcome 
reported) 
Koperna et al.  
Austria, 2000  
(Koperna and 
Schulz, 2000) 
523 
secondary 
peritonitis 
not 
reported 
retrospective single 
centre, case-control 
study to compare 
planned (PR) versus 
on demand (OR) 
repeat laparotomy 
54.5% (peri-operative – 
PR group) 
50.6% (peri-operative - 
OR group) 
age 
low albumin 
APACHE II 
Goris MOF 
delayed repeat 
laparotomy 
No 
Koperna et al.  
Austria, 2001  
(Koperna et 
al., 2001) 
85 
emergency 
surgical ICU 
admissions 
with APACHE 
II>10 
not 
reported 
prospective, single 
centre cohort to 
evaluate reliability of 
APACHE II score 
31.7% (ICU) APACHE II No 
Mulier et al.  
Belgium, 2003 
(Mulier et al., 
2003) 
96 
Generalized 
postoperative 
peritonitis 
admitted to 
ICU 
43 
(44.8%) 
retrospective, single 
centre audit to identify 
outcome predictors 
25% (ICU) 
30.2% (Hospital) 
source control  
age 
unconsciousness 
 
No 
Scapellato et 
al.  
Italy, 2004 
255 
Secondary 
acute 
32 
(12.5%) 
retrospective, single 
centre case series to 
identify outcome 
5.8% (peri-operative) MPI 
time to operation 
No 
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(Scapellato et 
al., 2004) 
peritonitis predictors 
Notash et al. 
Iran, 2005 
(Notash et al., 
2005) 
80 
secondary 
peritonitis 
20 (25%) prospective, single 
centre cohort to 
evaluiate MPI 
and Goris MOF 
17.5% (hospital) MPI 
Goris MOF 
No 
Horiuchi et al.  
China, 2007 
(Horiuchi et 
al., 2007) 
26 
colonic 
perforation 
26 (100%) retrospective, single 
centre case series, to 
evaluate three scoring 
systems (APACHE II, 
MPI, PIA II) 
23.1% (peri-operative) APACHE II 
hypotension 
raised creatinine 
No 
Torer et al. 
Turkey, 2010 
(Torer et al., 
2010) 
56 
re-operation  
(post-
operative 
peritonitis) 
27 
(48.2%) 
retrospective, single 
centre case series to 
identify outcome 
predictors 
32.1% (peri-operative) Goris MOF 
time to reoperation 
severity of peritonitis 
source control 
MPI 
No 
Singh et al. 
India, 2011 
(Singh et al., 
2011) 
84 
emergency 
perforation 
peritonitis  
0 (0%) prospective, single 
centre cohort to 
identify outcome 
predictors 
17.8% (peri-operative) age 
MPI 
duration of symptoms 
pre-operative 
glycaemia 
urea 
creatinine 
No 
van Ruler et 
al. 
The 
Netherlands 
2011 
(van Ruler et 
al., 2007, van 
Ruler et al., 
2011) 
221 (of 232 
from RCT) 
secondary 
peritonitis with 
APACHE II > 
10 
147 
(71.3%) 
Subset from a 
randomized, non-
blinded multicentre 
trial to evaluate the 
predictive value of 
multiple scoring 
systems  
28.6% (12 months- OR 
arm)  
36.3% (12 months- PR 
arm) 
APACHE II 
SAPS II 
MPI 
MODS 
SOFA 
APS 
No 
 
FP = faecal peritonitis, NYHA = New York Heart Association class, APACHE II = 
Acute Physiology and Chronic Health Evaluation II score, APS = acute part of 
APACHE II score, MPI = Mannheim Peritonitis Index, PIA II = Peritonitis Index 
Altona II, Goris MOF = Goris Multiple Organ Failure score, MODS = Multiple 
Organ Dysfunction Score, RCT = Randomized Controlled Trial, ICU = 
Intensive Care Unit, PR = planned repeat laparotomy, OR = on demand 
repeat laparotomy 
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Christou et al. performed a non-blinded, non-randomised trial of 239 patients 
treated with two different surgical techniques, in which the abdomen could not be 
closed at the first operation in a small proportion of the patients (the “open abdomen” 
group). The authors stated that there was no statistically significant difference 
between the two techniques, reporting mortality rates of 31% and 44% for patients 
treated with a "closed-abdomen" and those treated with variations of the "open-
abdomen" technique, respectively. Variables assessed by the authors as potential 
predictors of mortality were the type of surgical technique used (open versus closed) 
and other operative factors, origin of peritoneal contamination, previous medical 
treatments (radiotherapy, steroids, chemotherapy), presence of malignancy, 
comorbidities (renal failure, diabetes, smoking history) and pre-operative 
haematological and biochemical variables including haematocrit and bilirubin. After 
inclusion in multivariate analysis models, to account for confounding factors, this 
study found no influence of age or site of origin of peritoneal contamination on 
mortality; only the APACHE II score, serum albumin level, and New York Heart 
Association (NYHA) cardiac function status were significantly and independently 
associated with mortality. These findings appear to contradict the authors’ beliefs 
that the site of peritoneal contamination is a factor influencing mortality, as they use 
this argument to justify extreme variability of mortality rates amongst previously 
reported studies. Only 35 (14.6%) of the patients in the trial had suffered peritonitis 
as a consequence of disease of colorectal origin, hence its findings may not be 
applicable to the faecal peritonitis population (Christou et al. 1993). 
Ohmann et al. performed a prospective multicentre study involving 271 
patients from 12 surgical departments in Europe. The patients had peritonitis 
confirmed at laparotomy and the study aimed to identify factors predictive of mortality 
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within 30 days of operation, relying on each of three scores: APACHE II, MPI and 
PIA II. The assessment involved performing ROC curve analysis, as well as 
evaluating sharpness (degree of confidence associated with each prediction) and 
reliability (agreement between observed and predicted mortality). Thirty day mortality 
was 37.6% for the whole cohort, and 22% for the large bowel perforation subset. 
APACHE II was found to be superior to both MPI and PIA II in terms of 
discriminatory ability (ROC curve analysis) and reliability, but the other two scores 
were better at making "sharp" predictions. The authors concluded that none of the 
three scores can be relied upon to make outcome predictions for individual patients. 
The report specifies that 49 (18.1%) of the patients in the study had peritonitis of 
large bowel or rectal origin, which makes it difficult to generalize their findings and 
conclusions to the faecal peritonitis population (Ohmann et al. 1993). 
Demmel et al. conducted a prospective, single centre cohort study of 438 
patients with abdominal infection. The study aimed to evaluate the prognostic value 
of single clinical variables and the MPI. The large majority (300) of the patients 
enrolled were managed with a “closed” approach, by percutaneous drainage, while 
138 underwent planned repeat laparotomies. The mortality was 14.4% (63 patients). 
On stepwise logistic regression analysis pre-operative shock, MPI, concomitant 
disease and sepsis were all independent predictors of outcome. Only 55 (12.6%) of 
the patients in the study could be classified as having peritonitis of colo-rectal origin 
(Demmel et al. 1994). 
The largest study on prognostic evaluation of secondary peritonitis was 
conducted by Billing et al., who evaluated the sensitivity, specificity and accuracy of 
the MPI in 2003 patients from seven separate surgical centres in three European 
countries. The study included a wide variety of patients and reported a relatively low 
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mortality rate (19.5%), suggesting that the population considered was, overall, of 
lower prognostic risk compared to other studies. This study was specifically designed 
to evaluate the MPI prognostication capacity, and it is unclear what percentage of 
the patients included suffered from peritonitis of colo-rectal origin (Billing et al., 
1994).  
McLauchlan et al. studied 125 patients with abdominal sepsis admitted to 
critical care, evaluating the influence of age, diagnosis, APACHE II score and its 
subcomponents (the Acute Physiology component and the Chronic Health 
Evaluation components), coexisting diseases, time to operation, to ICU admission, 
length of stay in ICU, ward and hospital, site and type of sepsis source, presence of 
septic shock and success in clearance of the focus of infection. At multiple linear 
regression analysis age, APACHE II score and its Acute Physiology component, 
clearance of infection and gender were all significantly and independently associated 
with outcome, while delay to surgery, anastomotic leakage and presence of 
malignancy did not influence survival significantly. The hospital mortality rate was 
63%, suggesting a rather unwell patient sample. In the subset of patients with 
colonic origin of sepsis (37, 29.6%), those with faecal peritonitis tended to have a 
worse outcome than those with non-faecal peritonitis (McLauchlan et al., 1995). 
Pacelli et al. studied 604 consecutive patients who underwent emergency 
operations for intra-abdominal infections, including postoperative cases. They 
assessed the influence of age, sex, type (spontaneous versus postoperative) and 
extent of infection (localized versus diffuse), preoperative haematological and 
biochemical markers (albumin, cholesterol, haemoglobin, lymphocyte count) intra-
operative factors, pre-operative organ impairment, APACHE II score, the sepsis 
score of Elebute and Stoner, and the MPI. The authors found that by multivariate 
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logistic regression analysis APACHE II, MPI, hypoalbuminaemia, 
hypocholesterolaemia and preoperative organ impairment were independent 
predictors of mortality. Only 42 (7%) of the patients in the study had peritonitis of 
colo-rectal origin; their peri-operative mortality was 26.2%, much worse than for the 
overall cohort (13.9%). The authors also reported microbiological isolates, but a link 
was not established with outcome (Pacelli et al., 1996). 
Koperna et al retrospectively reviewed 523 consecutive patients with 
secondary peritonitis, specifically focussing on 105 patients, in whom standard 
surgical treatment of secondary peritonitis failed and who had to undergo repeat 
laparotomy for persisting abdominal sepsis. Patients with age above 70 years, with 
diffuse secondary peritonitis, with a greater degree of physiologic compromise (hypo-
albuminaemia, preoperative APACHE II scores above 20, and organ failure) were 
shown to be at higher risk of persistent intra-abdominal infection. The peri-operative 
mortality was 54.5% for the planned repeat laparotomy subset and 50.6% for the on 
demand repeat laparotomy group. Timely decisions about repeat laparotomy 
provided the only surgical option able to significantly improve outcome in this subset 
of patients. The number of patients with peritonitis of colo-rectal origin was not 
reported (Koperna & Schulz 2000). 
The same authors studied 85 emergency surgical critically ill patients, to 
evaluate the reliability of APACHE II. There was a significant increase in the 
APACHE II score after surgical intervention, as compared to prior to surgery. The 
ICU mortality was 31.7%. After the initial post-operative increase in the score, a 
continuous decrease in APACHE II in long-term patients from day 7 onwards 
appeared associated with a favourable outcome, while an increase in the APACHE II 
score strongly predicted mortality, although in the individual patient these trends 
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appeared of doubtful clinical significance. It is not clear what proportion of patients 
had peritonitis of colo-rectal origin (Koperna et al., 2001). 
Mulier et al. reported on a retrospective audit on 96 patients with generalised 
postoperative peritonitis (involving the four abdominal quadrants and occurring in the 
first month after an abdominal operation). The authors specifically aimed to assess 
prognostic factors. They evaluated over thirty variables potentially able to predict 
outcome (including age, sex, components of the APACHE II score, a large number of 
surgical and operative factors, source of contamination and therapeutic delay). The 
authors found that age, source control and unconsciousness predicted mortality, 
which was 25% and 30.2%, for ICU and hospital respectively. Forty-three (44.8%) of 
the patients had colorectal origin faecal peritonitis (Mulier et al., 2003). 
Scapellato et al. reviewed the cases of 255 patients with secondary peritonitis 
(only 32 patients, 12.5% of the total, had peritonitis of colo-rectal origin). The 
reported mortality rate was of 5.8%. The authors assessed as potential prognostic 
factors variables such as the aetiology of secondary peritonitis, age, gender, organ 
failures and presence of malignancy, concluding that time to intervention appeared 
the main determinant of outcome in their case series (Scapellato et al., 2004). 
Notash et al. studied 80 patients with secondary peritonitis, of which 20 (25%) 
were of colo-rectal origin. They reported the MPI and the Goris Multiple Organ 
Failure score as helpful predictors of mortality. The hospital mortality was 17.5% 
(Notash et al. 2005).  
Horiuchi et al. reported a small study of 26 patients, with a peri-operative 
mortality of 23.1%. The study focussed solely on peritonitis from colonic perforation, 
and suggested that the APACHE II score was a better predictor of outcome than MPI 
and PIA II (Horiuchi et al. 2007). 
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Torer et al. reported a relatively small series of 56 patients who underwent re-
operation for postoperative secondary peritonitis (27 patients, 48.2%, had colo-rectal 
origin of peritonitis). Amongst the factors assessed, the demographic features, 
comorbidities, presence of malignancy, organ failures, the type and timing of the 
primary operation, intra-operative findings, aetiology of postoperative peritonitis, 
number of repeat laparotomies, source control, MPI, time between first operation and 
repeat laparotomy, and between symptom onset and the second operation were 
evaluated as potential explanatory variables. The overall peri-operative mortality was 
32.1%. In this study, time to surgery and presence of organ failure were found to be 
the main determinants of outcome (Torer et al., 2010). 
A recent study by Singh et al. conducted on a heterogeneous population of 84 
patients with emergency perforation peritonitis, identified age, MPI, duration of 
symptoms, pre-operative glycaemia and markers of renal function (urea and 
creatinine) as useful predictors of outcome, although it did not include any cases of 
peritonitis secondary to contamination from a colorectal source. In this study the peri-
operative mortality was 17.8% (Singh et al., 2011). 
Van Ruler et al. utilized data from 221 patients, originally included in a 
randomized trial comparing two surgical strategies (van Ruler, Mahler, et al. 2007), 
for a second study to evaluate the APACHE II, SAPS II, MPI, MODS, SOFA and 
APS scores (van Ruler et al. 2011). One hundred and forty-seven (71.3%) of the 
patients had peritonitis of colo-rectal origin. Mortality at 12 month follow-up was 
28.6% in the on-demand repeat laparotomy arm, and 36.3% in the planned repeat 
laparotomy one. While all scores performed satisfactorily in predicting mortality, they 
all failed to identify patients with ongoing infection needing repeat laparotomy (van 
Ruler, Mahler, et al. 2007; van Ruler et al. 2011).  
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1.3.4 Limitations of current evidence 
 
1.3.4.1 Risk of bias in retrospective epidemiological studies 
The retrospective nature of many of the studies described above (McLauchlan 
et al., 1995, Pacelli et al., 1996, Koperna and Schulz, 2000, Mulier et al., 2003, 
Scapellato et al., 2004, Horiuchi et al., 2007, Torer et al., 2010) lends itself to the risk 
of selection and information bias. Selection bias can occur when the patients 
included in one study group present different baseline characteristics compared to 
those in the other group: if these characteristics are related to the exposure and/or to 
the outcome being considered the groups may not be comparable. An example of 
this is the study by Khoury and colleagues, retrospectively comparing two non-
randomised samples of patients receiving different treatments (Khoury et al., 2010). 
In this study it is possible (in fact, likely) that patients treated more aggressively with 
empirical anti-candida treatment may have been, at baseline, at higher mortality risk 
than the ones who did not undergo such treatment. Information bias can occur in 
retrospective epidemiological studies where either the exposure or outcome has 
been measured inaccurately “a posteriori”, with the potential of altering any 
association observed between them.  
 
1.3.4.2 Risk of false positive findings 
Many of the studies reported in literature did not perform any corrections for 
multiplicity of testing, which increases the likelihood of chance findings. The more 
tests are performed, the higher the experiment-wise error rate (the chance of a false 
positive finding increases with the number of tests). 
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1.3.4.3 Limited statistical power 
Some of the study populations appear to be too small to afford adequate 
power to detect statistically significant effects on mortality, even where differences in 
mortality were reported (Koperna et al., 2001, Mulier et al., 2003, Notash et al., 2005, 
Horiuchi et al., 2007, Singh et al., 2011, Torer et al., 2010).  
 
1.3.4.4 Heterogeneity of populations examined 
Virtually all of the studies described evaluated very heterogeneous 
populations, instead of focussing on specific aetio-pathological entities, such as 
faecal peritonitis (Christou et al., 1993, Ohmann et al., 1993, Demmel et al., 1994, 
Billing et al., 1994, McLauchlan et al., 1995, Pacelli et al., 1996, Koperna and 
Schulz, 2000, Koperna et al., 2001, Mulier et al., 2003, Scapellato et al., 2004, 
Notash et al., 2005, Torer et al., 2010, Singh et al., 2011, van Ruler et al., 2011). 
 
1.3.4.5 Limitations of the most commonly used scoring system 
The value of the APACHE II score, which has been the most widely utilised 
prognostic tool and has been found to strongly correlate with outcome in peritonitis, 
has been criticised as being unable to take into account factors related to surgical 
intervention, which in turn can potentially alter many physiological parameters. It has 
also been found to over-estimate or under-estimate mortality in low and high risk 
populations (Jones & de Cossart 1999; Moreno & Morais 1997; Fraccalvieri & 
Biondo 2009). APACHE II, like any scoring system, cannot be relied upon for the 
purposes of making prognostic assumptions on an individual patient (Berger & 
Buttenschoen 1998; Koperna et al. 2001; Jones & de Cossart 1999), while 
longitudinal use of APACHE II to detect trends in the ICU has been found to be of no 
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value, since laboratory and physiological parameters can be kept stable or corrected 
in the intensive care setting by providing support to the failing organs and therefore 
addressing physiological and metabolic derangement (Koperna & Schulz 1996). 
 
1.4 Conclusions  
The review of the literature presented in this chapter outlines the evidence 
surrounding secondary peritonitis in general and the scarce epidemiological 
evidence specifically pertaining to the natural history and outcome of patients with 
faecal peritonitis admitted to the critical care setting. 
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1.5 Rationale and opportunity for a new study 
The GenOSept (Genetics Of Sepsis and Septic Shock in Europe, 
https://www.genosept.eu/) study is a pan-European study conceived by the 
European Critical Care Research Network (ECCRN) of the European Society of 
Intensive Care Medicine (ESICM). This study aims to investigate the influence of 
genetics on the host response and outcome in patients with sepsis. The study has 
recorded comprehensive clinical phenotypic data and collected DNA from patients 
admitted to ICU with sepsis due to faecal peritonitis. The quality assured phenotypic 
database includes a wide range of clinical, physiological and laboratory information, 
as well as outcome data up to six months following ICU admission. Although 
specifically designed for the purposes of genetic epidemiology studies, to date, as far 
as the author is aware, the Genosept study cohort represents the largest and 
diagnostically most homogeneous collection of clinical data regarding intensive care 
patients specifically suffering with faecal peritonitis.  
GAinS (Genomic Advances in Sepsis) is a multi-centre UK-wide study 
supported by the UKCCG (UK Critical Care Genomics Group), a network of centres 
undertaking clinical functional genomics research in the critical care setting 
(http://www.ukccg-gains.org). 
Patients included in the GenOSept FP cohort were recruited from 102 centres 
across 16 European countries and those in the GAinS FP cohort were recruited from 
51 UK centres between September 2005 and March 2015. 
Analysis of these two large, quality controlled, databases constitutes a unique 
opportunity to gain insights into important epidemiological characteristics of patients 
with faecal peritonitis admitted to ICUs across Europe, including factors such as 
comorbidities, short and long term outcomes and factors influencing prognosis in this 
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particular subset of patients, where evidence is currently lacking. As these 
diagnostically homogeneous cohorts include data from FP patients with various 
degrees of illness severity, including potential risk modifiers and confounding factors 
(such as comorbidities, indices of acute physiological derangement, organ support, 
radiological and laboratory findings, origin of faecal peritonitis), they also provide 
high quality data well suited to the development and testing of a prognostic model 
specific to this post-operative patient population. 
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1.6 Hypothesis and Aims 
My hypothesis is that there are specific clinical features of sepsis induced by 
faecal peritonitis (independent of operative / surgical variables and findings), which 
are predictive of mortality. These aspects can be elicited, in the post-operative 
phase, on admission to the critical care setting, and described as absolute values, or 
identified as trends in specific clinical parameters over time. 
 
The thesis aims are to:  
 use the information derived from reviewing the existing literature on 
secondary peritonitis to identify the evidence relevant to patients with faecal 
peritonitis  
 define the methods used to analyse the largest international, and most 
diagnostically homogeneous, prospectively collected cohort of faecal peritonitis 
patients (GenOSept)  
 describe the epidemiological characteristics of the GenOSept faecal 
peritonitis cohort 
 define the predictors of outcome for the GenOSept  faecal peritonitis 
cohort, based on four time-points: ICU, hospital, 28 day and 6 month mortality 
 describe trends in physiological variables in the GenOSept faecal 
peritonitis cohort and their relationships with outcome 
 develop and validate a prognostic modelling tool able to stratify post-
surgical critically ill patients with FP, independently from intra-operative surgical 
findings, using prospectively collected data from both both the GenOSept and GAinS 
cohort studies 
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 explore the possibility that the prognostic parameters and trends 
identified may aid decision making regarding therapeutic support, care escalation 
and support prognostication 
 
This thesis is focused solely on the clinical aspects characterising the faecal 
peritonitis cohorts of the GenOSept and GAinS studies, making no attempt to 
explore the genetic variations underlying the individuals in these cohorts and their 
relationship to outcome from sepsis (these aspects are dealt with separately within 
other studies). The enrolment procedures for the two studies were separate and 
mutually exclusive, as they happened in different time periods. It was not possible to 
be recruited to both cohorts. 
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Chapter 2 - Methods 
 
2.1 Ethics, recruitment and data collection 
 
2.1.1 Ethics and consent 
The study was performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki and its later amendments. 
Ethics approval was granted either nationally or locally (for individual centres), 
or both. Written, informed consent for inclusion in the GenOSept study was obtained 
from all patients or a legal representative. A list of all ethical bodies that approved 
the study is included in the appendix. 
 
2.1.2 Recruitment 
Patients included in the GenOSept FP cohort were recruited from 102 centres 
across 16 European countries and those in the GAinS FP cohort were recruited from 
51 UK centres between September 2005 and March 2015 (see table 4). A full list of 
recruiting centres for both studies is provided in the appendix. 
The diagnosis of sepsis was based on the International Consensus Criteria of 
the European Society of Intensive Care Medicine and the American College of 
Physicians, which define sepsis as “the clinical syndrome defined by the presence of 
both infection and a systemic inflammatory response” (Levy et al. 2003).  
Follow up was for up to 6 months from enrolment, or until death.  
The same inclusion and exclusion criteria were used for both cohorts.  
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Table 4 Datasets used  
Study GenOSept GenOSept GAinS 
Cohort utilisation 
(Epidemiological analyses) 
Used Used Not used 
Cohort utilisation  
(Trends analyses) 
Used Used Not used 
Cohort utilisation  
(Scoring systems) 
Derivation  
 
Geographic 
validation  
Temporal 
validation 
Country UK non-UK UK 
Recruitment period 2005-2011 2005-2011 2011-2015 
Total number of patients 462 515 323 
Results described in 
Chapter 
3, 4, 5 3, 4, 5 5 
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2.1.3 Inclusion criteria 
Inclusion criteria were: adult patients (being aged 18 years or older), 
admission to a High Dependency Unit (HDU) or Intensive Care Unit (ICU) with faecal 
peritonitis. Faecal peritonitis was defined as visible inflammation of the serosal 
membrane that lines the abdominal cavity, secondary to contamination by faeces, as 
diagnosed by the operating surgeon at laparotomy.  
 
2.1.4 Exclusion criteria 
Exclusion criteria were: peritonitis due to gastric or upper GI-tract perforation 
(e.g. gastric or duodenal ulcer perforation, terminal ileum perforation), patient or legal 
representative unwilling or unable to give consent; patient pregnant; advanced 
directive to withhold or withdraw life sustaining treatment or admitted for palliative 
care only; patient already enrolled in an interventional research study of a 
novel/unlicensed therapy (patients enrolled in interventional studies examining the 
clinical application or therapeutic effects of widely accepted, “standard” treatments, 
were not excluded); patient immuno-compromised (known regular systemic  
corticosteroid therapy, exceeding 7mg/kg/day of hydrocortisone or equivalent, within 
three months of admission and prior to acute episode, known regular therapy with 
other immunosuppressive agents, e.g. azathioprine, known to be HIV positive or 
have acquired immunodeficiency syndrome as defined by the Centre for Disease 
Control, neutrophil count less than 1000 mm-3 due to any cause, including metastatic 
disease and haematological malignancies or chemotherapy, but excluding severe 
sepsis; organ or bone marrow transplant recipients receiving immuno-suppressive 
therapy). 
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2.1.5 Database, case report form and quality assurance 
The case report form (CRF) for the GenOSept study was developed and 
tested by Professor Charles Hinds (Barts and The London Queen Mary School of 
Medicine, London, UK), Dr Christopher Garrard (John Radcliffe Hospital, Oxford, 
UK), Dr Anthony Gordon (Imperial College, London, UK), Prof Jean-Daniel Chiche 
(Hospital Cochin, Paris, France) and Dr J. Millo (John Radcliffe Hospital, Oxford, UK) 
together with other members of the GenOSept Consortium. A specific eCRF 
(electronic Case Report Form) was developed by Lincoln, Paris, France, using 
software developed in collaboration with Prof Jean-Daniel Chiche. The database was 
password protected, allowing investigators to enter data on the eCRF online, and 
included audit trail capability for data entry and subsequent modifications. The eCRF 
is accessible online at www.genosept.eu.  
To minimize errors, logical range checks were in place so that the 
investigators would be alerted if an attempt was made to enter data values outside 
the expected ranges.  
Quality Assurance (QA) was performed by Paul Holloway (Imperial College, 
London, UK), Dr Christopher Garrard, Dr Andrew Walden (Royal Berkshire Hospital, 
Reading, UK), Dr Anthony Gordon and Professor Charles Hinds, who systematically 
reviewed all data. Data queries (DQs) were generated within the eCRF for missing or 
erroneous data, and sent electronically to the relevant investigators for action, where 
necessary. Up to the end of January 2011 an estimated 3986 valid DQs had been 
generated, with a response rate by the investigators of approximately 92%. The most 
common reasons for QA queries were missing information (particularly the 
Charleson Index, antimicrobial use, estimated day of onset of faecal peritonitis 
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before ICU admission, information about circumstances of GCS assessment, and 
outcome data) or data entered in incorrect units.  
All patients’ eCRFs were reviewed by experienced critical care physicians. 
Where the patient’s eligibility for inclusion in the relevant cohort was unclear, 
clarification was sought from the investigators. Regular QA reports were provided to 
the GenOSept Management Committee for review; the National Investigators were 
contacted regarding quality issues if necessary.  
Of the original 1123 records within the GenOSept database, pertaining to 
patients with any type of peritonitis, 146 were eliminated following QA, as not 
meeting the criteria for definition of peritonitis of faecal origin, leaving 977 patients 
records with faecal peritonitis. 
The GAinS study database included valid data on 323 critically ill patients, 
admitted to HDU or ICU following laparotomy, recruited in the UK between January 
2011 and March 2015. 
The case report form for the GAinS study mirrored the GenOSept CRF. All 
patients’ CRFs were reviewed by experienced critical care physicians, to confirm the 
patient’s eligibility for inclusion. Where necessary, clarification was sought from the 
investigators. Regular QA reports were created for the GAinS Management 
Committee to review; the investigators were contacted regarding quality issues, 
where necessary.  
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2.2 Patients and data  
 
Patients recruited to GenOSept and GAinS requiring admission to the ICU or 
HDU for faecal peritonitis were followed for up to a maximum of six months following 
first admission. As well as genetic epidemiological data, a variety of clinical 
phenotypes were collected at admission and at regular intervals throughout the 
admission (on days 1,2,3,5 and 7 of stay), including all variables required to 
calculate admission APACHE II and daily SOFA scores. Data extracted from the 
eCRF for the purposes of these analyses pertained either to the first 24 hours of ICU 
admission, or to the whole first week of admission; data for SOFA scoring, and other 
selected variables, were collected over the whole of the first week of ICU stay 
(Vincent et al. 1996).  
Investigator coded presence (or absence) of acute renal failure (ARF), 
corroborated by the renal SOFA score, was used as an objective measure of acute 
renal dysfunction. The study was started before the international definitions of acute 
kidney injury (AKI) had been developed. 
The cardiovascular SOFA was used to indicate the presence and severity of 
shock. Calculation of APACHE II scores was based on ICU Day 1 data (Knaus et al. 
1985).  
 
Comorbidity data 
Comorbidities were classified within the eCRF according to the modified 
Charlson scoring system (Charlson et al. 1987).  
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Records comprising 16 summary measures of comorbidity were found for 976 
patients. Variables indicating a history of major surgery (majsur) and radiotherapy 
(chradio) were excluded due to missing values in more than 10% of patients.   
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2.3 Statistical Methods for day 1 analyses  
Continuous data were summarized using mean ± standard deviation (SD) if 
normally distributed, as median and interquartile ranges (IQR) if not normally 
distributed. 
Patients were right censored at six month follow up. If an individual died 
during the follow up period, date and cause or causes of death were recorded. The 
primary study outcome was 6-month mortality. Secondary end-points were ICU, 
hospital and 28 days mortality. Person time was calculated, in days, from the date of 
admission to ICU to the date of death, or censor date. Time from estimated faecal 
peritonitis onset to diagnosis was calculated using the date of symptoms’ onset and 
date of confirmatory laparotomy. Kaplan-Meier survival analysis was performed to 
determine mortality rates. 
To determine risk factors for mortality, all of the 50 clinical variables available 
were analysed – the full list of variables tested is provided in the appendix. For each 
variable, Cox proportional hazards (PH) regression analysis, adjusted for age and 
gender, was performed for association with each endpoint (adjusted single variable 
analyses). 
Variables found to be significant in single variable analyses after Bonferroni 
correction for multiple testing (p value <0.001= 0.05/50 to take account of the 50 
variables tested) were selected for inclusion in the multivariate Cox proportional 
hazards (PH) model to determine independent risk factors for mortality. Stepwise 
regression in the multivariate Cox PH regression models was performed to 
determine independent predictors of mortality with adjustment for potential 
confounding factors.  
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2.3.1 Testing the Proportional Hazards assumption 
A test for PH using the Schoenfeld residuals was performed and, for 
covariates indicating evidence of non-proportionality, spline smooth estimates of time 
dependent hazard ratios with pointwise confidence bands were calculated 
(Schoenfeld 1982; Therneau & Grambsch 2000). 
Schoenfeld residuals for the Cox PH regression model were regressed 
against time to test for independence between residuals and time and test the PH 
assumption. The PH assumption was supported by a non-significant relationship 
between residuals and time, and refuted by a significant relationship. 
Where the PH assumption was not supported, smooth estimates of hazard 
ratios were calculated using the method of Therneau and Grambsch (Schoenfeld 
1982; Therneau & Grambsch 2000). 
 
2.3.2 Analyses of antimicrobials usage and effects 
A set of analyses were performed concerning the antibacterial and antifungal 
agents’ usage. Combinations of antimicrobials given up to 10 days before and 
including the day of admission to the ICU were recorded. Antimicrobial combinations 
occurring less than 10 times were recorded as “other”. Adequacy of antimicrobials 
administered (as judged by the relevant microbiological expert at the recruiting 
centre) and presence of antifungal agents were also recorded. Cox PH regression 
models with adjustment for age and gender were fitted to assess the effect of each 
antimicrobial combination, their adequacy and the presence of antifungal agents on 
outcome. 
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2.4 Statistical Analyses (variables trends) 
Clinical data of faecal peritonitis patients recruited to GenOSept were 
collected on days 1,2,3,5 and 7 of ICU stay, including all variables required to 
calculate admission APACHE II and daily SOFA scores (Knaus et al. 1985; Vincent 
et al. 1996). Data extracted from the electronic case report form (eCRF) for the 
purposes of this analysis pertained to the whole first week of ICU admission. 
The trends were calculated as linear change over the first week (obtained by 
subtracting the value on day 1 from the value on day 7), as a prospectively chosen 
summary measure for the primary analysis. The use of summary measures, to 
combine data obtained at multiple time points for the same individual, is a 
recommended statistical procedure; using such a measure allowed the identification 
of a general trend over the first week of ICU stay, while also avoiding common 
pitfalls in the analysis of serial measurements (Matthews et al. 1990). 
The primary study outcome was 6-month mortality. Secondary end-points 
were ICU, hospital and 28 day mortality. Shorter term trends were evaluated by 
subtracting the values on day 1 from the values on days 2, 3 and 5.  
Trends in all 35 variables where data were available for the first week of ICU 
stay were analysed. For each trend, Cox proportional hazards (PH) regression 
analyses, adjusted for age and gender, were performed, for each mortality endpoint. 
Trends found to be significant in these analyses, after Bonferroni correction for 
multiple testing (p value < 0.00143 = 0.05/35 to take account of the 35 variables 
tested) were entered into a multivariate Cox PH model, to identify those 
independently associated with mortality, adjusting for potential confounding factors. 
The full list of variables whose trends were tested is provided in the appendix. 
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The primary study outcome was 6-month mortality. Secondary end-points 
were ICU, hospital and 28 day mortality.  
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2.5 Statistical analyses (prognostic models) 
 
2.5.1 Prognostic model derivation 
In order to build the prognostic model, patients recruited up to January 2011 
were divided into two subsets of patients; one for derivation and the other for 
external geographic validation. To limit the effect of potentially unmeasured and 
unaccounted confounding factors, related to possible differences in national systems 
of healthcare provision among participating countries across Europe, these patients 
were divided into UK (derivation) and non-UK (geographic validation) sub-cohorts, 
with the aim of optimising homogeneity in the datasets and decreasing potential 
background noise, due to potential confounding factors related to different healthcare 
systems across countries. Subsequent patients, recruited in the UK between 
January 2011 and March 2015, were included in the temporal validation cohort. 
All 50 clinical and laboratory variables available on admission to critical care 
(day 1) were evaluated (for a full list, see appendix). The primary outcome was 6 
month mortality risk with the secondary outcome being 28 day mortality risk. To 
select the variables to include in the model, Cox proportional hazards regression 
analysis for 6 month mortality was fitted, using stepwise backwards selection, to 
determine the predictors to be included in the models from 50 bootstrapped samples 
derived from the derivation subset (nonparametric bootstrap procedure). Increasing 
the number of bootstrap replications did not alter the model significantly. The 
conventional p value cut-off used was 0.05. The same predictor variables were 
employed to construct a prognostic tool for the secondary outcome, 28 day mortality. 
The effect of multiple hypothesis testing was mitigated using bootstrapping. 
Resampling based techniques such as bootstrapping are used for dealing with 
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multiple hypotheses testing in various settings, including neuropsychological 
research and genome-wide expression studies (Zhang et al. 2012; Blakesley et al. 
2009). 
The procedure of bootstrapping is a re-sampling method which relies on 
random sampling with replacement of the available observations. This procedure 
allows evaluation of the characteristics of an estimator (such as its variance) by 
measuring those properties when obtaining multiple samples from the original 
dataset (and of size equal to the observed dataset) (Chen & George 1985)(Harrell et 
al. 1996). 
A final Cox proportional hazards regression analysis for both 6 month and 28 
day mortality was fitted using the set of variables found to be significant in the 
majority of bootstrap replications, for each outcome respectively. 
The proportional hazards assumption was confirmed as met by drawing 
Kaplan-Meier Curves and Nelson Aalen plots for the covariates after categorisation. 
Predictors which satisfied the proportional hazard assumption showed very similar 
curves, with the separation between them remaining proportional across analysis 
time (Hess 1995). The correctness of this assumption was also assessed testing on 
the basis of Schoenfeld residuals (Therneau & Grambsch 2000). 
In order to assess for the presence of collinearity (which happens when two 
variables are almost a perfect linear combination of one another), I calculated the 
variance inflation factors (VIFs). It is generally accepted that variables with VIFs 
greater than 10 merit further investigation (Slinker & Glantz 1985). 
The two models obtained were evaluated using Area under the Receiver-
Operator Characteristic curve (AuROC) analysis, which plots sensitivity against 1-
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specificity to describe the accuracy of a diagnostic test (Metz 1978; Hanley & McNeil 
1982), and to compare the performance of different tests (Zweig & Campbell 1993). 
 
2.5.2 Non-parametric bootstrapping and prognostic model derivation for 6 month and 
28 day mortality 
The bootstrapping procedure was performed using 50 repetitions based on 
the UK derivation cohort. A final Cox proportional hazards regression analysis for 6 
month mortality was fitted using the set of variables found to be significant in the 
majority of bootstrap replications. Saturation was reached after 50 bootstrap 
replications, with additional replications not yielding significantly different results.  
A set of 5 variables met this criterion (age, SOFA score, lowest temperature, 
highest heart rate, haematocrit). The Cox proportional hazards model estimates for 
those risk variables are presented in Table 5.  
The same five variables were employed to formulate the 6 month mortality 
prognostic tool by entering the estimates obtained from the Cox proportional hazards 
model in the following equation: 
 
FP score (6 month) = (103) * exp((0.0447387*A)+(-0.0313029*H)+(-0.2767377*T) 
+(0.0114629*HR)+(0.1812872*S)) 
 
Where: A = age at admission to critical care, H = haematocrit (as percentage points) 
on day 1 ICU, T = lowest recorded temperature (as degrees Celsius) on day 1 ICU, 
HR = highest recorded heart rate on day 1 ICU, S = SOFA score day 1 
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A separate Cox proportional hazards regression analysis was fitted for the 28 
day mortality outcome, utilising the same set of five variables. The resulting model 
estimates are presented in Table 4. The estimates were utilised to construct the 28 
day mortality prognostic tool as described in the following equation: 
 
FP score (28 day) = (104) * exp((0.048728*A)+(-0.0125259*H)+(0.2005776*S)+(-
0.3591817*T)+(0.0098462*HR)) 
 
While haematocrit and high heart rate did not offer independent predictive 
power in the 28 day mortality model, they were useful in explaining variability when 
retained in the model. 
 
2.5.3 Comparison of the prognostic models with pre-existing scores 
Comparison of the prognostic models with SOFA and APACHE II was 
performed graphically by drawing the superimposed ROC curves and testing the 
underlying AuROC obtained, taking into account that the data are correlated, using a 
nonparametric approach as suggested by DeLong et al. (DeLong et al. 1988). 
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Table 5 Variables found to be significant in the majority of bootstrap replications run 
on the UK derivation cohort for the two outcomes 
Variable HR HR 95% CI coeff coeff 95% CI p 
6 month mortality      
Age 1.05 1.03 - 1.07 0.045 0.02 - 0.06 <0.001 
SOFA score 1.20 1.12 - 1.28 0.18 0.11 - 0.25 <0.001 
low temperature 0.76 0.63 - 0.91 [-0.28] [-0.46] - [-0.09] 0.004 
high heart rate 1.01 1.01 - 1.02 0.01 0.01 - 0.02 0.007 
Haematocrit 0.97 0.94 - 0.99 [-0.031] [-0.059] - [-0.003] 0.028 
28 day mortality      
Age 1.05 1.03 - 1.08 0.049 0.03 - 0.07 <0.001 
SOFA score 1.22 1.12 - 1.33 0.2 0.11 - 0.29 <0.001 
low temperature 0.70 0.55 - 0.88 [-0.36] [-0.59] - [-0.13] 0.002 
high heart rate 1.01 1 – 1.02 0.01 [-0.001] - 0.2 0.07 
Haematocrit 0.99 0.95 - 1.02 [-0.013] [-0.047] - 0.022 0.47 
HR, hazard ratio; 95% CI, 95% confidence interval; coeff, coefficient; SOFA, 
Sequential Organ Failure Assessment; the use of the square brackets [ ] 
indicates negative values 
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2.6 Software employed 
Statistical analyses were performed using R version 2.11.1 (The R Project for 
Statistical Computing. <http://www.r-project.org/>) and STATA statistical software 
(STATA 10; STATA Statistics/Data Analysis, StataCorp, Lakeway Drive, College 
Station, Texas 77845 USA. <http://www.stata.com>). 
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Chapter 3 – Faecal peritonitis in the GenOSept cohort - an 
epidemiological survey 
 
3.1 Introduction 
Critically ill patients with faecal peritonitis represent a specific subgroup 
among septic patients. It is, therefore, important to define and characterise their 
epidemiological features and risk factors, in order to support clinical decision making 
and prognostication. As demonstrated in the literature review presented in chapter 1, 
the existing literature is limited, particularly regarding the features and outcomes of 
this patient group when admitted to critical care. The studies summarised in chapter 
1 section 1.3.3 have suggested that the outcome of patients with faecal peritonitis 
admitted to intensive care units may depend on key variables, specifically age, 
presence of malignancy (this feature has been deemed as protective), and hypo-
albuminaemia (Sayer et al. 2012; Pawa et al. 2009). I provide here the results of my 
analyses from the multi-national GenOSept cohort, the largest and most 
homogeneous cohort gathered of this patient group. 
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3.2 Baseline characteristics 
 
3.2.1 Patients’ baseline characteristics - period 
Data presented in this chapter pertains to day 1 admission to ICU (unless 
otherwise specifically stated) extracted from electronic case record forms (eCRFs). It 
pertains to 977 patients, admitted to critical care with a diagnosis of faecal peritonitis, 
following laparotomy, between 29/09/2005 and 05/01/2011. The patients were 
recruited from 102 centres across 16 countries for the GenOSept study.  
 
3.2.2 Participants’ recruitment by Country 
A large proportion of patients (462, 47.29%) were enrolled in the United 
Kingdom, although the majority were from mainland Europe. Table 6 lists 
participants by Country. 
Apart from being the single largest and most homogeneous prospective 
cohort collected so far on patients admitted with faecal peritonitis to critical care 
services, the GenOSept faecal peritonitis cohort is the only multinational one. The 
previously reported studies analysed smaller datasets gathered in single centre UK 
only cohorts (Pawa et al., 2009, Sayer et al., 2012). 
 
  
94 
 
Table 6 Participants’ recruitment by Country 
Country N n % 
 977   
 United Kingdom  462 47.3 
 Germany  124 12.7 
 Spain  95 9.7 
 Czech Republic  68 7.0 
 Italy  58 5.9 
 Ireland  49 5.0 
 Belgium  44 4.5 
 Poland  36 3.7 
 Serbia  17 1.7 
 France  6 0.6 
 Netherlands  4 0.4 
 Estonia  4 0.4 
 Croatia  4 0.4 
 Israel  3 0.3 
 Hungary  2 0.2 
 Greece  1 0.1 
 
N, number of observations; n = count, % = percentage 
 
 
3.2.3 Age and gender distribution  
Average (SD) age was 66.5 (14) years, median age (IQR) was 69.2 (58.3 - 
77.1) years. The distribution was largely skewed towards the older ages, with 
62.54% of patients being 65 years old or older, as described in Figure 2. 
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Figure 2 Histogram of the age distribution at ICU admission in the GenOSept faecal 
peritonitis cohort 
 
   
Age range (years) n % 
18-34 36 3.7% 
35-44 33 3.4% 
45-54 106 10.9% 
55-64 191 19.6% 
65-74 264 27% 
75-84 277 28.4% 
85-95 70 7.2% 
Total 977 100% 
n = count, % = percentage 
 
This age distribution is similar to that described by Pawa and co-workers in 
their cohort, which had a mean age of 70.8 years (Pawa et al., 2009).  
There was a slight male preponderance: of the 977 patients, 530 (54.3%) were male.  
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3.2.4 Ethnic distribution  
Ethnic origin data was available for 970 (99.3%) patients in the cohort: the 
overwhelming majority (956, 98.6%) were of Caucasian origin (Table 7). 
 
Table 7 Ethnic distribution in the faecal peritonitis cohort 
Race n %         
Caucasian 956       98.6% 
Asian 11 1.1% 
African 2 0.2% 
Mixed 1 0.1% 
Total 970 100 
n = count, % = percentage 
 
 
3.2.5 Acute physiological dysfunction  
APACHE II and SOFA scores were available for 974 (99.7%) patients in the 
GenOSept faecal peritonitis cohort. The median (IQR) APACHE II score was 16 (12-
21), the median (IQR) SOFA score was 7 (5-10). The distributions of APACHE II and 
SOFA scores are shown in Figure 3 and 4 respectively. Table 8 reports further 
indicators of acute physiological derangement. 
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Figure 3 Histogram of the APACHE II scores distribution in the GenOSept faecal 
peritonitis cohort      
 
 
Figure 4 Histogram of the SOFA scores distribution in the GenOSept faecal 
peritonitis cohort 
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Table 8 Patients’ baseline characteristics recorded on day 1 
Acute physiology indicator N     n or Mediana % or IQRb 
 977   
 Severe sepsis  959 98.2 
 Renal SOFA  1a 0-2b 
 Renal SOFA≥2  271 27.7 
 Cardiovascular SOFA  4a 1-4b 
 Cardiovascular SOFA≥1  835 85.7 
 Cardiovascular SOFA≥2  707 72.6 
 Cardiovascular SOFA≥3  674 69.2 
 Cardiovascular SOFA≥4  505 51.9 
 Acute renal failure (as per investigators)  282 29 
 Renal replacement therapy  115 11.8 
 Mechanical ventilation  742 76.2 
 Heart rate (bpm)  85a 73-99b 
 Temperature (⁰C)  36.2a 35.7-36.9b 
 pH  7.33a 7.25-7.40b 
 Haematocrit (%)  30.2a 27-35b 
 Platelets (10-9/l)  212.5a 145-300b 
 
Bpm, beats per minute; ⁰C, degrees centigrade; IQR, interquartile range; N, number 
of available observations; n = count, % = percentage; SOFA, Sequential 
Organ Failure Assessment.  
aMedian and bIQR are shown instead of count and %. 
 
Seven hundred and forty-two patients (76.2%) were mechanically ventilated, 
959 (98.2%) had severe sepsis, 835 (85.7%) had a cardiovascular SOFA score 1 
and 282 (29%) had acute renal dysfunction (based on investigators’ opinion), 271 
(27.7%) patients had a renal SOFA score ≥2 on day 1 (indicative of moderate to 
severe renal dysfunction), 11.8% required renal replacement therapy on day 1 and 
208 (21.3%) of patients received renal replacement therapy during the first week. 
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3.2.6 Comorbidities 
The most common co-morbidities were cardiovascular, malignant and respiratory 
diseases: a list is presented in Table 9. 
 
Table 9 Comorbidities in the faecal peritonitis cohort 
Medical comorbidities N n % 
 Cardiovascular disease 976 390 40.0 
 Respiratory disease 976 244 25.0 
 Neurological disease 976 106 10.9 
 Severe renal disease 941 96 10.2 
 Gastrointestinal disease 976 230 23.6 
 Malignancy 976 295 30.2 
 Diabetes 976 163 16.7 
  Previous serious infection* 976 33 3.4 
 Other illness 976 339 34.7 
 Severe exercise restriction 976 9 0.9 
 Chronic dialysis 971 13 1.3 
 Chronic steroids use** 976 10 1.0 
 
IQR, interquartile range; N, number of available observations; n = count, % = 
percentage; 
* Serious infection was defined as a serious, prolonged or recurrent infection.  
** Chronic steroid use was defined as taking corticosteroids below the 
immunosuppression dose (>7 mg/kg/days hydrocortisone), which would 
exclude patient from the study. 
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3.2.7 Length of stay and time to surgery 
The median ICU length of stay (LOS) was 10 days (IQR 5–21, range 1-160 
days); the median hospital LOS was 28 days (IQR 15–51). The distribution of the 
ICU length of stay is presented in Table 10. The median time from the estimated 
onset of symptoms to surgical intervention was 1 day (IQR 1-3). 
 
Table 10 ICU length of stay 
ICU length of stay (days)  n % 
0-3  151 15.5% 
4-7  238 24.4% 
8-14  222 22.7% 
15-28  191 19.5% 
29-56  129 13.2% 
57-160  46 4.7% 
 
 
Data available for 977 patients; n = count, % = percentage; 
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3.2.8 Cause of faecal peritonitis 
The most common causes of faecal peritonitis were perforated diverticular 
disease (32.1%) and surgical anastomotic breakdown (31.1%), followed by 
malignancy, trauma and other causes as indicated in Table 11. Surgical source 
control had been attempted in all patients, prior to admission to intensive care. 
 
Table 11 Cause of faecal peritonitis 
Cause of faecal peritonitis  n % 
Perforated diverticular disease  312 32.1% 
Anastomotic breakdown  302 31.1% 
Malignancy  129 13.3% 
Trauma  67 6.9% 
Other  162 16.7% 
 
Data available for 972 of 977 patients; n = count, % = percentage  
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3.3 Mortality 
 
3.3.1 Mortality rates 
Of the 977 patients admitted to ICU with a confirmed diagnosis of faecal 
peritonitis, 187 (19.1%) had died at 28 days, 204 (20.9%) died during their ICU stay, 
283 (28.7%) in hospital and 309 (31.6%) had died at six month follow-up (Table 12). 
 
Table 12 Mortality at the four time-points for the 977 patients in the GenOSept faecal 
peritonitis cohort 
Outcome 
time-point 
Status N  Deaths % Exposure 
time  
(person-
days) 
Crude morality rate 
(95%CI)   
(events/1000 person-
days) 
6 months Alive 668 31.6% 121498 2.54 (2.27-2.84) 
Dead 309 
ICU Alive 773 20.9% 16549 12.3 (10.8-14.1) 
Dead 204 
Hospital Alive 698 28.7% 37644 7.44 (6.62-8.36) 
Dead 283 
28 days Alive 790 19.1% 23707 7.89 (6.83-9.10) 
Dead 187 
 
CI, confidence interval; IQR, interquartile range; N, number of available 
observations, % = percentage 
 
Of those 105 patients who had survived ICU stay but had passed away by 6 
months, 31 (29.5%) had limitations in place at the time of death, 29 (27.6%) died 
with multi-organ and system failure which had failed to resolve, 24 (22.9%) had 
persistent or recurrent sepsis, 10 (9.5%) intractable cardiovascular failure and only 
13 (12.4%) died of causes considered to be unrelated. More than one mode of death 
was recorded for some patients. 
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3.3.2 Modes of death  
Investigators were asked to choose one or more “modes of death” from a list 
in the eCRF: more than one mode was recorded for some patients. Modes of death 
are presented in Table 13. 
 
Table 13 Mode of death for the 977 patients in the GenOSept faecal peritonitis 
cohort 
Mode of death N % 
Failure to resolve organ system dysfunction 154   49.5% 
Limitation of therapy 104 33.7% 
Persistent or recurrent sepsis 102 33% 
Intractable cardiovascular failure 60    19.4% 
Unrelated cardiac / pulmonary event 18      5.5% 
 
Of those patients on whom limitations of therapy had been placed, the 
majority (73, 70.2%) died in the ICU. 
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3.3.3 Individual variable analyses - results 
All variables measured on day 1 of ICU admission, and two derived from the 
data pertaining to week one ICU stay (cardiovascular and renal SOFA scores), were 
analysed to evaluate their influence on the 4 outcomes.  
The statistically significant results after Bonferroni correction for multiple 
analyses (p<0.001) are presented in the form of estimated hazard ratios (HRs) in 
Tables 14 to 17, for the primary (6 month mortality) and the secondary outcomes 
(ICU, hospital and 28 day mortality) respectively. 
The most significant associations with 6-month mortality (primary outcome) 
were the APACHE II score, total SOFA score on day 1, and the highest renal SOFA 
score during the first 7 days of ICU admission (used as a cumulative proxy marker of 
severity of renal dysfunction during this period). Other variables indicative of acute 
renal dysfunction were also significantly associated with 6-month mortality. These 
included investigator recorded presence of acute renal failure (ARF), need for renal 
replacement therapy (RRT), pH, highest and lowest recorded creatinine and highest 
recorded urea on day 1. The next most significant association with 6-month mortality 
was for the highest cardiovascular SOFA score during the first week of ICU stay. 
Many of the variables associated with 6-month mortality were also significantly 
associated with the other outcomes in single variable analyses.  
The variables found to be consistently associated with mortality at all the time 
points were age, the SOFA and APACHE II scores measured on day 1, indicators of 
renal dysfunction (highest renal SOFA score over week 1, investigators’ opinion of 
acute renal failure on day 1, pH, highest and lowest measured creatinine, need for 
renal replacement therapy [RRT] and highest measured urea on day 1 of ICU 
admission) and hypothermia. Indicators of cardiovascular dysfunction (highest 
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cardiovascular system [CVS] SOFA score measured over week 1, 
presence/absence of hypertension, highest and lowest measured heart rate on day 
1), haematocrit, temperature and platelets levels, bilirubin levels and P:F ratio 
(PaO2/FiO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen) 
were also significant predictors of multiple outcomes. 
The cause of faecal peritonitis, the presence of co-morbidities, the time from 
estimated faecal peritonitis onset to surgical intervention and the finding of bilateral 
infiltrates on chest radiography (seen in 220 patients and suggestive of acute lung 
injury [ALI]/acute respiratory distress syndrome [ARDS]) had no influence on survival 
at any time-point. 
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Hazard ratios for pH value on ICU admission showed evidence of non-
proportionality of hazards in a Cox proportional hazards regression for 6-month 
mortality (p value < 0.01). Figure 5 shows the estimated non-proportional time 
dependent hazard ratios for this variable and suggests that its effect on mortality 
over 6 months is greatest at admission to ICU and typically decreases to little or no 
effect over a six month period. The horizontal dotted line shows the estimated fixed 
hazard ratio. 
 
Figure 5 Estimated hazard ratio (solid line) with 95% confidence intervals (dashed 
lines) for the variable pH value 
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Table 14 Results of Cox PH regression analysis for 6 months mortality  
Variable Unit HR 95% CI p-value 
SOFA day 1 1 point 1.18 1.14-1.21 <1 x 10-16 
APACHE II 1 point 1.08 1.07-1.1 <1 x 10-16 
Age 1 year 1.04 1.03-1.05 3.3 x 10-16 
Highest renal SOFA a 1 point 1.42 1.32-1.52 <1 x 10-16 
Acute renal failure   2.32 1.85-2.92 3.2 x 10-13 
pH 1 point 0.80 0.75-0.86 3.9 x 10-9 
Highest creatinine  micromol/l 1.002 1.002-1.003 8.0 x 10-9 
Lowest creatinine micromol/l 1.002 1.002-1.003 9.5 x 10-8 
RRT  2.22 1.67-2.93 2.9 x 10-8 
Highest urea mmol/l 1.02 1.01-1.03 4.2 x 10-6 
Haematocrit % 0.96 0.94-0.98 1.4 x 10-5 
Highest CVS SOFA a  1 point 1.40 1.25-1.56 6.4 x 10-9 
Hypertension  1.24 1.14-1.34 1.6 x 10-7 
Highest heart rate 10 bpm 1.12 1.07-1.17 1.0 x 10-6 
Lowest heart rate 10 bpm 1.13 1.06-1.2 2.1 x 10-4 
P:F Ratio kPa 0.98 0.97-0.99 3.9 x 10-4 
Ventilatory support  1.93 1.40-2.67 6.1 x 10-5 
Lowest platelets 10-9/l  0.98 0.97-0.99 4.7 x 10-5 
Lowest temperature 1⁰C 0.79 0.70-0.88 6.7 x 10-5 
Highest bilirubin mmol/l 1.01 1.00-1.01 4.6 x 10-4 
 
Results are shown for variables with p-value < 0.05/50. Results are adjusted for age 
and gender (apart from age). 
CI, confidence interval; bpm, beats per minute; CVS, cardiovascular; HR = Hazard 
Ratio, PH, proportional hazard; SOFA, Sequential Organ Failure Assessment; 
APACHE, Acute Physiology and Chronic Health Evaluation; RRT, renal 
replacement therapy; P:F ratio, ratio of arterial oxygen partial pressure to 
fractional inspired oxygen. All variables refer to day 1 ICU admission, unless 
otherwise stated.  
a Variable recorded over week 1.   
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Table 15 Results of Cox PH regression analysis for ICU mortality 
Variable Unit HR 95% CI p-value 
SOFA day 1 1 point 1.09 1.04-1.14 7.5 x 10-5 
APACHE II 1 point 1.05 1.03-1.07 1.2 x 10-6 
Age 1 year 1.04 1.02-1.05 4.0 x 10-8 
Highest renal SOFAa 1 point 1.33 1.21-1.45 7.7 x 10-10 
Acute Renal Failure  1.99 1.51-2.63 1.3 x 10-6 
pH 1 point 0.84 0.78-0.91 1.8 x 10-5 
Lowest Temperature 1⁰C 0.8 0.7-0.91 5.2 x 10-4 
 
Results are shown for variables with p-value < 0.05/50. Results are adjusted for age 
and gender (apart from age).   
CI, confidence interval; bpm, beats per minute; CVS, cardiovascular; HR = Hazard 
Ratio, PH, proportional hazard; SOFA, Sequential Organ Failure Assessment; 
APACHE, Acute Physiology and Chronic Health Evaluation. All variables refer 
to day 1 ICU admission, unless otherwise stated.  
a Variable recorded over week 1.   
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Table 16 Results of Cox PH regression analysis for hospital mortality  
Variable Unit HR 95% CI p-value 
SOFA day 1 1 point 1.13 1.09-1.17 4.0 x 10-12 
APACHEII 1 point 1.07 1.05-1.08 6.3 x 10-13 
Age 1 year 1.05 1.03-1.06 1.6 x10-14 
Highest renal SOFAa 1 point 1.33 1.24-1.44 1.8 x 10-13 
Acute Renal Failure  2.1 1.66-2.67 8.4 x 10-10 
pH 1 point 0.84 0.78-0.9 2.5 x 10-6 
Highest Creatinine  micromol/l 1.002 1.001-1.003 6.6 x 10-6 
Lowest Creatinine micromol/l 1.002 1.001-1.003 4.3 x 10-5 
RRT  1.83 1.37-2.45 5.1 x 10-5 
Haematocrit % 0.96 0.94-0.98 4.9 x 10-4 
Highest CVS SOFAa 1 point 1.3 1.15-1.47 2.5 x 10-5 
hypertension  1.18 1.08-1.28 1.8 x 10-4 
Highest HR 1 bpm 1.009 1.004-1.014 5.4 x 10-4 
Lowest platelets 10-9/l  0.98 0.97-0.99 2.1 x 10-4 
Lowest Temperature 1⁰C 0.84 0.78-0.9 2.5 x 10-6 
 
Results are shown for variables with p-value < 0.05/50. Results are adjusted for age 
and gender (apart from age). 
CI, confidence interval; bpm, beats per minute; CVS, cardiovascular; HR = Hazard 
Ratio, PH, proportional hazard; SOFA, Sequential Organ Failure Assessment; 
APACHE, Acute Physiology and Chronic Health Evaluation; RRT, renal 
replacement therapy. All variables refer to day 1 ICU admission, unless 
otherwise stated.  
a Variable recorded over week 1.   
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Table 17 Results of Cox PH regression analysis for 28 day mortality 
Variable Unit HR 95% CI p-value 
SOFA day 1 1 point 1.16 1.11-1.21 3.1 x 10-12 
APACHE II 1 point 1.08 1.05-1.1 3.5 x 10-12 
Age 1 year 1.05 1.03-1.06 1.4 x 10-11 
Highest renal SOFAa 1 point 1.43 1.3-1.57 1.2 x 10-13 
pH 1 point 0.77 0.7-0.84 1.5 x 10-9 
Acute Renal Failure  2.47 1.85-3.3 1.1 x 10-9 
RRT  2.22 1.56-3.17 9.6 x 10-6 
Haematocrit % 0.95 0.93-0.98 1.7 x 10-4 
Highest CVS SOFAa 1 point 1.35 1.17-1.56 4.5 x 10-5 
Hypertension  1.24 1.12-1.38 6.6 x 10-5 
Highest HR 1 bpm 1.01 1.01-1.02 2.1 x 10-5 
P:F Ratio kPa 0.98 0.97-0.99 9.4 x 10-4 
Lowest platelets 10-9/l  0.97 0.96-0.98 9.33 x 10-6 
Lowest Temperature 1⁰C 0.73 0.63-0.85 4.35 x 10-5 
 
Results are shown for variables with p-value < 0.05/50. Results are adjusted for age 
and gender(apart from age).   
CI, confidence interval; bpm, beats per minute; CVS, cardiovascular; HR = Hazard 
Ratio, PH, proportional hazard; SOFA, Sequential Organ Failure Assessment; 
APACHE, Acute Physiology and Chronic Health Evaluation; RRT, renal 
replacement therapy; P:F ratio, ratio of arterial oxygen partial pressure to 
fractional inspired oxygen. All variables refer to day 1 ICU admission, unless 
otherwise stated.  
a Variable recorded over week 1.   
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3.3.4 Antimicrobials analyses - results 
The antimicrobial combinations administered on admission to ICU varied 
widely, but were deemed by the local investigators to be appropriate in 91.8% of 
cases. The most common combinations were piperacillin-tazobactam (12.1%) 
cefuroxime/metronidazole (5.4%) and amoxicillin-clavulanate (5.3%). Antifungal 
agents were included in 5.8% of initial antimicrobial combinations. In a post-hoc 
exploratory analysis, no specific antimicrobial combination was associated with 
improved survival for the primary outcome (6 month-mortality), although in a small 
sub-group the combination of amoxicillin-clavulanate/metronidazole appeared to be 
associated with significantly increased mortality at hospital discharge and 28-days, 
and in another the administration of metronidazole alone appeared to be associated 
with a significant increase in ICU mortality. Neither the co-administration of 
antifungals, nor the appropriateness of the antimicrobial combinations (as judged by 
the local investigators) had any significant influence on mortality. The analyses 
pertaining to the use of antimicrobials were possibly affected by the large number of 
antimicrobial combinations used (causing data fragmentation) and the significant 
lack of data (not available for 216, 22.1% of patients), both of which reduced the 
power of the analyses. Table 18 presents information related to the initial anti-
microbial and antifungal regimes administered. 
The results from the antimicrobials usage analyses are presented in Tables 19 - 22. 
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Table 18 Initial anti-microbial regimes and appropriateness 
Antimicrobials N % 
Initial anti-biotic regimesa 761   
 Ceftriaxone/Metronidazole  15 2 
 Cefuroxime/Gentamicin/Metronidazole  15 2 
 Cefuroxime/Metronidazole  41 5.4 
 Fluconazole/Piperacillin-Tazobactam  11 1. 5 
 Gentamicin  28 3.7 
 Imipenem/Cilastatine  25 3.3 
 Amoxicillin-Clavulanate  40 5.3 
 Amoxicillin-Clavulanate/Metronidazole  17 2.2 
 Meropenem  27 3.6 
 Metronidazole  17 2.2 
 Metronidazole/Piperacillin-Tazobactam  35 4.6 
 Piperacillin-Tazobactam  92 12.1 
 Other combinations   291 38.2 
 No antimicrobials given on day 1  107 14.1 
Co-administration of antifungal agent 654   
 Fluconazole  35 5.4 
 Caspofungin  1 0.2 
 Clotrimazole  1 0.2 
 Amphotericin B  1 0.2 
 No antifungal agent used  616 94.2 
Appropriateness of antimicrobial treatment b 734   
 Appropriate  674 91.8 
 Not appropriate  60 8.2 
 
a Data was available for 761 patients. Antimicrobial combinations administered on 
day one of ICU admission to 10 or more patients are shown, less common 
combinations are included in the “other combinations” category; for 107 
patients no antimicrobial treatment was recorded as having been given in the 
first 24hrs. 
b Appropriateness of antimicrobial treatment during first 24 hours ICU admission was 
based on local investigator opinion 
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Table 19 Cox PH regression analyses for antimicrobials administered at ICU 
admission and 6 month mortality  
 
Antimicrobial combination HR 95% CI p-value 
Ceftriaxone/Metronidazole 1.31 0.51-3.38 0.57 
Cefuroxime/Gentamicin/Metronidazole 0.49 0.12-2.06 0.33 
Cefuroxime/Metronidazole 1.18 0.62-2.26 0.61 
Fluconazole/Piperacillin-Tazobactam 1.62 0.68-3.9 0.28 
Gentamicin 0.91 0.43-1.92 0.81 
Imipenem/Cilastatine 0.82 0.34-1.96 0.65 
Amoxicillin-Clavulanate 0.87 0.43-1.78 0.71 
Amoxicillin-Clavulanate/Metronidazole 1.73 0.67-4.45 0.26 
Meropenem 1.58 0.81-3.07 0.18 
Metronidazole 1.18 0.46-3.02 0.73 
Metronidazole/Piperacillin-
Tazobactam 
0.67 0.3-1.52 0.34 
Piperacillin-Tazobactam 1.42 0.88-2.3 0.15 
Other combinations  1.21 0.81-1.81 0.35 
Co-administration of antifungal agent 1.19 0.71-1.98 0.51 
Appropriate antimicrobial treatment 0.85 0.54-1.35 0.5 
 
The group with no antimicrobials recorded for the first 24 hours is the reference 
category. HR, hazard ratio; CI, confidence interval. 
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Table 20 Cox PH regression analyses for antimicrobials administered at ICU 
admission and ICU mortality  
 
Antimicrobial combination HR 95% CI p 
Ceftriaxone/Metronidazole 1.48 0.51-4.31 0.47 
Cefuroxime/Gentamicin/Metronidazole 0.7 0.09-5.22 0.73 
Cefuroxime/Metronidazole 1.85 0.84-4.04 0.13 
Fluconazole/Piperacillin-Tazobactam 1.03 0.24-4.41 0.96 
Gentamicin 1.05 0.35-3.12 0.93 
Imipenem/Cilastatine 0.50 0.15-1.69 0.27 
Amoxicillin-Clavulanate 1.02 0.43-2.39 0.97 
Amoxicillin-Clavulanate/Metronidazole 2.77 0.82-9.35 0.10 
Meropenem 1.35 0.62-2.94 0.46 
Metronidazole 2.77 1.04-7.37 0.04 
Metronidazole/Piperacillin-
Tazobactam 
0.86 0.32-2.27 0.76 
Piperacillin-Tazobactam 1.39 0.78-2.49 0.26 
Other combinations  1.25 0.76-2.03 0.38 
Co-administration of antifungal agent 0.92 0.47-1.81 0.8 
Adequate antimicrobial treatment 0.9 0.55-1.46 0.66 
 
The group with no antimicrobials recorded for the first 24 hours is the reference 
category. HR, hazard ratio; CI, confidence interval.  
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Table 21 Cox PH regression analyses for antimicrobials administered at ICU 
admission and hospital mortality 
Antimicrobial combination HR 95% CI p 
Ceftriaxone/Metronidazole 1.26 0.44-3.59 0.67 
Cefuroxime/Gentamicin/Metronidazole 0.76 0.18-3.22 0.71 
Cefuroxime/Metronidazole 1.61 0.82-3.18 0.17 
Fluconazole/Piperacillin-Tazobactam 1.38 0.49-3.95 0.54 
Gentamicin 0.83 0.36-1.9 0.65 
Imipenem/Cilastatine 0.93 0.38-2.24 0.87 
Amoxicillin-Clavulanate 0.8 0.38-1.69 0.55 
Amoxicillin-Clavulanate/Metronidazole 3.42 1.31-8.9 0.01 
Meropenem 1.5 0.73-3.1 0.27 
Metronidazole 1.87 0.72-4.86 0.2 
Metronidazole/Piperacillin-
Tazobactam 
0.62 0.26-1.49 0.28 
Piperacillin-Tazobactam 1.60 0.98-2.63 0.06 
Other combinations  1.36 0.89-2.07 0.16 
Co-administration of antifungal agent 0.89 0.51-1.58 0.7 
Appropriate antimicrobial treatment 0.9 0.55-1.46 0.66 
 
The group with no antimicrobials recorded for the first 24 hours is the reference 
category. HR, hazard ratio; CI, confidence interval. 
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Table 22 Cox PH regression analyses for antimicrobials administered at ICU 
admission and 28 day mortality  
Antimicrobial combination HR 95% CI p 
Ceftriaxone/Metronidazole 1.71 0.49-5.92 0.4 
Cefuroxime/Gentamicin/Metronidazole 1.16 0.27-5.1 0.84 
Cefuroxime/Metronidazole 1.72 0.75-3.93 0.2 
Fluconazole/Piperacillin-Tazobactam 1.66 0.48-5.76 0.42 
Gentamicin 0.86 0.29-2.62 0.8 
Imipenem/Cilastatine 0.84 0.24-2.9 0.78 
Amoxicillin-Clavulanate 1.08 0.42-2.78 0.88 
Amoxicillin-Clavulanate/Metronidazole 3.36 1.22-9.26 0.02 
Meropenem 1.36 0.49-3.73 0.56 
Metronidazole 1.96 0.65-5.9 0.23 
Metronidazole/Piperacillin-
Tazobactam 
0.65 0.19-2.24 0.5 
Piperacillin-Tazobactam 1.87 0.97-3.61 0.06 
Other combinations  1.56 0.89-2.76 0.12 
Co-administration of antifungal agent 0.95 0.46-1.94 0.88 
Appropriate antimicrobial treatment 0.82 0.45-1.49 0.52 
 
The group with no antimicrobials recorded for the first 24 hours is the reference 
category. HR, hazard ratio; CI, confidence interval. 
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3.4 Results of Multivariate analyses 
 
Table 23 reports the results of a multivariate Cox PH regression model 
retaining the variables independently predictive of mortality at each endpoint. At all 
time points, age, highest recorded renal SOFA score over the first week of ICU stay 
and lowest recorded temperature on day 1 remained independently associated with 
mortality.  
For each unit increase in the highest renal SOFA score recorded during the 
first week of ICU stay, the hazard of death at 6 months increased by 26.4% 
(HR=1.26, 95% CI 1.16-1.38), and similar increases were seen for ICU and hospital 
mortality (25.4% and 24.8% respectively). This effect was more marked for 28 day 
mortality, where for each unit increase in renal SOFA score there was an increase in 
hazard of 34% (HR=1.34, 95% CI 1.21-1.49).  
The other consistent and independent predictor of outcome across all time 
points was hypothermia during day 1 of admission to ICU. Every degree centigrade 
increase in the lowest recorded temperature on day 1 reduced the mortality hazard 
at 6 months by 14.6% (HR=0.85, 95% CI 0.76-0.96). This effect was also present for 
ICU, hospital and 28 day mortality (17.1%, 12.5% and 18.4% respectively).  
The highest cardiovascular SOFA score (HR 1.26, 95% CI 1.16-1.38, per unit 
change in score), bradycardia (HR 1.08, 95% CI 1.02-1.16, per 10 beats/minute 
decrease in heart rate), haematocrit (HR 0.97, 95% CI 0.95-0.99, per percentage 
point) and APACHE II score (HR 1.04, 95% CI 1.02-1.06, per unit change in score) 
remained predictive of mortality at 6 months after adjustment for other variables in 
the multivariate model.  
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While the SOFA score was not retained as an independent predictor for 
outcome at any time point, the APACHE II score was an independent predictor of 6 
months and hospital mortality. For each unit increase in APACHE II score the 6 
months and hospital mortality risks increased by 3.5% (HR 1.035, 95% CI 1.015-
1.056) and 3.1% (HR 1.031, 95% CI 1.011-1.052) respectively.  
The presence of acidosis affected shorter term outcomes: lower values for pH 
on day 1 being predictive of mortality at 28 days (HR 0.89, 95% CI 0.79-1.0) and in 
ICU (HR 0.90, 95% CI 0.82-0.99).  
Thrombocytopaenia was an independent predictor of 28 day (HR 0.99, 95% 
CI 0.98-1.0) and hospital (HR 0.99, 95% CI 0.98-1.0) mortality. 
A higher haematocrit decreased the risk of death at 6 months (HR 0.97, 95% 
CI 0.95 – 0.99), 28 days (HR 0.97, 95% CI 0.94 – 0.99) and in hospital (HR 0.98 
95%CI 0.96 – 0.99). 
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Table 23 Independent predictors of outcome, after inclusion in multivariate (stepwise 
regression) analysis, after adjustment for age and gender  
Variable Unit HR 95% CI p value 
6-month mortality 
Age 1 year 1.04 1.03-1.05 3.0 x10-10 
Female gender  1.27 1.0-1.6 0.05 
Highest renal SOFA week 1 1 point 1.26 1.16-1.38 9.5 x10-8 
Highest CVS SOFA week 1 1 point 1.17 1.04-1.32 0.01 
Hematocrit 1% 0.97 0.95-0.99 2.9 x10-3 
Lowest temperature day 1 1⁰C 0.85 0.78-0.96 9.3 x10-3 
Lowest heart rate day 1 10 bpm 1.08 1.02-1.16 0.01 
APACHE II 1 point 1.04 1.02-1.06 7.8 x10-4 
ICU mortality 
Age  1 year 1.04 1.02-1.05 2.8 x10-7 
Female gender  1.29 0.97-1.72 0.08 
Highest renal SOFA week 1 1 point 1.25 1.14-1.38 3.0 x10-6 
Lowest temperature day 1 1⁰C 0.83 0.73-0.94 3.9 x10-3 
pH day 1 1 point 0.90 0.82-0.99 0.03 
Hospital mortality 
Age  1 year 1.04 1.03-1.05 6.1 x10-10 
Female gender  1.23 0.96-1.58 0.1 
Highest renal SOFA week 1 1 point 1.25 1.14-1.36 6.7 x10-7 
Haematocrit day 1  1% 0.98 0.96-1.0 0.02 
APACHE II  1 point 1.03 1.01-1.05 2.0 x10-3 
Lowest temperature day 1 1⁰C 0.88 0.78-0.99 0.03 
Lowest platelets day 1 10-9/l 0.99 0.98-1.0 0.03 
28 days-mortality 
Age  1 year 1.04 1.03-1.06 3.0 x10-8 
Female gender  1.09 0.81-1.48 0.57 
Highest renal SOFA week 1 1 point 1.34 1.21-1.49 4.1 x10-8 
Haematocrit day 1  1% 0.97 0.94-0.99 0.01 
Lowest platelets day 1 10-9/l   0.98 0.97-1.0 0.01 
Lowest temperature day 1 1⁰C 0.82 0.70-0.95 0.01 
pH day 1 1 point 0.89 0.79-1.0 0.04 
Highest heart rate day 1 10 bpm 1.08 1.01-1.15 0.02 
 
bpm, beats per minute; CVS, cardiovascular, HR, hazard ratio, CI, confidence 
interval 
 
  
120 
 
Figures 6 – 13 are selected Kaplan-Meier curves for the 6-months survival 
estimate, showing the influence on survival of selected variables measured at day 
one of ICU admission (APACHE II, SOFA score, haematocrit, age, 
thrombocytopaenia, hypothermia, acute renal failure, need for renal replacement 
therapy) that were significant in individual variable analyses. The intervals shown in 
each graph refer to ranges for the indicated variable. 
Of the 104 patients with treatment limitations, 57 (50%) were 75 years of age 
or older. Of these 57 patients aged above 75 and with treatment limitations, the 
majority (39, 68.4%) died in ICU.   
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Figure 6 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of APACHE II (day 1 of ICU admission) 
 
 
  
122 
 
Figure 7 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of SOFA score (day 1 of ICU admission) 
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Figure 8 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of haematocrit (day 1 of ICU admission) 
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Figure 9 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of age at admission to ICU 
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Figure 10 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of thrombocytopaenia (day 1 of ICU admission) 
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Figure 11 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of hypothermia (day 1 of ICU admission) 
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Figure 12 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of investigators’ opinion of acute renal failure (ARF) (day 
1 of ICU admission) 
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Figure 13 Kaplan-Meier curves for the 6-months survival estimate, showing the 
influence on survival of investigators’ opinion of need for renal replacement 
therapy (RRT) (day 1 of ICU admission) 
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3.5 Summary of results 
Faecal Peritonitis is a common cause of sepsis and admission to the Intensive 
Care Unit (ICU). The Genetics of Sepsis & Septic Shock in Europe (GenOSept) 
project is investigating the influence of genetic variation on the host response and 
outcomes in a large cohort of patients with sepsis admitted to ICUs across Europe.  
Here I describe an epidemiological survey of the subset of patients with faecal 
peritonitis. 
I aimed to define the clinical characteristics, outcomes and risk factors for 
mortality in patients with faecal peritonitis admitted to ICUs across Europe. 
Data was extracted from electronic case report forms. Phenotypic data was 
recorded using a detailed, quality assured clinical database. Patients were followed 
for six months. Kaplan-Meier analysis was used to determine mortality rates. Cox 
Proportional Hazards (PH) regression analysis was employed to identify independent 
risk factors for mortality. 
Data for 977 faecal peritonitis patients admitted to 102 centres across 16 
countries between 29/09/2005 and 5/01/2011 was extracted. The median age was 
69.2 years (IQR 58.3-77.1), with a male preponderance (54.3%). The most common 
causes of faecal peritonitis were perforated diverticular disease (32.1%) and surgical 
anastomotic breakdown (31.1%). The ICU mortality rate at 28 days was 19.1%, 
increasing to 31.6% at six months (the primary outcome measure). The cause of 
faecal peritonitis, pre-existing co-morbidities and time from estimated onset of 
symptoms to surgery did not impact on survival. The strongest independent risk 
factors associated with an increased rate of death at 6 months included age, higher 
APACHE II score, acute renal and cardiovascular dysfunction within one week of 
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admission to ICU, hypothermia, lower haematocrit and bradycardia on day 1 of ICU 
stay. 
In this large cohort of patients admitted to European ICUs with faecal 
peritonitis the 6 month mortality was 31.6%. The most consistent predictors of 
mortality across all time-points were increased age, development of acute renal 
dysfunction during the first week of admission and hypothermia on day 1 of ICU 
admission. 
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Chapter 4 – Faecal peritonitis in the GenOSept cohort - Association 
between trends in clinical variables and outcome  
 
4.1 Introduction 
Patients admitted to intensive care following surgical management for faecal 
peritonitis present particular challenges in terms of clinical management and risk 
assessment. Collaborating surgical and intensive care teams need shared 
perspectives on trends in illness severity and likely outcomes. Dynamic assessment 
of trends and the response to treatment, including evaluation of changes in 
laboratory tests and dependence on organ support, may be more informative than 
isolated initial measurements when assessing the prognosis of individual patients. 
Several methods have been evaluated for dynamic assessment of critically ill 
patients (Bion et al. 1988; Yu et al. 2014; Ferreira et al. 2001; Timsit et al. 2002); 
including those undergoing surgery, and some have examined dynamic changes in 
patients with peritonitis (Hernández-Palazón et al. 2013; Paugam-Burtz et al. 2002; 
Zügel et al. 2011; Hynninen et al. 2008; van Ruler et al. 2011). The burden of data 
collection is considered by many to be a deterrent to routine use (Barnett & 
Moonesinghe 2011), however, and one study found that existing scoring systems 
were inadequate for this purpose (van Ruler et al. 2011). These studies were 
relatively small, though; the largest reported data on 163 patients only. 
Given the paucity of data on the association between trends in clinical 
variables during the early stages of ICU admission following surgical intervention for 
faecal peritonitis and outcomes, I have used a large international database of faecal 
peritonitis patients, with the aim of analysing trends in all available clinical variables 
during the first week of ICU stay and relating these to outcome.  
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Intra-abdominal infections and in particular faecal peritonitis, although 
affecting all age groups, are conditions which typically affect the elderly. The severity 
of sepsis, and the likelihood of an adverse outcome, are both reflected in persisting 
organ system failures, and may be aggravated by limited physiologic reserve, the 
presence of comorbidities, and impaired wound healing  (Podnos et al. 2002). With 
an ageing population, the incidence of faecal peritonitis is likely to increase, adding 
pressure on already scarce healthcare resources (Angus et al. 2000; Nguyen et al. 
2011). In this setting detecting trends in key laboratory and physiological variables, 
and in the severity of organ dysfunction could prove useful in supporting decision 
making with regards to escalating, limiting or withdrawing treatment and might help 
reduce variability in critical care decision-making (Boumendil et al. 2012). 
To date the GenOSept cohort includes the largest and diagnostically most 
homogeneous collection of clinical data on critically ill patients with faecal peritonitis. 
I have already described the outcome analyses from this cohort, based on data from 
day 1 of admission to critical care (chapter 3). The aim of the analyses presented in 
this chapter is to establish potential relationships between trends in key clinical and 
laboratory parameters and outcomes for this population of FP patients.  
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4.2 Results 
4.2.1 Trends in variables over first week of ICU stay 
 
I analysed trends in physiological and laboratory variables during the first 
week of ICU stay in the 977 patients from 102 centres across 16 European countries 
enrolled in the GenOSept cohort. The primary outcome was 6-month mortality. 
Secondary end-points were ICU, hospital and 28 day mortality. For each trend, Cox 
proportional hazards (PH) regression analyses, adjusted for age and gender, were 
performed for each endpoint. Trends remaining significant after Bonferroni correction 
for multiple testing were entered into a multivariate Cox PH model to determine 
independent associations with mortality. 
 
Of 977 patients, 937 patients stayed in ICU for at least 2 days, hence they 
could be included in the analysis of dynamic trends; of the remaining 40 (4.1%), 11 
died on day 1 and 29 were discharged alive from ICU on day 1 (of whom 21 were 
alive at 6 months and 8 were censored alive at hospital discharge). Also 321 
individuals did not have data for day 7; 237 did not have data at day 5 and 107 did 
not have data at day 3, (either because they had died or they had been discharged 
alive from ICU).  
 
Table 24 describes trends in clinical variables between day 1 and day 7 of 
ICU stay (for values related to days 2, 3 and 5 see later in this section). During the 
observed period, the proportion of patients suffering with acute renal failure (ARF) 
decreased from 29.1% (283 of 974) to 24.1% (159 of 659), the proportion of those 
receiving ventilatory support, Continuous Positive Airways Pressure (CPAP) or 
134 
 
invasive mechanical ventilation, decreased from 76.3% (743 of 974) to 62.9% (413 
of 657), while the proportion of those receiving any inotropic and/or vasopressor 
therapy decreased from 72.6% (707 of 974) to 34.2% (226 of 660). The median 
(IQR, interquartile range) SOFA score decreased from 7 (5-10) to 5 (2-8), mainly due 
to a decrease in the cardiovascular and renal components. 
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Table 24 Trends in variables during first 7 days ICU stay 
 
Day Day 1 Day 7 
Characteristics N n or Median
a
 % or IQR
b
 N n or Median
a
 % or IQR
b
 
Organ failure and support       
ARF 974 283 29.1 659 159 24.1 
RRT 974 115 11.8 659 104 15.8 
Ventilatory support  974 743 76.3 657 413 62.9 
Inotropes/vasopressors use* 974   660   
None  267 27.4  434 65.8 
A  33 3.4  36 5.5 
B  169 17.4  105 15.9 
C  505 51.9  85 12.9 
SOFA  974 7
a
 5-10
b
 659 5
a
 2-8
b
 
GCS SOFA 974 0
a
 0-1
b
 674 0
a
 0-1
b
 
CVS SOFA 974 4
a
 1-4
b
 671 1
a
 0-3
b
 
Coagulation SOFA 974 0
a
 0-1
b
 674 0
a
 0-1
b
 
Respiratory SOFA 974 2
a
 2-3
b
 659 2
a
 1-3
b
 
Renal SOFA 974 1
a
 0-2
b
 674 0
a
 0-1
b
 
Bilirubin SOFA 974 0
a
 0-1
b
 674 0
a
 0-0
b
 
Laboratory variables       
Serum bicarbonate 893 21
a
 18-24
b
 580 26
a
 23-29.1
b
 
paO2 (kPa) 945 11.3
a
 9.6-13.9
b
 590 10.8
a
 9.2-13.6
b
 
paCO2 (kPa) 938 5.2
a
 4.6-6
b
 535 5.2
a
 4.7-6
b
 
Highest creatinine (µmol/l) 974 106.6
a
 76-160
b
 654 81.5
a
 53.9-132
b
 
Lowest creatinine (µmol/l) 974 100
a
 70-144
b
 642 81.5
a
 54-130
b
 
Highest WCC (10
-9
/l) 974 12
a
 7.1-18
b
 643 15.3
a
 11-20.4
b
 
Lowest WCC (10
-9
/l) 974 9.4
a
 4.6-15
b
 643 15
a
 10.5-20
b
 
Lowest platelets (10
-9
/l) 974 212.5
a
 145-300
b
 640 234.5
a
 132-352.5
b
 
Highest bilirubin (mmol/l) 974 13
a
 8-22
b
 650 10
a
 5-19
b
 
Highest urea (mmol/l) 908 11
a
 6.4-17.1
b
 607 11.6
a
 7.2-20.8
b
 
Chest radiography findings      
Localised infiltrates 973 115 11.8 672 68 10.1 
Lobar infiltrates 973 61 6.3 672 32 4.8 
Diffuse bilateral infiltrates 973 148 15.2 672 109 16.2 
Physiological parameters       
Highest temperature (°C) 974 37.7
a
 37-38.3
b
 656 37.4
a
 37-38
b
 
Lowest temperature (°C) 974 36.2
a
 35.7-36.9
b
 656 36.5
a
 36-37
b
 
Highest SBP (mmHg) 974 140
a
 125-155
b
 655 150
a
 135-170
b
 
Lowest SBP (mmHg) 972 90
a
 80-100
b
 655 108
a
 95-120
b
 
Highest MAP (mmHg) 972 91
a
 82-103
b
 649 98
a
 89-110
b
 
Lowest MAP (mmHg) 970 62
a
 56-70
b
 649 71
a
 63-80
b
 
Highest Heart Rate (bpm) 974 117
a
 103-130
b
 655 104
a
 90-118
b
 
Lowest Heart Rate (bpm) 971 85
a
 73-99
b
 655 80
a
 70-90
b
 
Respiratory rate (breath/minute) 966 18
a
 14-24
b
 638 20
a
 16-27
b
 
Urine volume (ml/24 hours) 973 1375
a
 790-2100
b
 644 2276.5
a
 1333.5-
3411.5
b
 
P:F ratio (kPa) 942 27.8
a
 19.6-37.7
b
 573 30.7
a
 23.1-39.2
b
 
 
* Inotropic and vasopressors use was coded as follows: A = Dopamine ≤ 5 μg/kg/min or Dobutamine, 
B = Dopamine > 5 μg/kg/min or adrenaline/noradrenaline ≤0.1 μg/kg/min, C = Dopamine > 15 
μg/kg/min or adrenaline/noradrenaline > 0.1 μg/kg/min 
n, absolute count; IQR, interquartile range; N, number of available observations; SOFA, Sequential 
Organ Failure Assessment; GCS, Glasgow Coma Scale; ARF, Acute Renal Failure; RRT, 
Renal Replacement Therapy; CVS, cardiovascular; paO2, arterial partial pressure of oxygen; 
paCO2, arterial partial pressure of carbon dioxide; WCC, White Cell Count; SBP, Systolic 
Blood Pressure; MAP, Mean Arterial Pressure; bpm, beats per minute; P:F, ratio of partial 
pressure arterial oxygen and fraction of inspired oxygen; 
a
Median and 
b
IQR are shown instead of absolute count (n) and percentage (%).  
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Table 25 shows the estimated hazard ratios (HRs) for trends in variables that 
were associated with 6 month, ICU, hospital and 28 day mortality, after adjusting for 
multiple testing in individual variable analyses and after inclusion in multivariate 
analyses. 
The trends in variables over the first 7 days ICU stay that remained significant 
and were independently associated with 6 months outcome were: worsening 
thrombocytopaenia and renal function (total daily urine output and renal component 
of the SOFA score), highest recorded level of bilirubin and GCS component of the 
SOFA score. 
Changes in renal function (total daily urine output and renal component of the 
SOFA score), GCS component of the SOFA score, total SOFA and worsening 
thrombocytopaenia were also independently associated with secondary outcomes. 
Dynamic trends in all other measured laboratory and physiological variables 
and in radiological findings failed to be independently associated with outcome on 
multivariate analyses. Furthermore, changes in respiratory support, renal 
replacement therapy and inotrope and/or vasopressor requirements were not 
independently associated with any of the primary or secondary outcomes. 
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Table 25 Factors independently associated with 6 month, ICU, hospital and 28 day 
mortality, after adjustment for age and gender  
Significant variables grouped by outcome Unit HR 95% CI p value 
6 month mortality     
Deterioration of thrombocytopaenia 10 x 10
-9
/l  1.02 1.01-1.03 <0.001 
Decrease in daily urinary volume  100 ml 1.02 1.01-1.03 <0.001 
Decrease in highest recorded bilirubin  mmol/l 0.99 0.99-0.99 0.020 
Improvement in GCS SOFA  1 point 0.81 0.68-0.98 0.028 
Improvement in renal SOFA  1 point 0.87 0.75-0.99 0.047 
ICU mortality     
Decrease in daily urinary volume  100 ml 1.02 1.01-1.03 0.005 
Improvement in total SOFA  1 point 0.91 0.85-0.98 0.009 
Hospital mortality     
Deterioration of thrombocytopaenia 10 x 10
-9
/l  1.02 1.01-1.03 0.001 
Decrease in daily urinary volume  100 ml 1.02 1.01-1.03 <0.001 
Improvement in GCS SOFA  1 point 0.8 0.68-0.95 0.011 
Improvement in renal SOFA  1 point 0.87 0.77-0.99 0.043 
28 day mortality     
Decrease in daily urinary volume  100 ml 1.02 1.01-1.03 0.001 
Improvement in GCS SOFA  1 point 0.75 0.61-0.93 0.010 
Improvement in renal SOFA  1 point 0.79 0.66-0.95 0.013 
 
SOFA, Sequential Organ Failure Assessment, SBP, Systolic Blood Pressure; CPAP, Continuous 
Positive Airways Pressure; CXR, chest radiography; RRT, Renal Replacement Therapy; 
GCS, Glasgow Coma Score; SBP, Systolic Blood Pressure; HR, Hazard Ratio; CI, confidence 
interval 
 
 
Figure 14 displays trends over the first week of ICU admission in the five 
variables independently associated with 6 month outcome (thrombocytopaenia, daily 
urinary volume, renal and GCS components of the SOFA score, serum bilirubin 
concentration).  
138 
 
Figure 14 Trends in variables independently associated with 6 month survival (primary outcome) 
 
 
Sections A1-A3. Daily lowest platelet count, 24 hour urinary volume, highest recorded bilirubin concentration. The boxes indicate 
median and inter-quartile range, the whiskers extend to include 1.5 x IQR, dots include outliers outside this range. 
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Sections B1-B2. Daily GCS and renal components of the SOFA score. Proportions of different values of the renal and GCS 
components of the SOFA are indicated for survivors and non-survivors. 
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Survivors and non-survivors displayed differences in both absolute values and 
trends in these variables during their ICU stay. The platelet count remained 
consistently lower throughout the observation period and decreased more markedly 
in non-survivors compared to survivors. The daily total urine output was consistently 
greater and increased more markedly in survivors compared to non-survivors, 
throughout the 7 days (Table 26). The highest measured bilirubin showed an 
improvement during the 7 days observation period in survivors, but not in non-
survivors. The GCS component of the SOFA score for non-survivors was worse and, 
in general, deteriorated further during the observation period, while the renal 
component of the SOFA scores was consistently worse in non-survivors. 
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Table 26 Trends during first 7 days ICU stay (in survivors and non-survivors at six 
months) for variables which were independently associated with outcomes at 
multivariate analyses 
Day Day 1 Day 7 
Characteristics N n or 
Median
a
 
% or IQR
b
 N n or 
Median
a
 
% or IQR
b
 
Lowest platelets (10-9/l)       
Survivors 667 226
a
 159-316
b
 426 267
a
 164-388
b
 
Non-survivors 307 185
a
 113-280
b
 214 146
a
 78-274
b
 
Urine volume (ml/24 hours)       
Survivors 666 1499
a
 916-2170
b
 429 2460
a
 1680-3633
b
 
Non-survivors 307 1080
a
 475-1915
b
 215 1750
a
 471-2774
b
 
Highest bilirubin (mmol/l)       
Survivors 667 13
a
 8-21
b
 433 9
a
 5-17
b
 
Non-survivors 307 14
a
 8-25
b
 217 14
a
 6-25
b
 
GCS SOFA       
Survivors 667 0
a
 0-0
b
 453 0
a
 0-0
b
 
Non-survivors 307 0
a
 0-2
b
 221 1
a
 0-2
b
 
Renal SOFA       
Survivors 667 0
a
 0-1
b
 453 0
a
 0-1
b
 
Non-survivors 307 1
a
 0-3
b
 221 1
a
 0-3
b
 
 
n, absolute count; IQR, interquartile range; N, number of available observations; 
SOFA, Sequential Organ Failure Assessment; GCS, Glasgow Coma Scale; 
 aMedian and bIQR are shown instead of absolute count (n) and percentage (%).  
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4.2.2 Shorter term trends (2, 3 and 5 days) 
The analyses of trends over the first 2, 3 and 5 days yielded similar results 
(Table 27). 
The trends over the first 48 hours ICU stay independently associated with 
outcomes were deteriorating thrombocytopaenia and renal function (urinary output 
and renal SOFA score) and total SOFA score (Table 28). The trends over the first 3 
days ICU independently associated with outcomes were  thrombocytopaenia, renal 
function (urinary output and renal SOFA score), total SOFA score and, for 28 day 
mortality only, GCS SOFA score, MAP and P:F ratio (Table 29). The trends over the 
first 5 days ICU independently associated with outcomes were thrombocytopaenia, 
renal function (urinary output, renal SOFA score and highest recorded serum urea) 
and total SOFA score (Table 30). 
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4.2.3 The importance of Trends 
Although the hazard ratios presented in tables 25 and 30, for example, appear 
to be small, the larger the change in the underlying variable, the larger the effect 
(proportionally) on mortality. For example a reduction in platelet count of 50 (*10-9/l) 
is associated with a hazard ratio for 6 month mortality of 1.10 (95% confidence 
interval of 1.05-1.16, p<0.001), indicating a 10% increase in risk of death at 6 
months. Similarly, a reduction in 24 hour urine output of just 500 ml is associated 
with a hazard ratio for 6 month mortality of 1.09  (95% confidence interval 1.04-1.14, 
p<0.001), which translates into a 9% increase in risk of death. Such trends are 
therefore potentially relevant to the practicing clinician and will contribute to bedside 
assessment of severity of illness in patients with faecal peritonitis. 
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Table 27 Trends in variables (days 2, 3 and 5 ICU stay) 
Day Day 2 Day 3 Day 5   
Characteristics N n or 
Median
a
 
% or IQR
b
 N n or 
Median
a
 
% or IQR
b
 N n or 
Median
a
 
% or IQR
b
 
Organ failure and support          
ARF 939 274 29.2 873 251 28.8 742 203 27.4 
RRT 939 151 16.1 873 158 18.1 743 132 17.8 
Ventilatory support  938 627 66.8 872 569 65.3 742 490 66 
Inotropes/vasopressors use* 938   873   742   
None  276 29.4  345 39.5  421 56.7 
A  31 3.3  50 5.7  47 6.3 
B  209 22.3  192 22  119 16 
C  422 45  286 32.8  155 20.9 
SOFA  939 7
a
 4-10
b
 873 7
a
 3-9
b
 743 6
a
 3-9
b
 
GCS SOFA 940 0
a
 0-1
b
 877 0
a
 0-1
b
 755 0
a
 0-1
b
 
CVS SOFA 939 3
a
 1-4
b
 877 3
a
 0-4
b
 752 1
a
 0-3
b
 
Coagulation SOFA 940 0
a
 0-1
b
 877 0
a
 0-1
b
 755 0
a
 0-1
b
 
Respiratory SOFA 939 2
a
 1-3
b
 873 2
a
 1-3
b
 743 2
a
 1-3
b
 
Renal SOFA 940 1
a
 0-2
b
 877 0
a
 0-2
b
 755 0
a
 0-2
b
 
Bilirubin SOFA 940 0
a
 0-1
b
 877 0
a
 0-0
b
 755 0
a
 0-0
b
 
Laboratory parameters          
Serum bicarbonate 845 22.4
a
 20-25,6
b
 782 24
a
 21-27
b
 657 25.2
a
 22.9-29
b
 
paO2 (kPa) 883 10.9
a
 9.6-13.2
b
 807 11
a
 9.2-13.3
b
 679 10.8
a
 9.1-13.2
b
 
paCO2 (kPa) 819 5.3
a
 4.7-6.1
b
 749 5.3
a
 4.7-6.1
b
 623 5.3
a
 4.7-6
b
 
Highest creatinine (µmol/l) 938 105.3
a
 75-158
b
 870 96.4
a
 68-150
b
 740 87
a
 59.3-141
b
 
Lowest creatinine (µmol/l) 935 100
a
 70-150
b
 869 94
a
 66-146
b
 732 85.4
a
 58.3-136
b
 
Highest WCC (10
-9
/l) 937 13.2
a
 9.3-19
b
 870 14.3
a
 9.8-18.9
b
 725 13.5
a
 10.2-18.9
b
 
Lowest WCC (10
-9
/l) 937 12.4
a
 8.4-18
b
 869 13.2
a
 9.4-18.4
b
 725 13
a
 9.8-18.1
b
 
Lowest platelets (10
-9
/l) 937 204
a
 130-294
b
 868 189
a
 115-286
b
 726 180.5
a
 102-285
b
 
Highest bilirubin (mmol/l) 938 11
a
 6.8-20
b
 871 10
a
 6-18
b
 739 10
a
 5-19
b
 
Highest urea (mmol/l) 874 10.7
a
 7-18
b
 815 10.6
a
 6.7-18
b
 687 11.4
a
 6.6-20.1
b
 
Chest radiography findings         
Localised infiltrates 939 76 8.1 876 78 8.9 752 77 10.2 
Lobar infiltrates 939 37 3.9 876 28 3.2 752 43 5.7 
Diffuse bilateral infiltrates 939 109 11.6 876 122 13.9 752 126 16.8 
Physiological parameters          
Highest temperature (°C) 936 37.5
a
 37-38
b
 870 37.3
a
 36.9-38
b
 740 37.4
a
 36.9-38
b
 
Lowest temperature (°C) 936 36.4
a
 36-37
b
 870 36.4
a
 36-36.9
b
 740 36.4
a
 36-37
b
 
Highest SBP (mmHg) 938 142
a
 130-160
b
 872 150
a
 130.5-168
b
 740 151
a
 135-170
b
 
Lowest SBP (mmHg) 936 100
a
 90-110
b
 872 105
a
 93-118
b
 738 110
a
 96-120
b
 
Highest MAP (mmHg) 929 95
a
 84-105
b
 860 98
a
 88-110
b
 733 100
a
 88-112
b
 
Lowest MAP (mmHg) 927 66
a
 60-74
b
 859 70
a
 61-78
b
 730 70
a
 64-80
b
 
Highest Heart Rate (bpm) 938 110
a
 98-125
b
 872 106
a
 94-120
b
 740 103
a
 90-119
b
 
Lowest Heart Rate (bpm) 935 83
a
 72-95
b
 871 80
a
 70-90
b
 737 80
a
 70-90
b
 
Respiratory rate (breath/minute) 929 18
a
 15-24
b
 861 20
a
 15-24
b
 729 20
a
 16-26
b
 
Urine volume (ml/24 hours) 931 1580
a
 926-2460
b
 868 1869
a
 1012.5-2882.5
b
 733 2200
a
 1280-3375
b
 
P:F ratio (kPa) 880 29.3
a
 21-39.1
b
 803 30.3
a
 21.4-38.6
b
 666 30.7
a
 22.3-39.1
b
 
* Inotropic and vasopressors use was coded as follows: A = Dopamine ≤ 5 μg/kg/min or Dobutamine, 
B = Dopamine > 5 μg/kg/min or adrenaline/noradrenaline ≤0.1 μg/kg/min, C = Dopamine > 15 
μg/kg/min or adrenaline/noradrenaline > 0.1 μg/kg/min 
n, absolute count; IQR, interquartile range; N, number of available observations; SOFA, Sequential 
Organ Failure Assessment; GCS, Glasgow Coma Scale; ARF, Acute Renal Failure; RRT, Renal 
Replacement Therapy; CVS, cardiovascular; paO2, arterial partial pressure of oxygen; paCO2, arterial 
partial pressure of carbon dioxide; WCC, White Cell Count; SBP, Systolic Blood Pressure; MAP, 
Mean Arterial Pressure; bpm, beats per minute; 
 
a
Median and 
b
IQR are shown instead of absolute count (n) and percentage (%).  
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Table 28 Analyses conducted on trends over the first 2 days ICU stay showing 
factors independently associated with 6 month, ICU, hospital and 28 day mortality, 
after adjustment for age and gender 
Variable Unit HR 95% CI p value 
6 month mortality     
Deterioration of 
thrombocytopaenia 
10 x 10-9/l 
platelets 
1.025 1.01-1.04 0.004 
Improvement in total SOFA 1 point 0.93 0.87-0.99 0.02 
Decrease in daily urinary 
volume  
100 ml 1.01 1-1.02 0.025 
ICU mortality     
Improvement in renal SOFA 1 point 0.84 0.71-0.99 0.05 
Hospital mortality     
Improvement in total SOFA  1 point 0.93 0.87-0.99 0.03 
Improvement in renal SOFA  1 point 0.86 0.75-0.99 0.04 
28 day mortality     
Improvement in total SOFA  1 point 0.87 0.8-0.94 <0.001 
 
SOFA, Sequential Organ Failure Assessment; HR, Hazard Ratio; CI, confidence 
interval 
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Table 29 Analyses conducted on trends over the first 3 days ICU stay showing 
factors independently associated with 6 month, ICU, hospital and 28 day mortality, 
after adjustment for age and gender. 
Variable Unit HR 95% CI p value 
6 month mortality     
Deterioration of 
thrombocytopaenia 
10 x 10-9/l 
platelets 
1.03 1.02-1.05 <0.001 
Improvement in renal SOFA  1 point 0.78 0.69-0.89 <0.001 
Decrease in daily urinary 
volume  
100 ml 1.01 1-1.02 0.040 
ICU mortality     
Improvement in renal SOFA 1 point 0.84 0.73-0.97 0.016 
Improvement in total SOFA  1 point 0.92 0.87-0.97 0.004 
Hospital mortality     
Deterioration of 
thrombocytopaenia 
10 x 10-9/l 
platelets 
1.02 1.01-1.04 0.014 
Improvement in total SOFA  1 point 0.94 0.89-0.99 0.025 
Improvement in renal SOFA  1 point 0.81 0.71-0.92 0.001 
28 day mortality     
Worsening in P:F ratio  1 kPa 1.03 1.02-1.04 <0.001 
Improvement in GCS SOFA  1 point 0.78 0.62-0.98 0.033 
Improvement in renal SOFA  1 point 0.74 0.61-0.89 0.002 
Deterioration in lowest MAP 1 mmHg 1.02 1-1.03 0.024 
 
SOFA, Sequential Organ Failure Assessment, GCS, Glasgow Coma Score; MAP, 
Mean Arterial Pressure; P:F, ratio of partial pressure arterial oxygen and fraction of 
inspired oxygen; HR, Hazard Ratio; CI, confidence interval 
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Table 30 Analyses conducted on trends over the first 5 days ICU stay showing 
factors independently associated with 6 month, ICU, hospital and 28 day mortality, 
after adjustment for age and gender 
Variable Unit HR 95% CI p value 
6 month mortality     
Deterioration of 
thrombocytopaenia 
10 x 10-9/l 
platelets 
1.02 1.01-1.03 0.003 
Improvement in renal SOFA  1 point 0.74 0.56-0.99 0.040 
ICU mortality     
Improvement in total SOFA  1 point 0.92 0.88-0.97 0.001 
Hospital mortality     
Deterioration of 
thrombocytopaenia 
10 x 10-9/l 
platelets 
1.02 1-1.03 0.025 
Decrease in daily urinary 
volume  
100 ml 1.01 1-1.02 0.010 
Improvement in total SOFA  1 point 0.89 0.81-0.99 0.030 
28 day mortality     
Improvement in renal SOFA  1 point 0.81 0.69-0.96 0.015 
Improvement in highest 
recorded urea 
mmol/l 0.99 0.98-0.99 <0.001 
 
SOFA, Sequential Organ Failure Assessment; HR, Hazard Ratio; CI, confidence 
interval 
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4.3 Summary of results 
Patients admitted to intensive care following surgery for faecal peritonitis 
present particular challenges in terms of clinical management and risk assessment.  
Collaborating surgical and intensive care teams need shared perspectives on 
prognosis. I aimed to determine the relationship between dynamic assessment of 
trends in selected variables and outcomes. 
I have analysed trends in all variables available for the first week of ICU stay 
in 977 patients from the GenOSept FP cohort. The primary outcome was 6 month 
mortality. Secondary end-points were ICU, hospital and 28 day mortality. For each 
trend, Cox proportional hazards (PH) regression analyses, adjusted for age and 
gender, were performed for each endpoint. Trends found to be significant in these 
analyses, after Bonferroni correction for multiple testing, were entered into a 
multivariate Cox PH model, to determine independent associations with mortality. 
The trends over the first 7 days ICU stay (primary analysis) retained as 
independently associated with 6 months outcome were worsening 
thrombocytopaenia (mortality HR=1.02, 95% CI 1.01-1.03, p<0.001) and renal 
function (total daily urine output HR=1.02, 95%CI 1.01-1.03, p<0.001; renal SOFA 
sub-score HR=0.87, 95%CI 0.75-0.99, p=0.047), highest recorded level of bilirubin 
(HR=0.99, 95%CI 0.99-0.99, p=0.02) and GCS SOFA sub-score (HR=0.81, 95%CI 
0.68-0.98, p=0.028). Changes in renal function (total daily urine output and renal 
component of the SOFA score), GCS component of the SOFA score, total SOFA 
and worsening thrombocytopaenia were also independently associated with 
secondary outcomes (ICU, hospital and 28 day mortality). Dynamic trends over the 
first 7 days ICU stay in all other measured laboratory and physiological variables and 
in radiological findings failed to be retained as independently associated with 
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outcome on multivariate analyses. Furthermore, changes in respiratory support, 
renal replacement therapy and inotrope and/or vasopressor requirements were not 
independently associated with any of the primary or secondary outcomes. 
Secondary post-hoc analyses of trends over the first 2, 3 and 5 days 
corroborated these findings. 
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Chapter 5 - Derivation and Validation of a prognostic model 
 
5.1 Introduction 
Prognostic scores and models of illness severity are useful both clinically and 
for research. They support critical care physicians in decision making through more 
accurate prognostication, they describe and summarize case mix, and inform health 
economic evaluations of cost-effectiveness.  Many types of models exist and their 
roles are not mutually exclusive, as their combined use may afford better prognostic 
reliability (Vincent & Moreno 2010). These tools are usually insufficiently accurate to 
be useful for predicting individual survival and are generally reserved for 
benchmarking quality of care and for research studies (Eachempati 2014; Breslow & 
Badawi 2012; Bouch & Thompson 2008), for example when examining heterogeneity 
of treatment effect in clinical trials (Iwashyna et al. 2015). 
The International Sepsis Forum Consensus Conference on Deﬁnitions of 
Infection in the Intensive Care Unit describes intra-abdominal infections as a “very 
heterogeneous group of infectious processes that share an anatomical site between 
the diaphragm and the pelvis” (Calandra & Cohen 2005). The anatomical, clinical 
and pathophysiological heterogeneity of these infections, together with their varied 
etiology and prognosis, have given rise to a range of prognostic instruments tailored 
to specific populations. 
Generic “peritonitis” prognostic tools (aimed at peritonitis of any origin), such 
as the Mannheim Peritonitis Index (MPI) or the Peritonitis Index of Altona II (PIA II), 
rely on factors such as age, degree of organ failure, origin of sepsis and intra-
operative findings to risk stratify different types of peritonitis, but, given the 
considerable heterogeneity of intra-abdominal infections, these scoring systems may 
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not be sufficiently specific in terms of etiology (Wacha et al. 1987; Wittmann et al. 
1987). Other scoring systems have been devised to explicitly address the issue of 
prognostication in selected forms of peritonitis, such as the left colonic Peritonitis 
Severity Score (PSS), developed for patients with distal large bowel peritonitis of 
various origins (Biondo et al. 2000). The Physiological and Operative Severity Score 
for the enUmeration of Mortality and morbidity (POSSUM) is another risk adjustment 
model, developed in 1991 for use in surgical patients (Copeland et al. 1991). A 
modification of this prognostic model, obtained by excluding some of the 
physiological factors of the original POSSUM, was developed for use specifically in 
patients undergoing surgery for colorectal cancer (CR-POSSUM) (Tekkis et al. 
2004). Importantly, all of these scores incorporate intra-operative findings, and are 
either designed to cater for the heterogeneous spectrum of peritoneal infections 
(such as the MPI and PIA II), or to focus on a very narrow subset of peritonitis, 
identified by location (left colonic, in the case of PSS) or aetiology (colorectal 
malignancy, as in CR-POSSUM). To date no prognostic score has been developed 
for the critically ill patient with FP in the post-operative phase.  
International multicentre prospectively collected patient datasets, such as The 
GenOSept and GAinS cohorts, provide an opportunity to develop and evaluate such 
prognostic systems. 
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5.2 Results 
5.2.1 Baseline and outcome data 
The derivation cohort included 462 patients with FP recruited in the United 
Kingdom between September 2005 and January 2011. Their median (Inter-Quartile 
Range, IQR) age was 69.4 (58.6-77.2) years. The geographic validation (non-UK) 
cohort included 515 FP patients recruited to the GenOSept study from the other 
European countries during the same period. Their median (IQR) age was 69.1 (58-
77) years. The temporal validation cohort included 323 FP patients recruited in the 
UK between January 2011 and March 2015 to the GAinS study. Their median (IQR) 
age was 68.3 (57.6-77.2) years. For details of the recruiting centres, please see 
appendix. 
The baseline characteristics and the outcomes of the three cohorts are 
presented in Tables 31 and 32, respectively.  
The age distribution was not significantly different across the cohorts, 
although the derivation cohort had a higher proportion of patients aged over 75. 
Males predominated in all cohorts. The racial distribution was more heterogeneous 
in the geographic validation cohort, while the derivation and the temporal validation 
cohorts were almost entirely Caucasian. Among the comorbidities diabetes, previous 
serious infections and other illnesses were more prevalent in the geographic 
validation cohort, compared to the other cohorts. The underlying causes for faecal 
peritonitis varied across cohorts, with anastomotic breakdown being particularly 
common in the geographic validation cohort. Baseline SOFA (Sequential Organ 
Failure Assessment) and APACHE II (Acute Physiology and Chronic Health 
Evaluation II) scores and prevalence of mechanical ventilation on day one were 
comparable across the cohorts. The occurrence of acute renal failure on day one 
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was more frequent in the geographic validation cohort, with differences with the other 
cohorts (32.7%, 42.8% and 23.3% for the derivation, geographic and temporal 
validation cohorts, respectively), accompanied by a difference in the utilisation of 
renal replacement therapy (21%, 21.3% and 7.5% for the derivation, geographic and 
temporal validation cohorts, respectively) on day one. The geographic validation 
cohort was characterised by higher mortality rates (at all time points) and longer ICU 
stay, compared to the other two cohorts; this latter feature was also reflected, 
although to a lesser extent, in the length of hospital stay.  
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Table 31 Patients’ baseline characteristics for the derivation, geographic and 
temporal external validation sub-cohorts  
Cohort  Derivation  
(UK until  Jan 2011) 
GenOSept UK 
Geographic validation  
(non-UK) 
GenOSept Europe 
Temporal validation (UK 
post Jan 2011) 
GAinS 
Total number of patients 462 515 323 
Characteristics Median or n IQR or % Median or n IQR or % Median or n IQR or % 
Age       
Available data 462 100% 515 100% 323 100% 
 18-34 11 2.4% 25 4.9% 11 3.4% 
 35-44 15 3.3% 18 3.5% 16 5% 
 45-54 54 11.7% 52 10.1% 38 11.8% 
 55-64 93 20.1% 98 19% 73 22.6% 
 65-74 113 24.5% 151 29.3% 88 27.2% 
 75-84 149 32.3% 149 28.9% 75 23.2% 
 85-95 27 5.8% 22 4.3% 22 6.8% 
Gender       
Available data 462 100% 515 100% 323 100% 
 Male 236   51.1% 304 59% 171 52.9% 
 Female 226  48.9% 211 41% 152 47.1% 
Race        
Available data 460 99.6% 510 99% 323 100% 
  Caucasian 454 98.7% 502 98.4% 315 97.5% 
  Asian 4 0.9% 7 1.4% 3 0.9% 
  African 1 0.2% 1 0.2% 3 0.9% 
  Mixed 1 0.2% 0 0% 2 0.6% 
Medical comorbidities       
Available data 462 100% 515 100% 323 100% 
 Heart and vascular disease 187 40.6% 202 39.2% 117 36.2% 
 Respiratory disease 111  24.1% 133 25.8% 97 30% 
 Neurological disease 48   10.4% 57 11.1% 24 7.4% 
 Severe renal disease 39 8.6% 21 4.3% 16 5% 
 Gastrointestinal disease 98 21.3% 132 25.7% 76 23.5% 
 Malignancy 135     29.3% 160 31.1% 84 26% 
 Diabetes 61 13.2% 102 19.8% 44 13.6% 
  Previous serious infection* 8 1.7% 25 4.9% 5 1.6% 
 Other illness 130  28.2% 210 40.8% 83 25.7% 
 Severe exercise restriction 3  0.7% 6 1.2% 1 0.3% 
 Chronic dialysis 5         1.1% 8 1.6% 5 1.6% 
 Chronic steroids use** 2         0.4% 9 1.8% 5 1.6% 
Cause of FP       
Available data 461 99.8% 511 99.2% 323 100% 
 Perforated diverticulum 137 29.7% 175 34.3% 89 27.6% 
 Anastomotic breakdown 115 25% 187 36.6% 61 18.9% 
 Malignancy 65 14.1% 64 12.5% 35 10.8% 
 Trauma 22 4.8% 45 8.8% 16 5% 
 Other 122 26.5% 40 7.8% 124 38.4% 
Time to surgery (days) 1 1-3 1 1-3 1 1-3 
Acute physiology       
Available data 461 99.8% 513 99.6% 321 99.4% 
 APACHE II score 15 12-20 17 13-22 16 12-21 
 SOFA score 7 5-9 7 5-11 6 5-8 
 Acute renal failure 129 32.7% 214 42.8% 70 21.8% 
 Renal replacement therapy 81 21% 105 21.3% 26 8.1% 
 Mechanical ventilation 346 75.1% 397 77.4% 228 71% 
APACHE, Acute Physiology and chronic Health Evaluation; SOFA, Sequential Organ Failure 
Assessment;  
* Serious infection was defined as a serious, prolonged or recurrent infection.  
** Chronic steroid use was defined as taking corticosteroids below the immunosuppression dose (>7 
mg/kg/days hydrocortisone), which would exclude patient from inclusion in the study. 
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Table 32 Outcomes for the derivation, geographic and temporal external sub-cohorts 
Cohort  Derivation  
(UK until  Jan 
2011) 
Geographic 
validation  
(non-UK) 
Temporal 
validation (UK post 
Jan 2011) 
Total number of 
patients 
462 
GenOSept UK 
515 
GenOSept Europe 
323 
GAinS 
Characteristics       
Length of stay (days) Median IQR Median IQR Median IQR 
Available data 462 100% 515 100% 322 99.7% 
 ICU 7 4-14 14 7-29 6 3-11 
 Hospital 26 14-47 30 17-54 29 18-47 
Mortality n  %  n % n % 
Available data 462 100% 515 100% 321 99.4% 
 6 month  124 26.8% 185 35.9% 64 19.9% 
 ICU  73 15.8% 131 25.4% 24 7.5% 
 Hospital  109 23.6% 171 33.2% 29 9.8% 
 28 day  79 17.1% 171 33.2% 40 12.4% 
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5.2.2 Performance of the prognostic tools 
When evaluated using a Receiver Operator Characteristics (ROC) curve the 
discriminatory performance of the 6 month prognostic model in the UK derivation 
sub-cohort yielded an AuROC of 0.81 (95% Confidence Interval, CI, 0.76 - 0.86) as 
indicated in Figure 15 (panel A). At geographic validation in the non-UK sub-cohort, 
the 6 month prognostic model produced an AuROC of 0.73 (95% CI 0.69 - 0.78; 
Figure 15, panel B). At temporal validation the 6 month model yielded an AuROC of 
0.76 (95% CI 0.69-0.83; Figure 15, panel C). 
The 28 day prognostic tool also performed similarly, yielding an AuROC 0.82 
(95% CI 0.77 - 0.88; Figure 16, panel A) for the derivation UK sub-cohort. At 
geographic validation in the non-UK sub-cohort, the 28 day prognostic model 
produced an AuROC of 0.75 (95% CI 0.69 - 0.80; Figure 16, panel B). In the 
temporal validation cohort the 28 day model yielded an AuROC of 0.79 (95% CI 
0.71-0.87; Figure 16, panel C). 
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Figure 15 Receiver Operator Characteristics (ROC) curve obtained when applying 
the 6 month prognostic model to the derivation (panel A), geographic validation 
(panel B) and temporal validation sub-cohorts (panel C) respectively  
 
AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval;  
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Figure 16 Receiver Operator Characteristics (ROC) curve obtained when applying 
the 28 day prognostic model to the derivation (panel A), geographic validation (panel 
B) and temporal validation sub-cohorts (panel C) respectively 
 
AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval;  
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The 6 month FP score produced numerical values which can be stratified 
within 5 intervals (0 to 2; above 2 to 4; above 4 to 6; above 6 to 12; above 12) 
corresponding to five levels of 6 months mortality risk. The 28 day mortality FP score 
produces values classified within 5 intervals, corresponding to different risk 
categories for the outcome (0 to 2; above 2 to 4; above 4 to 8; above 8 to 16; above 
16). The observed mortality rates corresponding to each class of risk for the two 
scoring systems are presented in Table 33 for all three cohorts (Figures 17 and 18 
display the corresponding histograms of mortality). A 6 month FP score above 12 is 
consistently associated with a greater than 50% mortality risk at 6 months across all 
cohorts. A 28 day FP score above 16 is associated with a greater than 40% mortality 
risk for the 28 day outcome for the derivation and geographic validation cohorts, but 
not for the temporal validation cohort, in which the highest observed mortality risk 
was around 22%. 
 
Table 33 Observed 6 month and 28 day mortality rates for the derivation, geographic 
and temporal external validation sub-cohorts, stratified by FP score interval 
Cohort Derivation  
(UK until  Jan 2011) 
Geographic validation  
(non-UK) 
Temporal validation  
(UK post Jan 2011) 
FP score Deceased Deceased  Deceased  
6 month mortality 
0 to 2 3 (3.7%) 14 (13.7%) 5 (6.3%) 
>2 to 4 11 (10.8%) 25 (22.5%) 7 (10.5%) 
>4 to 6 14 (20%) 29 (36.3%) 12 (26.1%) 
>6 to 12 29 (31.9%) 44 (40.7%) 15 (28.9%) 
>12 67 (57.3%) 73 (64%) 22 (59.5%) 
28 day mortality 
0 to 2 0 (0%) 10 (9.9%) 2 (2.7%) 
>2 to 4 8 (8.3%) 12 (12%) 3 (5.4%) 
>4 to 8 10 (9.5%) 17 (15.3%) 8 (11.1%) 
>8 to 16 14 (16.5%) 27 (26.2%) 12 (22.2%) 
>16 47 (45.6%) 42 (42%) 15 (22.4%) 
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Figure 17 Observed 6 month mortality in the derivation, geographic and temporal validation sub-cohorts, by FP score interval 
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Figure 18 Observed 28 day mortality in the derivation, geographic and temporal validation sub-cohorts, by FP score interval 
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5.2.3 The discriminatory capabilities of the FP prognostic tools versus the SOFA and 
APACHE II scores in the FP cohorts 
 
To assess how the FP models compare, as prognostic tools, to the routinely 
used SOFA and APACHE II scores, I calculated AuROCs for these scoring systems, 
to predict 6 month and 28 day mortality, in order to compare each tool across all 
cohorts and for both outcomes. For 6 month mortality, the SOFA score produced 
AuROCs of 0.73 (95% CI 0.68-0.78), 0.68 (95% CI 0.63-0.72) and 0.62 (95% CI 0.54 
- 0.7) in the derivation, geographic and temporal external validation cohorts, 
respectively, while the APACHE II score yielded AuROCs of 0.74 (95% CI 0.7-0.79), 
0.71 (95% CI 0.66-0.75) and 0.69 (95% CI 0.62-0.77) for those cohorts, respectively. 
For the 28 day mortality outcome, the SOFA score produced AuROCs of 0.76 (95% 
CI 0.7-0.82), 0.66 (95% CI 0.6-0.73) and 0.67 (95% CI 0.58-0.77) in the derivation, 
geographic and temporal external validation cohorts, respectively, while the same 
AuROCs for the APACHE II score were 0.71 (95% CI 0.64-0.77), 0.69 (95% CI 0.63-
0.75) and 0.75 (95% CI 0.67-0.83), respectively. 
The AuROCs obtained using the FP scores were consistently superior to 
those obtained with the SOFA score, with statistical significance across all cohorts 
(derivation, geographic and temporal external validation) and for both 6 month and 
28 day mortality outcomes (Figures 19 and 20, respectively). 
The AuROCs obtained using the FP scores were also superior to those 
derived using the APACHE II score for both outcomes, although statistical 
significance was not consistently achieved across all cohorts (Figures 21 and 22, for 
6 month and 28 day mortality, respectively). 
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Figure 19 Comparison of the AuROCs obtained when applying the SOFA and the FP 
scores, for 6 month mortality outcome, to the derivation (panel A), geographic 
(panel B) and temporal validation sub-cohorts (panel C) 
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AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval 
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Figure 20 Comparison of the AuROCs obtained when applying the SOFA and the FP 
scores, for 28 day mortality outcome, to the derivation (panel A), geographic 
(panel B) and temporal validation sub-cohorts (panel C) 
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AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval 
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Figure 21 Comparison of the AuROCs obtained when applying the APACHE II and 
the FP scores, for 6 month mortality outcome, to the derivation (panel A), 
geographic (panel B) and temporal validation sub-cohorts (panel C) 
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AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval 
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Figure 22 Comparison of the AuROCs obtained when applying the APACHE II and 
the FP scores, for 28 day mortality outcome, to the derivation (panel A), 
geographic (panel B) and temporal validation sub-cohorts (panel C) 
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AuROC, Area under the Receiver Operating Characteristic curve; CI, Confidence 
Interval 
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5.3 Summary of results 
Prognostic scores and models of illness severity are useful both clinically and 
for research. The aim of the analyses in this chapter was to develop two prognostic 
models for the prediction of long term (6 months) and 28 day mortality of post-
operative critically ill patients with faecal peritonitis.  
Five variables (age, SOFA score, lowest temperature, highest heart rate, 
haematocrit) were entered into the prognostic models. The discriminatory 
performance of the 6 month prognostic model yielded an AuROC 0.81 (95% 
Confidence Interval, CI, 0.76 - 0.86), 0.73 (95% CI 0.69 - 0.78), and 0.76 (95% CI 
0.69-0.83) for the derivation, geographic and temporal external validation cohorts, 
respectively. The 28 day prognostic tool yielded an AuROC 0.82 (95% CI 0.77 - 
0.88), 0.75 (95% CI 0.69 - 0.80) and 0.79 (95% CI 0.71-0.87) for the same cohorts. 
These AuROCs were consistently superior to those obtained with the SOFA and 
APACHE II scores. 
Hence, the two prognostic models developed for 6 month and 28 day mortality 
prediction in critically ill septic patients with FP, in the post-operative phase, 
enhanced the SOFA score's predictive utility by adding few key variables: age, 
lowest recorded temperature, highest recorded heart rate and haematocrit. External 
validation in larger cohorts of their predictive capability is needed, before introduction 
of the scores into clinical practice to inform decision making and the design of clinical 
trials. 
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Chapter 6 
 
6.1 Discussion 
 
In my thesis I have presented a contemporary pan-European view of the 
clinical characteristics, outcomes and independent risk factors for mortality for 
patients admitted to ICU with faecal peritonitis. The data used has been derived from 
two of the largest, prospectively collected and most diagnostically homogeneous 
cohort of critically ill patients with faecal peritonitis, the GenOSept and the GAinS 
cohorts. These rigorously quality assured cohorts have provided unique insights into 
the epidemiology and associations between trends in clinical variables and short and 
long term outcomes of post-operative critically ill patients with this condition (relying 
on the GenOSept cohort only). The derivation of a prognostic model has been 
possible in the UK subset of the GenOSept cohort. The non-UK subset of the 
GenOSept cohort, and the patients subsequently recruited to the GAinS cohort have 
been used as geographic and temporal external validation, respectively. 
Faecal peritonitis continues to be associated with a high mortality. 
Approximately one out of five critically unwell patients with FP in Europe will die in 
the intensive care unit. Mortality in this cohort was 19.1% at 28 days, 20.9% in the 
ICU, 28.7% at hospital discharge and 31.6% at 6 months. The ICU mortality is 
similar to that observed in the APACHE II 2011 model (23.4%) and that found in a 
recently reported, smaller single-centre study specifically investigating faecal 
peritonitis outcome in ICU (Sayer et al., 2012), although much higher mortality rates 
were reported in another earlier study (Pawa et al., 2009). Both these studies were 
smaller and only reported in the form of conference abstracts. Sayer et al. have 
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reported in-hospital mortality rates of 21.6% and 38.1%, for the malignancy and non-
malignancy sub-groups respectively (Sayer et al. 2012), while Pawa et al. reported 
30 day mortality rates of 46% for patients aged <75 years and 78% for patients aged 
> 75 years, suggesting that different local practices of critical care admission, periods 
considered, evolution in concurrent treatments and underlying characteristics of the 
populations (other than admission diagnosis) may have influenced results (Pawa et 
al. 2009). Pawa and co-workers report age as the strongest outcome predictor, while 
Sayer and colleagues suggests that hypo-albuminaemia and the presence of 
malignancy influence mortality (Pawa et al. 2009). None of the studies reported 
microbiological isolates or the relationship between trends in clinical variables and 
outcomes. Other studies have evaluated heterogeneous populations of patients with 
peritonitis of multiple aetiologies, with several different predictors of outcome 
identified. The variability in determinants of outcome and in mortality rates is high, 
depending on the patient case mix (van Ruler et al. 2011; Torer et al. 2010; Horiuchi 
et al. 2007).  
 
The prognostic factors identified 
In my research, the strongest independent risk factors, on admission, 
associated with an increased rate of death at 6 months included age, higher 
APACHE II score, acute renal and cardiovascular dysfunction within one week of 
admission to ICU, hypothermia, lower haematocrit and bradycardia on day 1 of ICU 
stay. The most consistent predictors of mortality across all time-points were 
increased age, development of acute renal dysfunction during the first week of 
admission and hypothermia on day 1 of ICU admission. When evaluating the trends 
over the first 7 days ICU stay, the variables retained as independently associated 
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with outcomes, most consistently across the various time points, were worsening 
thrombocytopaenia, deteriorating renal function (urine output and renal SOFA sub-
score) and deterioration in GCS SOFA sub-score. The risk prediction models 
described in this chapter improved the SOFA score's predictive power for mortality at 
6 months and 28 days, by adding a few key variables: age, lowest recorded 
temperature, highest recorded heart rate and haematocrit on admission to intensive 
care. I am not aware of any prognostic tool designed to assess the risk of long term 
mortality specifically in the critically ill post-surgical FP patient. The 6 month mortality 
model demonstrates AuROCs of 0.81 (0.76-0.86), 0.73 (0.69-0.78) in the derivation 
and geographic validation cohorts, respectively, while the 28 day prognostic tool 
yielded AuROCs of 0.82 (0.77-0.88) and 0.75 (0.69-0.80) for the same cohorts. An 
area under the ROC curve over 0.8 is generally regarded as indicating a good 
discriminatory capacity (Tape 2016). When validated externally, the 6 month and 28 
day mortality models yielded AuROC of 0.76 (95% CI 0.69-0.83) and 0.79 (0.71-
0.87), respectively. The models, therefore, retained reasonable discriminatory 
capability, and systematically outperformed the other scoring systems tested (SOFA 
and APACHE II), in these cohorts. 
This FP prognostic tool may, therefore, be useful to complement the currently 
used risk scores and bedside clinical assessment, enhancing the critical care 
clinician’s capacity to predict long term outcome and thereby supporting the clinical 
decision making process in the post-operative phase.  
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Effect of Age 
Although not exclusively, faecal peritonitis is a condition presenting primarily 
in older age, a fact highlighting the relevance of contemporary studies on this 
subject, conducted on ageing populations, such as the European and other across 
the Western countries. This aspect of the condition has wide implications, especially 
in the context of finite resources, with important ethical ramifications. Unexpectedly, 
given its importance, the topic of faecal peritonitis appears to be a relatively 
“evidence free” area, with scarcity of studies detected on the specific topic in 
literature.  
The GenOSept faecal peritonitis cohort was characterized by an elderly 
population, with a high prevalence of cardiovascular, malignant and respiratory co-
morbidities. Populations across Western countries are aging, with an inevitable 
impact on the use and availability of critical care resources (Angus et al., 2000). This 
cohort reflects this trend; more than 60% of patients included were aged above 65 
years and almost one third were more than 75 years old. In keeping with previous 
studies I found older age to be significantly and consistently associated with an 
increased risk of death (Rosenthal et al., 2002, Van Den Noortgate et al., 1999). It is 
possible that a potential confounding effect, in this study, of the relationship between 
mortality and age, may be related to treatment limitations in the more elderly 
patients, particularly those above the age of 75. 
 
Effect of Acute renal dysfunction 
Acute renal dysfunction has been shown in previous large series of critically ill 
patients to be independently associated with higher ICU and hospital mortality rates 
(Uchino et al. 2005; Metnitz et al. 2002; Ostermann & Chang 2008; Barrantes et al. 
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2008). In the GenOSept faecal peritonitis cohort, the presence of acute renal 
dysfunction during the first week of ICU stay was strongly associated with mortality, 
the effect being more marked for the shorter term outcomes (ICU and 28 day 
mortalities), but remaining significant at 6 months. Raised creatinine and urea, acute 
renal dysfunction and the need for renal replacement therapy (RRT) on day 1 of 
admission to ICU were also all associated with worse outcomes in the single variable 
analyses. Debate continues as to whether the excess mortality associated with renal 
dysfunction is simply a reflection of the severity of the underlying illness, or whether 
the worse outcomes are directly attributable to the effects of renal dysfunction. While 
renal impairment tends to accompany other organ dysfunctions in the critically ill, 
there is evidence to suggest that acute kidney injury contributes independently to 
poor outcomes (Barrantes et al., 2008). 
Impaired renal function has also been linked to impaired immune function 
(Barrantes et al. 2008; Ostermann & Chang 2008; Ostermann & Chang 2005; Mehta 
et al. 2011). In the study by Barrantes et al. of 496 critically ill patients, the mortality 
rate of patients with acute kidney injury (AKI) was significantly higher than those 
without (Barrantes et al. 2008). Ostermann et al. examined the effect of AKI on over 
22000 adult general ICU patients, and found that the AKI classification correlated 
with outcome (Ostermann & Chang 2008). In a study conducted in an unselected 
ICU population of almost 42000 patients, the same authors examined the criteria for 
acute renal injury, acute renal failure syndrome and severe acute renal failure 
syndrome, and found that worsening degrees of renal impairment correlated with 
mortality (Ostermann & Chang 2005). Mehta et al. studied 611 unselected ICU 
patients, highlighting the higher incidence of sepsis amongst those with AKI (Mehta 
et al. 2011). 
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Effect of Hypothermia 
The adverse effect of hypothermia on the outcome of critically ill patients has 
been described by other authors, although data on the relevance of hypothermia to 
outcomes remains conflicting (Laupland, Zahar, Adrie, Minet, et al. 2012; Tiruvoipati 
et al. 2010). An association between severe hypothermia and the risk of ICU 
acquired infections has also been reported among medical patients (Laupland, 
Zahar, Adrie, Schwebel, et al. 2012). A large multicentre cohort study, including over 
10,000 patients (not undergoing therapeutic hypothermia) suggested that after 
controlling for confounding variables, hypothermia was a strong and independent 
predictor of mortality (Laupland et al., 2012b).  Tiruvoipati et al. reported data from 
175 elderly ICU patients, identifying lower temperatures and the Simplified Acute 
Physiology Score II (SAPS II) during the first day of ICU admission as being 
independently associated with higher hospital mortality (Tiruvoipati et al. 2010; Le 
Gall et al. 1994). At present it is not known whether active re-warming to correct 
hypothermia improves outcomes (Tiruvoipati et al., 2010). 
 
Effect of Haematocrit 
A low haematocrit on day 1 was associated with worse short and long term 
outcomes in this study. The reason for this is unclear, but anaemia in patients 
undergoing both cardiac and non-cardiac surgery, has previously been shown to be 
associated with worse outcomes (Shander et al., 2004, Qiu et al., 2010, Vignot and 
Spano, 2005, Halm et al., 2004, Beattie et al., 2009), although the effects of blood 
transfusion have not been fully clarified (Oliveros and Linares, 2012, Hung et al., 
2011). All of the patients with faecal peritonitis in the GenoSept study underwent 
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laparotomy (a requirement for making the diagnosis). In addition, a significant 
proportion of patients (40%) were documented to have cardiovascular co-morbidity, 
a group in which anaemia has been shown to be associated with increased mortality 
and major adverse cardiovascular events. A previously reported large observational 
study showed a higher 30-day survival rate in patients who received a blood 
transfusion compared to those who did not receive a transfusion (Vincent et al., 
2008). The contribution of dilutional anaemia as a result of fluid resuscitation is 
unclear, but this could also be postulated to have had an adverse effect by 
compromising tissue oxygen delivery during early (<6 hours) fluid resuscitation 
(Rivers et al. 2001). Beattie and co-workers performed a retrospective observational 
study of 7759 non-cardiac surgical patients to establish the relationship between 
preoperative anemia and postoperative mortality, and found that preoperative 
anemia was common and strongly linked with postoperative mortality, even after 
adjustment for major confounders (Beattie et al. 2009).  
Although anaemia may be associated with a poor outcome, data on the 
effects of blood transfusion is conflicting, with most reports not demonstrating benefit 
from transfusion aimed at achieving a higher haemoglobin threshold (Hébert et al. 
1999; Holst et al. 2015). 
 
The effect of Acidosis 
The observation that acidosis influenced short term outcomes, (ICU and 28 
day mortality) suggests a possible association with renal dysfunction. This 
association is unlikely to reflect acid-base disturbance secondary to respiratory 
acidosis, as none of the respiratory variables seemed to have an effect on any 
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mortality end-point. Alternatively metabolic acidosis may reflect impaired tissue 
perfusion and inadequate resuscitation. 
 
The effect of Thrombocytopaenia 
Thrombocytopaenia on admission was amongst the independent predictors of 
hospital and 28 day mortality. A link between thrombocytopaenia and the outcome of 
critical illness has been previously reported. Thrombocytopenia is a marker of 
disease severity, co-administration of blood products and development of 
consumption coagulopathy, with an increased risk of death (Stephan et al. 1999; Lee 
et al. 1993; Williamson et al. 2013; Crowther et al. 2005; Sharma et al. 2007; 
Vanderschueren et al. 2000; Strauss et al. 2002). My findings suggest that 
thrombocytopaenia is a marker of severity of illness in patients admitted to ICU with 
faecal peritonitis, perhaps in association with the development of consumption 
coagulopathy. Furthermore, the importance of the role of platelets in the innate 
immune response is increasingly being recognised (Morrell et al. 2014). 
In the GenOSept cohort, worsening thrombocytopaenia over the first 7 days 
ICU stay was also found to be independently associated with the primary (6 month 
mortality) and two of the secondary outcomes (hospital and 28 day mortality). 
Thrombocytopaenia is a common finding following operative intervention for intra-
abdominal sepsis, and a falling platelet count has been reported to be useful for 
distinguishing infected from non-infected peritonitis (Iberti et al. 1986). In the study 
by Vanderschueren and colleagues, in an unselected population of intensive care 
patients, the development of thrombocytopaenia and a reduction from baseline of 
50% or more in platelet count had more explanatory power for ICU mortality than 
admission variables (Vanderschueren et al. 2000). The study by Williamson et al. 
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examined the effects of prevalent and incident thrombocytopenia in an unselected 
population of over 20000 critically ill patients, demonstrating an independent 
association of low platelet counts with mortality. This association was stronger for 
specific admission diagnoses, in particular for the cancer, respiratory, digestive, 
genitourinary, and infectious categories (Williamson et al. 2013). In the study by 
Strauss et al. a decrease in platelet count ≥30% was significantly linked to higher 
mortality in 145 unselected critically ill patients (Strauss et al. 2002). A prospective 
observational study by Sharma et al. evaluated the incidence of various degrees of 
severity of thrombocytopenia in 69 septic shock patients, concluding that 
thrombocytopenia is associated with worse clinical outcomes in this unselected 
population of critically ill patients (Sharma et al. 2007). Crowther et al. also found that 
the development of thrombocytopaenia was strongly associated with mortality in 261 
unselected critical care patients (Crowther et al. 2005). 
 
Effect of Comorbidities, Time to surgery and Cause of FP 
Unexpectedly, neither the presence of co-morbidities nor time from presumed 
onset of symptoms to surgery, nor the underlying cause of faecal peritonitis 
appeared to influence survival. In the present study there appeared to be no effect of 
co-morbidities on mortality at any time point. This finding is in agreement with most 
(Koperna & Schulz 2000; Ohmann et al. 1993; Billing et al. 1994; van Ruler et al. 
2011; Singh et al. 2011) but not all (Pacelli et al. 1996; Demmel et al. 1994) of the 
previously published studies of patients with secondary peritonitis. Differences in the 
populations studied and their heterogeneity may explain such discrepancies. 
Interestingly, neither the cause of faecal peritonitis nor the time from onset of 
symptoms to surgery influenced survival in this cohort. This finding contrasts with 
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previously published studies of secondary peritonitis in which time to reoperation, 
source control and indices of physiological derangement have been the strongest 
outcome predictors (Pacelli et al. 1996; Koperna & Schulz 2000; Ohmann et al. 
1993; Demmel et al. 1994; Billing et al. 1994; van Ruler et al. 2011; Singh et al. 
2011). It is possible that in the GenOSept cohort the degree of acute physiological 
derangement overwhelmed the influence of the time to operative intervention, or that 
significant delay was unusual. In the cohort reported here the median time delay 
between onset of symptoms and surgery was 1 (IQR = 1-3) day, which is 
comparable with previously published data (Singh et al., 2011). 
 
Effect of Antimicrobial Therapy 
As might be expected in a pan-European study involving a large number of 
centres from 16 countries, a wide variety of initial antimicrobial combinations were 
administered to these patients with faecal peritonitis. Consequently it was not 
possible to draw firm conclusions from this observational study as to whether the 
initial choice of antimicrobial (which was considered by the local investigator to be 
appropriate in more than 90% of cases) might influence outcome. These 
observations are in keeping with a recent Cochrane review that studied 16 different 
antimicrobial regimes but was unable to make any specific recommendations for the 
first line treatment of secondary peritonitis as all showed equivalent efficacy (Wong 
et al., 2005). I am not aware of any other epidemiological studies of patients with 
faecal peritonitis that have documented antimicrobial regimes or identified any 
associations with outcome. 
The inability to detect a correlation between outcome and the use of different 
antimicrobial therapies requires additional investigation, to establish whether there is 
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a potential antimicrobial combination able to yield survival benefit. It is possible that, 
as the GenOSept and GAinS studies had not been designed to explore the effect of 
different antimicrobial combinations, the analyses were under-powered and affected 
by data incompleteness and fragmentation. 
 
Effect of SOFA 
The SOFA score was developed in a mixed (medical and surgical) ICU 
population (Vincent et al. 1996) and has been subsequently externally validated in 
various populations (Vincent & Moreno 2010), such as cardiac surgical patients 
(Ceriani et al. 2003) and critically ill burn patients (Lorente et al. 2009).  
Although the SOFA score was originally conceived as a tool for describing the 
evolution of dysfunction in various organs, rather than to predict outcome, both 
admission SOFA and trends in the global SOFA scores (and in the specific 
components renal and GCS), were closely associated with mortality. Furthermore, 
the FP prognostic indices included SOFA together with few additional key variables. 
In the prognostic indices analyses, neither the SOFA nor the APACHE II scores, 
when used in isolation, performed as well as the tools developed in this thesis. In 
fact SOFA has been used in combination with other parameters in previous studies 
(Zügel et al. 2011; Matsumura et al. 2014), for the purpose of outcome prediction.  
These findings are compatible with those from a recently reported prospective 
observational cohort study, investigating the systems that most contribute to the 
development of multiple organ system failure (MOSF). That study of 102 patients 
with abdominal sepsis highlighted the importance of trends in the SOFA score, 
demonstrating how the value on day 4 (as opposed to admission SOFA) had a high 
precision in predicting 28 day mortality, with MOSF being mainly contributed to by 
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renal, central nervous and respiratory system dysfunction (Hernández-Palazón et al. 
2013). In another study, which included 62 critically ill patients with post-operative 
peritonitis, investigators demonstrated the importance of trends in SOFA scores 
calculated serially over a 5 day post-operative period to distinguish between patients 
with or without persistent post-operative intra-abdominal sepsis (Paugam-Burtz et al. 
2002). In a prospective observational study of 56 secondary peritonitis patients, 
researchers measured several inflammatory parameters and multiple severity 
scoring systems pre-operatively and over a 5 days post-operative period, in a serial 
fashion. That study showed that combining the SOFA scores with measurement of 
serum neopterin concentration (a specific cellular immune system activation marker) 
and TNF (Tumour Necrosis Factor) receptor II levels yielded the highest predictive 
sensitivities and specificities for pre- and post-operative outcomes (Zügel et al. 
2011). In a study of 163 consecutive ICU patients with secondary peritonitis, hospital 
mortality was accurately predicted by the post-operative SOFA score (Hynninen et 
al. 2008). In a large trial comparing on-demand versus planned repeat laparotomy 
for severe peritonitis, the SOFA score showed good discriminatory power to predict 
hospital mortality, although it was unable to predict the need for repeat laparotomy 
(van Ruler, Mahler, et al. 2007; van Ruler et al. 2011). In a retrospective cohort study 
by Sumi et al. both the SOFA and POSSUM (Physiological and Operative Severity 
Score for the enUmeration of Mortality and Morbidity) scores were able to risk stratify 
patients undergoing surgical intervention for colorectal perforation (Copeland et al. 
1991; Sumi et al. 2014). Similarly, Matsumura et al. studied 218 general medical and 
surgical ICU patients, and showed that serum procalcitonin levels and SOFA score 
at ICU discharge could predict post-ICU mortality and survival time (Matsumura et al. 
2014). Jones et al. studied 248 emergency department patients with severe sepsis 
184 
 
and evidence of hypoperfusion at presentation, concluding that the SOFA score had 
prognostic value for in-hospital survival (Jones et al. 2009). 
When considering the importance of the GCS component of the SOFA score, 
a relevant study was reported by Mulier et al., who have previously demonstrated the 
influence of coma on mortality in a study of generalized post-operative peritonitis 
patients, independently of age and source control (Mulier et al. 2003).  
  
Effect of Heart rate  
An increased heart rate is a physiological response to infection and sepsis, 
and part of the systemic inflammatory response syndrome (SIRS).  
Sprung and colleagues found that the presence of SIRS predicts infection, 
severity of illness, organ failure and outcome, with the two most common SIRS 
criteria met during ICU stay being respiratory rate (82%) and heart rate (80%) 
(Sprung et al. 2006). Morelli and co-workers randomised a total of 154 septic shock 
patients to receive a continuous infusion of esmolol (targeting a heart rate of 80-94 
bpm) or standard treatment in an open label trial. The patients in the esmolol arm 
achieved lower heart rates, without an increase of adverse events. Interestingly, an 
improvement in survival and other secondary outcomes was also reported (Morelli et 
al. 2013). Others have found that a high daily mean heart rate was a significant 
predictor of ICU mortality (Park et al. 2011).  
 
Effect of Hyperbilirubinaemia 
Post-operative hyperbilirubinaemia has been linked to persistent post-surgical 
infection and a poor prognosis  (Nishida et al. 2002). In a study of patients with 
peritonitis, hyperbilirubinaemia, together with age and organ/system failures, was 
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found to be amongst a number of mortality predictors on univariate analysis 
(Barthlen et al. 1992).  
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6.2 Limitations 
Although larger than any previous series of patients admitted to ICU with 
faecal peritonitis, these analyses have a number of important limitations.  
Firstly recruitment was based on a clinical diagnosis of faecal peritonitis, but 
participating centres were at liberty to decide which patients they would recruit. While 
the inclusion and exclusion criteria were very precisely defined, making the 
population under exam extremely homogeneous, the subjects were not enrolled 
consecutively, thereby introducing a potential for selection bias. A second potential 
issue is the considerable variation in the numbers of patients recruited in each 
country. Some centres contributed very small numbers of patients. Nevertheless the 
wide range in participant ages, severity of physiological derangement and other 
characteristics, suggests that a significant systematic selection bias is unlikely. 
Therefore, for the two reasons identified above, this observational prospective cohort 
study may have suffered from some selection bias. Nevertheless there was a wide 
range in participant ages, severity of physiological derangement and co-morbidities, 
suggesting that a significant systematic selection bias is unlikely.  
Thirdly, the Bonferroni correction to address multiple tests performance (in the 
analyses of day one predictor variables and trends) was used. This technique is a 
very conservative method and avoids the scientific concerns related to the risks of 
false positive results. Such an approach is justified given the large amount of tests 
performed and the importance of avoiding excessive false positive results.  
Furthermore, in common with all but one of the previous epidemiological 
studies of peritonitis (which found no relationship between microbial isolates and 
outcome) (Pacelli et al., 1996) microbiological data were not collected. The 
GenOSept and GAinS studies were not designed to evaluate the influence on 
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outcome of the timing and adequacy of source control or antimicrobial treatment. All 
patients included in these cohorts received source control via surgical laparotomy 
prior to recruitment and the overwhelming majority of the patients (91.8%) received 
antimicrobial therapy deemed to be adequate. As the timing and adequacy of source 
control or antimicrobial treatment were not a focus of the epidemiological data 
collected, it is difficult to establish how these factors may have influenced outcomes, 
or how they could have affected the performance of the prognostic models. 
The failure to detect a relationship between outcome and antimicrobial use 
was almost certainly an inevitable product of insufficient power resulting from the 
many drug combinations utilised.   
The potential for unmeasured (known or unknown) factors to confound the 
associations detected must be acknowledged, in this as in any other observational 
study. Subsequent prospective studies, specifically aimed at confirming the potential 
predictive accuracy of the day one admission factors and the trends identified here 
as of prognostic value, would be required to further assess their value in clinical 
practice. 
The prognostic models presented here have some strengths, particularly as 
they have been derived and externally validated using large and recently gathered 
cohorts of FP patients (hence reflecting current practices and therapies). They could 
not be compared to other scoring systems such as the colorectal POSSUM, the MPI, 
PIA II or the PSS using the GenOSept and GAinS datasets, as these systems all 
require some intra-operative or pre-operative findings, not available to me. The lack 
of comparison with alternative and more recent versions of the severity scores, such 
as the Simplified Acute Physiology Score (SAPS) 3, the APACHE III or IV or the 
Mortality Prediction Model (MPM) III, may have an impact on the validity of the 
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results. Nevertheless, multiple studies have shown that the performance of such 
tools, even in their more recent versions, is not significantly improved (Lee et al. 
2014). Furthermore, despite the existence of updated versions, the APACHE II score 
has remained the most widely used severity scoring system in the ICU (Vincent & 
Moreno 2010; Eachempati 2014; Bouch & Thompson 2008) and the comparator of 
choice in multiple other recently published studies (Donnino et al. 2013; Naeini et al. 
2015). The SOFA score may be a less than ideal comparator, as it had not been 
developed for prognostication. Nevertheless, SOFA has been used for that purpose 
in multiple studies, both in isolation (Hynninen et al. 2008; van Ruler et al. 2011; van 
Ruler, Lamme, et al. 2007; Sumi et al. 2014; Jones et al. 2009) and in combination 
with other parameters (Zügel et al. 2011; Matsumura et al. 2014), for outcome 
prediction. Biondo and colleagues have recently evaluated the performance of the 
MPI as a predictor of immediate postoperative mortality, demonstrating an AuROC of 
0.72 (95% CI 0.65-0.79), while, for the more specific left colonic Peritonitis Severity 
Score (PSS), the AuROC was 0.79 (95% confidence interval 0.72-0.85) for this 
outcome (Biondo et al. 2006). 
The overwhelming majority of patients enrolled in this study were Caucasian 
and, therefore, caution should be exercised when extrapolating these findings to 
different ethnic populations.  My findings are applicable to faecal peritonitis patients 
who stayed in ICU for at least 2 days. Only 40 (4.1%) of the 977 faecal peritonitis 
patients in this cohort had a shorter stay, hence I consider it unlikely that this 
generated significant bias.   
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6.3 Summary and Implications of the findings  
This is the largest cohort of patients admitted to ICU with faecal peritonitis 
reported to date, providing a contemporary European view of their clinical 
characteristics, outcomes and prognostic features. The ICU mortality rate was 
20.9%, reaching 31.6% at six months. The studies reported in the thesis examine the 
impact on outcome of admission variables and trends, presenting novel, and 
sometimes unexpected, findings. Age, renal dysfunction, hypothermia and lower 
haematocrit on admission were consistently associated with an increased risk of 
death. Changes in routinely measured, readily available at the bedside, clinical, 
physiological and laboratory parameters were also associated with outcome. In 
particular, the deterioration in renal function, thrombocytopaenia and SOFA score 
over the first 2, 3, 5 and 7 days were consistently associated with mortality. 
Derangement in other laboratory variables, radiological findings, physiological 
parameters or even changes in respiratory support, renal replacement therapy and 
inotrope and/or vasopressor requirements, as analysed here on admission or over 
multiple time intervals, appeared not to be independently and consistently associated 
with any of the primary or secondary outcomes.  
The data also allowed the development of two prognostic models for the risk 
of 6 month and 28 day mortality in critically ill septic patients with FP, following 
laparotomy for source control. The tools incorporate five of the major independent 
risk factors identified (SOFA score, age, heart rate, temperature and haematocrit), 
and combine them to produce a numerical value associated with mortality risk over 6 
months or 28 days. In the setting of post-operative FP patients admitted to critical 
care, the tools outperformed other existing scoring systems, such as SOFA and 
APACHE II.  
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External validation in larger cohorts, such as the NELA (National Emergency 
Laparotomy Audit) or other databases (Odor & Grocott 2016), of the reliability of the 
admission variables and dynamic trends identified, and the predictive capability of 
the scoring tools are needed. In particular, further confirmation would be needed if 
the scores are to be relied upon for prognostication and escalation of care purposes. 
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6.4 Future Research 
Subsequent prospective cohort studies should be specifically aimed at 
confirming (or refuting) whether the few key variables and the specific dynamic 
trends identified in my thesis can explain variability in outcomes. Ideally, they should 
aim at recruiting patients by enrolling consecutively all suitable candidates and 
across multiple centres and countries. Also, as the overwhelming majority of patients 
enrolled in this study were Caucasian, confirming these findings across other 
populations remains necessary. 
Furthermore, a new prospective cohort study should collect variables useful 
for stratifying patients based not only on acute physiological derangement, 
comorbidities and organ support requirements, but also additional relevant factors. 
The supplementary variables to be considered are surgical techniques (collecting 
data for the calculation of other scoring systems, such as the colorectal POSSUM, 
the MPI, PIA II or the PSS, to compare to those developed here), type of healthcare 
system, other existing or novel surgical scoring systems, microbiological isolates and 
antimicrobial therapies used (to overcome the power limitations of the current 
analyses). Further evaluation of the predictive accuracy of the models described 
here, to decide their value in clinical practice, would be more feasible with a larger 
and adequately structured database. 
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Appendix 
 
Lists of variables available for analyses 
 
List of Variables included in the Cox proportional hazard univariate analysis (day 1 
epidemiological survey) 
 
Generic 
Cause of faecal peritonitis 
APACHE II score 
Time to surgery 
 
Variables related to organ failure and support 
Presence of acute renal failure (ARF) (day 1) 
Need for renal replacement therapy (RRT) (day 1) 
Need for ventilatory support (day 1) 
Total SOFA score (day 1) 
Highest renal component of SOFA score (during first week of admission) 
Highest cardiovascular component of SOFA score (during first week of admission) 
 
Comorbidities 
Cardiovascular disease 
Respiratory disease 
Gastroenterological disease 
Neurological disease 
Renal disease 
Underlying malignancy 
Diabetes mellitus 
History of previous serious infection 
History of severe exercise limitation 
Chronic dialysis 
Other illness 
History of chronic steroids use 
 
Laboratory parameters (day 1) 
Haematocrit  
Highest recorded serum sodium 
Lowest recorded serum sodium 
Highest recorded serum potassium 
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Lowest recorded serum potassium 
pH value 
Serum bicarbonate 
Arterial partial pressure of O2  
Arterial partial pressure of CO2 
Highest recorded serum creatinine 
Lowest recorded serum creatinine 
Highest recorded WCC (White Cell Count) 
Lowest recorded WCC 
Lowest recorded platelets 
Highest recorded serum bilirubin  
Highest recorded serum urea  
 
Radiological changes (day 1) 
Diffuse bilateral infiltrates on chest radiography (day 1) 
 
Physiological parameters (day 1) 
Highest recorded temperature 
Lowest recorded temperature 
Highest recorded SBP (systolic blood pressure) 
Lowest recorded SBP 
Highest recorded MAP (mean arterial pressure) 
Lowest recorded MAP 
Highest recorded HR (heart rate) 
Lowest recorded HR 
Respiratory rate 
Urine volume 
P:F ratio 
Use of inotropes/vasopressors 
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List of variables available for trends testing 
Variables related to organ failure and support 
Presence of acute renal failure (ARF)  
Need for renal replacement therapy (RRT)  
Need for ventilatory support  
Total SOFA (Sequential Organ Failure Assessment) score  
GCS (Glasgow Coma Scale) SOFA score 
CVS (Cardiovascular) SOFA score 
Coagulation SOFA score 
Respiratory SOFA score 
Renal SOFA score 
Bilirubin SOFA score 
 
Laboratory parameters 
Serum bicarbonate 
Arterial partial pressure of O2  
Arterial partial pressure of CO2 
Highest recorded serum creatinine 
Lowest recorded serum creatinine 
Highest recorded WCC (White Cell Count) 
Lowest recorded WCC 
Lowest recorded platelets 
Highest recorded serum bilirubin  
Highest recorded serum urea  
 
Radiological changes 
Localised infiltrates on chest radiography 
Lobar infiltrates on chest radiography 
Diffuse bilateral infiltrates on chest radiography 
 
Physiological parameters 
Highest recorded temperature 
Lowest recorded temperature 
Highest recorded SBP (systolic blood pressure) 
Lowest recorded SBP 
Highest recorded MAP (mean arterial pressure) 
Lowest recorded MAP 
Highest recorded Heart Rate 
Lowest recorded Heart Rate 
Respiratory rate 
Urine volume 
P:F ratio 
Use of inotropes/vasopressors 
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List of Variables used for derivation of the prognostic model 
Variables related to organ failure and support 
Presence of acute renal failure (ARF)  
Need for renal replacement therapy (RRT)  
Need for ventilatory support  
Inotropic support 
Total SOFA (Sequential Organ Failure Assessment) score  
GCS (Glasgow Coma Scale) SOFA score 
CVS (Cardiovascular) SOFA score 
Coagulation SOFA score 
Respiratory SOFA score 
Renal SOFA score 
Bilirubin SOFA score 
 
Laboratory parameters 
Serum bicarbonate 
Arterial partial pressure of O2  
Arterial partial pressure of CO2 
Highest recorded serum creatinine 
Lowest recorded serum creatinine 
Highest recorded WCC (White Cell Count) 
Lowest recorded WCC 
Lowest recorded platelets 
Highest recorded serum bilirubin  
Highest recorded serum urea  
 
Radiological changes 
Localised infiltrates on chest radiography 
Lobar infiltrates on chest radiography 
Diffuse bilateral infiltrates on chest radiography 
 
Physiological parameters 
Highest recorded temperature 
Lowest recorded temperature 
Highest recorded SBP (systolic blood pressure) 
Lowest recorded SBP 
Highest recorded MAP (mean arterial pressure) 
Lowest recorded MAP 
Highest recorded Heart Rate 
Lowest recorded Heart Rate 
Respiratory rate 
Urine volume 
P:F ratio 
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List of Study Personnel Responsible for Database Development and Quality Control 
 
C.H. – Charles Hinds, Professor of Intensive Care Medicine, William Harvey 
Research Institute, Barts and the London Queen Mary School of Medicine 
C.G. – Dr Chris Garrard, Consultant in Intensive Care Medicine, John Radcliffe 
Hospital, Oxford. 
A.G. – Prof Anthony Gordon, Professor of Anaesthesia and Critical Care, Imperial 
College London. 
P.H. – Ms Paula Hutton, Senior research nurse, John Radcliffe Hospital, Oxford 
A.W. – Dr Andrew Walden, Consultant in Acute and Intensive Care Medicine Royal 
Berkshire Hospital, Intensive Care Unit, Berkshire, UK 
J-D.C. – Prof Jean-Daniel Chiche, Réanimation Médicale, Hȏpital Cochin, Paris, 
France 
  
211 
 
Additional Information 
The GenOSept (Genetics of Sepsis and Septic Shock in Europe) and GAinS 
(Genomic Advances in Sepsis) are prospectively gathered cohorts of adult critically 
ill septic patients with faecal peritonitis (FP), admitted to intensive care units, from 
multiple centres in Europe. Patients included in the GenOSept FP cohort were 
recruited from 102 centres across 16 European countries and those in the GAinS FP 
cohort were recruited from 51 UK centres between September 2005 and March 
2015. 
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GenOSept study - additional information 
 
GenOSept (Genetics Of Sepsis and Septic Shock in Europe) is a multi-centre 
pan-European part-FP6-funded study conceived by the ECCRN (European Critical 
Care Research Network) of the ESICM (European Society for Intensive Care 
Medicine) to investigate the potential impact of genetic variation on the host 
response and outcomes in sepsis (https://www.genosept.eu/).  
GenOSept study consortium: ESICM, Belgium; University of Bonn, Germany; 
Wellcome Trust Centre for Human Genetics, Oxford University, UK; Cochin Institute, 
France; University of Torino, Ospedale San Giovanni Battista, Italy; University Roviri 
and Virgili of Terragona, Hospital Joan XXIII, Spain; Helmholtz Zentrum Munchen, 
Germany; Hadassah Medical Centre, Israel; SIRS-Lab GMBH, Germany; University 
of Ulm, Germany; University of Jena, Germany; Mazaryk University, Czech Republic; 
National Medical Centre, Hungary; Tartu University Clinics, Estonia. 
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GenOSept study  - List of Contributing Centres  
 
Belgium:  
Intensive Care Unit, AZ-VUB university hospital, 101 Laarbeeklaan, Brussels; 
Intensive Care Unit, Chu Charleroi, 92 Boulevard Janson, Charleroi; Soins Intensifs, 
Clinique Saint Pierre, 9 Avenue Reine Fabiola, Ottignies; Intensive Care, Cliniques 
Universitaires Saint Luc (UCL), 10 Avenue Hippocrate, Brussels; Intensive Care, 
University hospital, 185 De Pintelaan, Gent; Soins Intensifs, Cliniques de l'europe - 
St Michel,150 Rue de Linthout, Brussels. 
 
Croatia: 
Medic, Emergency and Intensive Care Medicine/Internal Medicine, Clinical 
hospital Rebro, 12 Kispaticeva, ZagrebAnestesiology and ICU, Clinical Hospital 
Rebro, 12 Kispaticeva, Zagreb. 
 
Czech Republic:  
Anesteziologicko-reuscitacni klinika, Fakultní Nemocnice u Svaté Anny, 53 
Pekařská, Brno; Anesteziologicko-resuscitacni oddeleni, Fakultni Nemocnice Brno, 
20 Jihlavská, Brno-Bohunice; Klinika anestezie, resuscitace a intenzivni mediciny, 
Fakultni Nemocnice Hradec Kralove, 581 Sokolská, Hradec Kralove; Chirurgicka 
klinika, Fakultní Nemocnice s Poliklinikou Ostrava, 1790 listopadu, Ostrava-Poruba; 
Anesteziologicko-resuscitacni klinika, Fakultni Nemocnice Plzen, 80 Alej Svobody 
Plzen; Anestezie, resuscitace a intenzivni medicina, Masarykova Nemocnice, 
3316/12A Sociální péče, Ústi Nad Labem; Anesteziologicko-resuscitacni oddeleni, 
Nemocnice Znojmo, 11 Janského, Znojmo; Anesteziologicko-resuscitacni oddeleni, 
Krajska Nemocnice Liberec, 10 Husova, Liberec. 
 
Estonia:  
General ICU, Tartu University Hospital, 1a L. Puusepa, Tartu; Pulmonary ICU, 
Tartu University Hospital,1a L. Puusepa, Tartu. 
 
France:  
Service de Réanimation Médicale, Hopital Cochin, 27 rue du Fbg St Jacques, 
Paris; Service de Réanimation Médicale, HEGP, 20 rue Leblanc, Paris; Service de 
Réanimation Médicale, Hotel Dieu, 1 place du Parvis Notre Dame, Paris; Service de 
Réanimation Médicale, Saint Joseph, 185 rue Raymond Losserand, Paris; Service 
de Réanimation Médicale, Chru Angers, 4 rue Larrey, Angers; Service de 
Réanimation Médicale, Chu de Nice, Rte St Antoine Ginestière, Nice; Service de 
Réanimation Médicale, Chu Purpan, Chu Toulouse- Hôpital Purpan, Toulouse; 
Service de Réanimation Médicale, Ch Versailles, 177 rue de Versailles, Le Chesnay. 
 
Germany:  
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Klinik für Herzchirurgie, Klinikum der Stadt Ludwigshafen am Rhein GGMBH, 
79 Bremserstraße, Ludwigshafen; Klinik und Poliklinik für Anästhesiologie und 
Intensivmedizin, Klinikum Greifswald, 23b Friedrich-Loeffler-Straße, 
Greifswald; Klinik fur Anästhesiologie und operative Intensivmedizin, Klinikum 
Augsburg, 2 Stenglinstr., Augsburg; Klinik und Poliklinik für Anaesthesiologie und 
Intensivtherapie, Universitätsklinikum Dresden, 74 Fetscherstrasse, Dresden; 
Klinik für Anästhesiologie und Intensivtherapie, Klinikum der Friedrich Schiller 
Universität, 101 Erlanger Allee, Jena; Klinik für Anästhesie und Intensivmedizin, 
Westküstenklinikum Heide, 50 Esmarchstraße, Heide; Abt. fur Anästhesiologie und 
Intensivtherapie, Fachkrankenhaus Coswig - centre for pneumology and thoracic 
surgery, 21 Neucoswiger Str., Coswig; Klinikum der Medizinischen Fakultät der 
Martin Luther Universität Halle-Wittenberg, 40 Ernst-Grube-Str., Halle; Klinik für 
Intensivmedizin, University medical center Eppendorf, 52 Martinistr., Hamburg; Klinik 
und Poliklinik für Anästhesiologie und Operative Intensivmedizin (Turmgebäude 2OG 
Zimmer 221), Universitätsklinikum Bonn, 25 Sigmund-Freud-Str., Bonn; Internal 
Medicine, Universitätsklinikum Mainz, 1 Langenbeckstrasse, Mainz. 
 
Greece: 
Intensive Care, Sismanoglion general hospital, Marousi, Athens; Critical care, 
Attikon university hospital, 1 Rimini, Xaidari. 
 
Hungary: 
Surgery 1St, Semmelweis University, 78 Ulloi Ut, Budapest  
 
Eire: 
Intensive care unit, St James hospital, James Street, Dublin; Intensive care 
unit, Adelaide Meath and national children’s hospital, Tallaght, Dublin; Anaesthesia 
and Intensive care, National university hospital Galway, Newcastle Road, Galway; 
Anaesthesia & Intensive Care Medicine, James Connolly memorial hospital, 
Blanchardstown, Dublin; Department of Anaesthesia and Intensive Care Medicine, 
Cork university hospital, Wilton, Cork. 
 
Israel:  
Carmel medical center, Haifa; General Intensive care unit, Haemek medical 
center, Afula; Anaesthesiology and critical care medicine, Hadassah medical center, 
Kiryat Hadassah, P.O. Box 12000, Jerusalem 
 
Italy:  
Anestesiologia e Rianimazione 3, Ospedale S. Giovanni Battista – Molinette, 
88 Corso Bramante, Torino; Anestesia e Rianimazione, Ospedale S.Giovanni Bosco, 
3 Piazza Donatori del Sangue, Torino; Dr Rianimazione SOD 2, AOU Careggi, 85 
Viale Morgagni, Firenze; Anestesia e Rianimazione, Ospedale Maggiore, 35 Via 
Francesco Sforza, Milano; Terapia Intensiva, Universita Degli Studi Milano Bicocca 
A.O. San Gerardo, 106 Via Donizetti, Monza; Anestesia e Rianimazione, Ospedale 
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S.Orsola Malpighi, 9 Via Massarenti, Bologna; Anestesia e Rianimazione, Ospedale 
S.Giovanni Addolorata, 8 Via dell'Amba Aradam, Roma; Scienze Anestesiologische, 
Medicina Critica e Terapia del Dolore, Policlinico Umberto I, 155 Viale del Policlinico, 
Roma. 
 
Netherlands:  
Intensive care unit, Erasmus medical centre, 230 Gravendijkwal, Rotterdam. 
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hospital; the Great Western hospital; the James Cook University hospital; The 
Whittington hospital; UCLH  Middlesex hospital; University hospital Lewisham; 
University hospital of Wales; University hospital, Coventry; Worthing hospital; 
Wythenshawe Hospital 
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GenOSept e-CRF synopsis (from GenOSept publishable executive summary - 
https://www.genosept.eu/doc/Executive%20summary%20year%202.pdf) 
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Gains study - additional information 
GAinS (Genomic Advances in Sepsis) is a multi-centre UK-wide study 
supported by the UKCCG (UK Critical Care Genomics Group), a network of centres 
undertaking clinical functional genomics research in the critical care setting 
(http://www.ukccg-gains.org). 
GAinS study Sponsor: University of Oxford 
GAinS study collaborators: Sainsbury Family Charitable Trust; Wellcome 
Trust Centre for Human Genetics, Oxford; Queen Mary University of London; Barts 
and The London School of Medicine and Dentistry 
GAinS Study ClinicalTrials.gov identifier: NCT00131196 
(https://clinicaltrials.gov/ct/show/NCT00131196) 
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Homerton University Hospital, London, UK 
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Funding 
 
GenOSept is a pan-European part-FP6-funded study 
 
CIBERES is a Spanish research network which was used to identify investigators 
and contributed to funding through supporting logistics for the GenOSept study in 
Spain. A grant in partial support of FP6 projects was provided by the Spanish 
minister of Health. 
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List of ethical bodies that approved the studies 
 
MREC, Multicentre Research Ethics Committee 
 
The MRECs gave overall approval for the studies to be conducted in the UK 
 Scotland  A Research Ethics Committee  
 Berkshire Research Ethics Committee  
 
 
REC, Research Ethics Committee  
 
Ethic Commissions / Bodies  
 
Address 
Ethikkommission 
Land Salzburg Ethik Kommission fur das 
Bundesland Salzburg 
  
Ethikkommission für das Bundesland 
Salzburg 
Sebastian-Stief-Gasse 2 
5020 Salzburg 
Postanschrift: 
 
Amt der Salzburger Landesregierung 
Ethikkommission für das 
Bundesland Salzburg 
Postfach 527 
5010 Salzburg 
Comite d’Ethique ISPPC 
 
Chu - Charleroi 
Boulevard Zoé Drion, 1 
6000 Charleroi 
Comite d’Ethique Hospitalo-Faculatiare de 
Liege   
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Liège  
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B-4000 Liège 
Belgique 
 
Clinique Saint Pierre, Avenue Reine 
Faibiola, 9 
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Stanovisko multicentricke Eticke Komis 
Fakultni Nemoncnice U SV. Anny V 
Brno 
 
Faculty hospital Brno 
Jihlavská 20 
625 00  Brno 
Czech Republic  
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Ethics Committee of Faculty Hospital 
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Czech Republic 
 
Ethics Committee of the University 
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Czech Republic 
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FN a LF UK Plzeň 
tř. Dr. E. Beneše 13 
305 99 Plzeň 
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Usti n.Labem 
 
Socialni pece 3316/12 A 
401 13 Usti n. Labem  
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Ethics Committee for multicenter clinical 
trials County Hospital Liberec  
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Str. 23d 17487 Greifswald 
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Israel 
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 Marousi 151 26 
Greece 
Ethics Commission University College 
Cork, Ireland 
Lancaster Hall, 6 Little Hanover Street, 
Cork, Ireland  
  
Ethics Commission The Adelaide & Meath 
Hospital, Dublin  
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Poland 
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Kragujevac 
 
CLINICAL CENTER KRAGUJEVAC 
Zmaj Jovina street 30 
Kragujevac 
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Alicante 
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Alicante 
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Spain 
Comite Etico 
Hospital Universitario de Gran Canaria   
 
Calle Dr. Alfonso Chiscano Díaz, 338 
35010 Las Palmas de Gran Canaria,  
Las Palmas,  
Spain 
Comite Etico 
Hospital Universitario de La Princesa 
Madrid 
Calle de Diego Leon, 62,  
28006 Madrid,  
Spain 
Comite Etico 
Hospital General Universitario Reina Sofia 
de Murcia  
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Carrer Prolongació Cirera, s/n,  
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Profesor Martín Lagos, S/N 
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Spain 
Comite Etico 
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Comite Etico 
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Avenida Ramón y Cajal, S/N,  
46520 Sagunt, Valencia,  
Spain 
Comite Etico 
Centro Medico Delfos 
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48013 Bilbao, Vizcaya, Bizkaia,  
Spain 
Comite Etico 
Hospital  Santa Maria del Rosell 
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JOHN RADCLIFFE HOSPITAL Oxfordshire REC B 
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Swindon 
Swindon REC 
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THE JAMES COOK UNIVERSITY 
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